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Abstract
HIV-associated neurocognitive disorders (HAND) affect up to 50% of HIV-infected adults despite potent
viral suppression with antiretroviral therapy (ART) and are associated with persistent neuronal damage,
monocyte/macrophage activation, chronic inflammation, and oxidative stress. Heme oxygenase-1 (HO-1) is
a highly inducible, detoxifying enzyme critical for limiting oxidative stress, inflammation, and cellular injury
within the central nervous system (CNS) and other tissues. Our analysis of HO-1 expression in the brain
prefrontal cortex from HIV-infected individuals demonstrated a significant HO-1 protein deficiency, even in
HIV-infected subjects treated with ART. This HO-1 deficiency associated with a diagnosis of HAND and
HIV-encephalitis (HIVE) as well as with elevated CNS HIV replication, type I interferon responses, and
macrophage activation. Within this cohort longer variants of a HO-1 promoter region (GT)n microsatellite
polymorphism, which cause reduced HO-1 gene expression, associated with increased risk of HIVE and
elevated CNS macrophage activation. HIV replication in macrophages, a primary CNS HIV reservoir,
selectively reduced HO-1 protein and RNA expression and induced production of neurotoxic levels of
glutamate. This HO-1 deficiency and associated neurotoxin production was a conserved feature of infection
with macrophage-tropic HIV-1 and HIV-2 strains that correlated closely with the extent of replication. ART
regimens applied to macrophages after HIV infection was established failed to prevent this HO-1 loss and
associated neurotoxin production. HO-1 siRNA knockdown and enzymatic inhibition in HIV-infected
macrophages increased supernatant glutamate and neurotoxicity. In contrast, increasing HO-1 expression
through siRNA derepression or with pharmacologic inducers, including the CNS-penetrating drug dimethyl
fumarate (DMF), decreased supernatant glutamate and neurotoxicity. These findings identify HO-1 as a host
factor that is deficient in the brains of HIV-infected individuals and suggest that loss of HO-1 and its
protective functions may contribute to HIV neuropathogenesis. Moreover, this work defines a predictable and
conserved relationship between HIV replication, HO-1 loss, and neurotoxin production in macrophages that
likely reflects processes in place in the HIV-infected brain of individuals receiving ART. Correcting this HO-1
deficiency could provide a novel approach for neuroprotection in individuals with or at risk for developing
HAND above that provided by current ART.
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ABSTRACT 
 
A NOVEL ROLE FOR AND POTENTIAL THERAPEUTIC TARGETING OF  
HEME OXYGENASE-1 IN HIV NEUROPATHOGENESIS 
 
Alexander J. Gill 
Dennis L. Kolson, M.D., Ph.D.  
 
HIV-associated neurocognitive disorders (HAND) affect up to 50% of HIV-infected adults despite 
potent viral suppression with antiretroviral therapy (ART) and are associated with persistent 
neuronal damage, monocyte/macrophage activation, chronic inflammation, and oxidative stress. 
Heme oxygenase-1 (HO-1) is a highly inducible, detoxifying enzyme critical for limiting oxidative 
stress, inflammation, and cellular injury within the central nervous system (CNS) and other 
tissues. Our analysis of HO-1 expression in the brain prefrontal cortex from HIV-infected 
individuals demonstrated a significant HO-1 protein deficiency, even in HIV-infected subjects 
treated with ART. This HO-1 deficiency associated with a diagnosis of HAND and HIV-
encephalitis (HIVE) as well as with elevated CNS HIV replication, type I interferon responses, and 
macrophage activation. Within this cohort longer variants of a HO-1 promoter region (GT)n 
microsatellite polymorphism, which cause reduced HO-1 gene expression, associated with 
increased risk of HIVE and elevated CNS macrophage activation. HIV replication in 
macrophages, a primary CNS HIV reservoir, selectively reduced HO-1 protein and RNA 
expression and induced production of neurotoxic levels of glutamate. This HO-1 deficiency and 
associated neurotoxin production was a conserved feature of infection with macrophage-tropic 
HIV-1 and HIV-2 strains that correlated closely with the extent of replication. ART regimens 
applied to macrophages after HIV infection was established failed to prevent this HO-1 loss and 
associated neurotoxin production. HO-1 siRNA knockdown and enzymatic inhibition in HIV-
infected macrophages increased supernatant glutamate and neurotoxicity. In contrast, increasing 
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HO-1 expression through siRNA derepression or with pharmacologic inducers, including the 
CNS-penetrating drug dimethyl fumarate (DMF), decreased supernatant glutamate and 
neurotoxicity. These findings identify HO-1 as a host factor that is deficient in the brains of HIV-
infected individuals and suggest that loss of HO-1 and its protective functions may contribute to 
HIV neuropathogenesis. Moreover, this work defines a predictable and conserved relationship 
between HIV replication, HO-1 loss, and neurotoxin production in macrophages that likely reflects 
processes in place in the HIV-infected brain of individuals receiving ART. Correcting this HO-1 
deficiency could provide a novel approach for neuroprotection in individuals with or at risk for 
developing HAND above that provided by current ART.  
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Introduction 
 
As of 2013, approximately 35 million people are living with human immunodeficiency virus (HIV) 
infection worldwide. The continued increase in prevalence from previous years is a result of both 
an estimated 2.1 million new HIV infections globally in 2012 (a 38% decline in incidence from 
2001) and an increase in the number of infected people living longer due to life-saving 
antiretroviral therapy (ART). Standard ART treatment consist of a combination of at least three 
antiviral drugs that decrease HIV replication to undetectable levels by standard clinical assays (< 
50 copies HIV RNA/ml). This reduction in HIV replication prevents HIV-mediated loss of CD4+ T-
lymphocytes and the resulting progression to acquired immune deficiency syndrome (AIDS), the 
final and most serious stage of untreated HIV disease. As of June 2014, approximately 13.5 
million adults living with HIV (~38%) had access to and were receiving ART. This increased 
access to ART and other global health initiatives aimed at limiting HIV transmission have resulted 
in a 35% decrease in AIDS-related deaths since the peak of 2.4 million deaths in 2005 (1). ART 
has fundamentally changed HIV-infection from a rapidly lethal disease into a manageable chronic 
condition. Today, a 20 year-old individual with HIV infection and starting ART is now expected to 
live into his or her 60s (2).  
 
Despite the many success of ART, virally suppressed HIV-infected patients continue to 
demonstrate chronic low-level immune activation, inflammation, and oxidative stress (reviewed in 
(3) and (4); see Chapter 2). This persistent inflammation and oxidative stress is believed to drive 
numerous non-communicable, age-related morbidities in HIV-positive individuals (5), including 
neurocognitive deficits known as HIV-associated neurocognitive disorders (HAND) (see Chapter 
3 and 4). Currently, ART is the only approved treatment for HAND. However, a significant 
proportion of patients on ART (30-50%) continue to develop neurocognitive impairment (6-17) in 
association with systemic and central nervous system (CNS) inflammation (18-24), particularly 
within the monocyte/macrophage compartment. Persistent systemic and CNS markers of 
3 
  
monocyte/macrophage activation predict neurocognitive impairment (25-33), even in individuals 
with excellent virological suppression (34-40). Supporting these previous findings, we have 
demonstrated a positive correlation between expression of cerebrospinal fluid markers of 
monocyte/macrophage activation and neuronal injury in a HIV-infected cohort (see Chapter 7). 
Within the CNS, effects of infection are driven in part by HIV replication within the 
macrophage/microglia reservoir (41). These infected macrophages/microglia promote neuronal 
injury and associated neurocognitive impairment through the release of cytokines and 
chemokines that drive neuroinflammation and through the direct release of numerous 
neurotoxins, including the excitotoxin glutamate.  Thus current research highlights the central role 
of macrophages/microglia and persistent neuroinflammation and oxidative stress in HAND in 
individuals receiving ART and underscores a critical need for adjunctive therapies that target 
these persistent neuropathological processes.  
 
To this end we studied the endogenous antioxidant response pathway in HIV-infection in vivo in 
brain tissue and in vitro in HIV-infected macrophages and have identified heme oxygenase-1 
(HO-1) as a potential therapeutic target in HAND (42, 43). HO-1 is a rapidly inducible detoxifying 
enzyme that is a critical effector for limiting oxidative stress, inflammation, and cellular injury 
within the CNS and other tissues in both physiological and disease states (see Chapter 5). These 
protective functions of HO-1 have been linked to its degradation of heme and the subsequent 
generation of carbon monoxide, biliverdin, and bilirubin, which have immunomodulatory and anti-
oxidative properties (reviewed in (44)). Numerous studies have demonstrated that ability of the 
HO-1 pathway and its products to limit the clinical severity of a variety of conditions in animal 
disease models that are characterized by oxidative stress and inflammation, including ischemia-
reperfusion injury, autoimmune neuroinflammation, inflammatory lung diseases, and 
infection/sepsis models. Moreover, clinical human studies have demonstrated associations 
between HO-1 promoter region polymorphisms and altered incidence and/or progression of 
various diseases associated with inflammation, including cardiovascular disease (e.g. coronary 
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artery disease), pulmonary disease (e.g. lung function in smokers), and infectious disease (e.g. 
sepsis sand pneumonia) (reviewed in (45)). These complimentary animal and human studies 
highlight the broad role of HO-1 in modulating pathological conditions, particularly those with 
inflammatory and oxidative stress pathology, such as HAND.  
 
This body of work describes a heretofore unreported deficiency of the sentinel cytoprotective 
enzyme HO-1 in the brains of HIV-infected individuals that may promote neuronal injury through 
inflammation-associated excitotoxic injury, particularly from the CNS macrophage/microglia 
reservoir. Our analysis of HO-1 expression in the brain prefrontal cortex of HIV-infected 
individuals from a well-characterized post-mortem autopsy cohort demonstrated a significant loss 
of HO-1 protein expression that was particularly striking in individuals with a pathological 
diagnosis of HIV-encephalitis (HIVE). Moreover, this HO-1 deficiency associated with a clinical 
diagnosis of HAND as well as with elevated CNS HIV replication, type I interferon responses, and 
macrophage activation (see Chapter 8). Further linking HO-1 to HIV neurological disease, 
individuals within this cohort with longer variants of a HO-1 promoter region (GT)n microsatellite 
polymorphism, which are linked to reduced HO-1 gene expression, associated with increased risk 
of HIVE and elevated CNS macrophage activation (see Chapter 9). These results suggest an 
association between HO-1 and HIV neurological disease progression and neuroinflammation and 
are consistent with an anti-inflammatory role of HO-1. Specifically, these data link HO-1 with CNS 
macrophage activation and suggest that altered HO-1 protein expression or gene regulation may 
modulate inflammation within the CNS of HIV-infected individuals.  
 
To further define the role of HO-1 in HIV neuropathogenesis, we examined HO-1 expression and 
the effects of modulating HO-1 in our in vitro HIV neurotoxicity model (see Chapter 10). In this 
model primary human monocyte-derived macrophages, a major CNS HIV reservoir, are infected 
with HIV resulting in robust viral replication and production of neurotoxic levels of the excitotoxin 
glutamate (46). HIV replication in macrophages predictably reduced HO-1 protein expression in a 
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time and replication dependent manner in association with elevated supernatant neurotoxicity and 
glutamate levels. We determined that this macrophage HO-1 deficiency and associated 
neurotoxin production did not require the HIV-1 accessory genes nef, vpr, and vpu and, 
moreover, was a conserved feature of infection with macrophage-tropic HIV-1 and HIV-2 strains. 
While pre-treatment of macrophages with ART prior to infection could prevent HIV replication and 
the associated HO-1 loss and neurotoxin production, the application of ART after HIV infection 
was established failed to prevent both HO-1 loss and neurotoxin production. These findings 
demonstrate that this HO-1 deficient neurotoxic phenotype is a relatively conserved feature of 
macrophage HIV infection that is resistant to ART once infection is established.  
 
This association between HO-1 deficiency and glutamate production suggests that loss of HO-1 
may promote macrophage neurotoxin production and further suggests a potential therapeutic 
benefit of restoring HO-1 expression in HIV-infected brain macrophages. This benefit of restoring 
HO-1 may be particularly critical as this HO-1 deficient phenotype may persist in long-lived HIV-
infected macrophage reservoirs in the presence of ART. To this end, we have shown that 
knockdown and enzymatic inhibition of HO-1 in HIV-infected macrophages increased supernatant 
glutamate and neurotoxicity. Moreover, we have demonstrated by using both pharmacological 
and genetic approaches that HO-1 induction decreased HIV-infected macrophage glutamate 
production and associated neurotoxicity independent of viral replication (see Chapter 11). 
Specifically, we demonstrated that the clinically prescribed HO-1 inducing drug dimethyl fumarate 
(DMF) and its primary CNS-penetrating metabolite monomethyl fumarate (MMF) can effectively 
suppress production of neurotoxic levels of glutamate from HIV-infected macrophages at in vivo 
relevant concentrations. These findings in conjunction with DMF’s other known anti-inflammatory 
and anti-oxidative effects highlight the potential role for DMF as an adjunctive therapy to limit 
HAND and other inflammation-associated comorbidities in HIV-infected individuals on ART (see 
Chapter 12). These data provide evidence that HIV-mediated macrophage HO-1 deficiency 
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augments neurotoxin production and that correction of this deficiency may in turn ameliorate 
neurotoxin production and associated neuronal injury.  
 
The findings presented in this thesis identify HO-1 as a host factor that is deficient in the brains of 
HIV-infected individuals with HAND and suggest that loss of HO-1 and its protective functions 
may contribute to HIV neuropathogenesis. Moreover, this work defines a predictable and 
conserved relationship between HIV replication, HO-1 loss, and neurotoxin production in 
macrophages that likely reflects processes in place in the HIV-infected brain of individuals 
receiving ART. These studies provide evidence for induction of HO-1 expression as a protective 
strategy against HIV macrophage-mediated neurological disease progression in patients with 
HAND, and they further suggest that HO-1 inducing drugs such as DMF could serve this 
therapeutic role.  
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2.1 Introduction 
 
Human immunodeficiency virus (HIV) is a member of the family retroviridae and genus lentivirus. 
HIV expresses archetypal retroviral structural proteins and enzymes encoded by gag, pol, and 
env genes that allow for replication in host cells through the process of reverse transcribing viral 
genomic RNA into DNA that is subsequently stably integrated into the host genome. In addition, 
HIV expresses several regulatory and accessory proteins that promote virus propagation. Virions 
of HIV, like other lentiviruses have spherical envelopes (80-100nm in diameter) that appear rough 
with ~8nm spikes, isometric nucleocapsids, and concentric and truncated cone shape nucleoids 
(Figure 2.1). The provirus genomic organization of HIV reveals multiple overlapping open reading 
frames (Figure 2.2). Human lentiviruses, HIV type 1 (HIV-1) and HIV type 2 (HIV-2), are 
distinguished by their use of the CD4 surface protein as a receptor, thus limiting their tropism to 
CD4+ cells. This section will briefly discuss the basic biology and clinical disease of HIV-1, the 
primary pandemic lentivirus infecting humans.  
 
2.2 HIV Biology and Viral Life Cycle 
 
HIV tropism 
 
The CD4 glycoprotein has been identified as the primary essential receptor for HIV-1 entry (47). 
However, CD4 receptor expression is not sufficient for HIV entry and additional co-receptors are 
required for entry and infection of target cells (48). Two co-receptors utilized by HIV-1 are the 
chemokine receptors CCR5 and CXCR4 (49-51). Transmitted/Founder HIV-1 virions, the viruses 
that are transmitted from person to person and establish clinical infection, are almost always 
CCR5-tropic (R5), with CXCR4-tropic (X4) strains evolving later in disease (52-54). Notably, 
individuals homozygous for CCR5Δ32 (a 32 base pair deletion in CCR5 gene resulting in protein 
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Figure 2.1 Diagram of mature HIV viral particle.  
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Figure 2.2 Organization of the HIV-1 and HIV-2 genomes. 
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truncation and lack of surface expression) are almost completely resistant to HIV-1 infection, 
highlighting the importance of CCR5 in HIV transmission (55). CD4 is found on the surface of 
immune cells, such as T helper cells, monocytes, macrophages, microglia, and dendritic cells. 
CCR5 is predominantly expressed on T cells, macrophages, dendritic cells, eosinophils, and 
microglia. In contrast, CXCR4 is widely expressed on most cell types, including hematopoietic 
(e.g. T cells, B cells, monocytes, macrophages, neutrophils, and eosinophils) lung, colon, heart, 
kidney, liver, endothelial, and epithelial cells in addition to cells of the central nervous system 
(CNS), including astrocytes and microglia (56-58). Thus, productive HIV infection is largely 
restricted to CD4+ and CCR5+/CXCR4+ T-cells, macrophages, and microglia. 
 
CCR5 is the main co-receptor used by HIV-1 to infect macrophages and microglia (50, 51, 59, 
60), thus CCR5-using viruses are often referred to as macrophage-tropic (M-tropic). However, 
CCR5-tropism is not required for infection of microglia, as some CXCR4 HIV-1 isolates can 
productively infect microglia (61) and some CCR5 isolates do not replicate in macrophages (62), 
indicating additional factors, beside co-receptor usage, involved in regulating macrophage and 
microglia tropism. One such factor is the ability of HIV-1 viruses to utilize low levels of CD4, as 
macrophages and microglia express much lower surface CD4 expression than CD4+ T-cells (63). 
The ability of HIV to infect macrophages and microglia is believed to be a central neuropathologic 
driver of HIV CNS disease (see section 3.4)  
 
HIV life cycle: entry through viral particle release 
 
This section presents a brief overview of the HIV life cycle (Figure 2.3; reviewed in (64)), with the 
roles for specific HIV-1 proteins presented subsequently. Upon binding to CD4 and an 
appropriate co-receptor, the HIV-1 virion fuses with the cell, depositing the viral core in the 
cytoplasm. After breakdown of the viral core and shedding of the capsid proteins, the viral 
genome is reverse transcribed from RNA into double-stranded DNA. Upon completion of reverse 
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Figure 2.3 HIV-1 viral life cycle.  
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transcription, the now formed DNA pre-integration complex is transported to the nucleus where it 
is integrated into the cellular chromosomal DNA, forming the provirus. HIV-1 proviral transcription 
results in the production of viral RNA and mRNA that are transported to the cytoplasm and 
translated into viral proteins, many of which require post-translational processing and/or 
proteolytic processing by the viral and cellular proteases. The exact mechanism of viral assembly, 
packing viral proteins and genomic viral RNA, and maturation is not completely understood. 
However, upon maturation viral particles are able to bud from the cell membrane by the process 
of exocytosis, where they are released into the extracellular space and can infect a new target 
cell. 
 
HIV structural proteins 
 
Group Specific Antigen (Gag): The gag gene produces a polyprotein precursor containing the 
myristylated protein (Pr55 Gag), which is subsequently proteolytically processed by the viral 
protease into three structural proteins: Matrix Antigen (MA/p17), Nucleocapsid (NC/p7), Capsid 
Antigen (CA/p24) (Figure 2.1). MA is responsible for targeting Gag polyprotein to the plasma 
membrane and is involved in recruiting env glycoproteins to viral budding sites (65). Additionally, 
MA may have a role in viral uncoating. NC is important for the encapsidation of full-length 
genomic RNA into forming virions (66). After viral maturation CA, also commonly referred to as 
p24, forms the viral capsid and assists in viral budding. CA/p24 is commonly quantified by ELISA 
as a measure of viral replication and is one of three major proteins tested, along with gp120/160 
and gp41, by Western blot to detect HIV-infection (67).  
 
DNA Polymerase (Pol): The pol gene is the most conserved region of HIV-1 and the three viral 
enzymes encoded, reverse transcriptase (RT), integrase (IN), and protease (PR) (Figure 2.1), are 
targets for currently used antiretroviral drugs in HIV-infected individuals. These enzymes are 
initially encoded as part of a Gag-Pol precursor polyprotein, which is processed by the viral 
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protease. RT is an RNA-dependent DNA polymerase that converts the HIV genomic RNA into 
both minus and plus strands of viral DNA as well as degrading the HIV genomic RNA present in 
the RNA-DNA hybrid intermediates (68). Enzymatic activity of RT is commonly assayed as a 
measure of viral replication in cell culture. IN mediates the integration the full-length HIV DNA 
genome produced by RT into the host cell genome (69). PR is responsible for processing 
precursor polyproteins into their individual components and is essential for viral infectivity (70).  
 
Envelope (Env): Env gene translation produces a heavily glycosylated precursor protein (gp160) 
that is cleaved by endogenous proteases into the surface (gp120) and transmembrane (gp41) 
subunits (Figure 2.1), which trimerize to form the native gp120-gp140 glycoprotein complex (71). 
This glycoprotein complex is responsible for viral particle binding and fusion on target cells 
through interaction with cell surface receptors CD4 and either co-receptor CCR5 or CXCR4 (72).  
 
HIV regulatory proteins 
 
HIV encodes two essential regulatory proteins, transactivator of transcription (Tat) and regulator 
for expression of viral proteins (Rev). Tat binds to the trans-activating response element (TAR), 
found at the 5’ ends of nascent HIV-1 transcripts, and activates transcription elongation by 
recruiting endogenous cellular proteins, resulting in increased steady-state levels of viral RNA by 
several hundred fold (73). Rev binds to an Rev responsive element (RRE) sequence present in 
the viral unspliced and partially spliced Gag-Pol, Gag, and Env mRNAs and promotes their 
nuclear export, allowing them to be efficiently translated by ribosomes in the cytoplasm (74).  
 
HIV accessory proteins 
 
HIV-1 encodes an additional four proteins (Nef, Vif, Vpr, and Vpu) that are referred to as 
accessory proteins as initial reports suggested that they were not essential for HIV-1 replication. 
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However, more recent evidence has demonstrated a vital role of these HIV proteins in promoting 
steps in viral replication and counteracting cellular proteins that interfere with HIV replication, 
most notably anti-viral host restriction factors (75). 
 
Negative Factor (Nef): Nef manipulates multiple cellular host factors to provide optimal conditions 
for viral replication and propagation. These changes include modulation of cell surface expression 
(decreased CD4 and CTLA-4), cytoskeletal remodeling (reduce T-cell receptor signaling during 
early infection), and signal transduction (increased IL-2 production) (76). These effects are 
important in modulating the activation state of infected cells, which plays an important role in the 
success rate of HIV-1 infection. While Nef often markedly elevates viral titers, it is often 
considered dispensable for HIV-1 replication.  
 
Viral Infectivity Factor (Vif): Vif disrupts the antiviral activity of the endogenous human restriction 
factor APOBEC3G through induction of polyubiquitination and subsequent degradation (77). 
APOBEC3G limits HIV replication through deamination of cystidine (C) to urinidine (U) in the first 
newly synthesized DNA-strand of HIV-1, resulting in guanosine (G) to adenosine (A) mutations in 
the complementary strand (78). Vif expression is essential for viral replication in primary CD4+ T-
cells and macrophages.  
 
Viral Protein R (Vpr): Vpr is involved in the nuclear import of the HIV-1 pre-integration complex, 
growth arrest of target ells in G2 phase, and transactivation of viral genes (79).  
 
Viral Protein U (Vpu): Vpu enhances the degradation of CD4 in the endoplasmic reticulum (ER), 
likely to prevent improper Env assembly into virions as a result of Env-CD4 binding in the ER 
(80). Vpu also promotes the release of viral particles from the plasma membrane through 
neutralization of the cellular restriction factor tetherin, which impedes release of viral particles 
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through physical tethering of virions to each other and the plasma membrane through binding to 
the viral envelope (80)..  
 
2.3 HIV Pathogenesis and Disease 
 
Transmission of HIV 
 
As HIV infection is restricted to humans, with no animal reservoir or vector, HIV transmission 
occurs exclusively from one human to another. Transmission can occur when certain bodily fluids 
from an HIV-infected individual (blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and 
breast milk) come into contact with a mucous membrane, damaged tissue, or the bloodstream. 
The most commons modes of transmission are vaginal or anal sex and sharing needles, 
syringes, or other equipment used for intravascular drug used (81). Other less common modes of 
transmission include mother-to-child transmission during pregnancy, birth, or breastfeeding; being 
stuck with an HIV-contaminated needle or sharp object; receiving blood, blood products, or 
organ/tissue transplants contaminated with HIV; and oral sex (fellatio, cunnilingus, and rimming) 
(82-84).  
 
Acute infection of HIV-1 
 
Acute or primary HIV infection occurs within the first 2-4 weeks after transmission and 
establishment of infection. During this stage the virus is replicating rapidly within the CD4+ T-cell 
compartment, with peak viremia reaching 106 to 107 virus particles per milliliter of blood (85) 
(Figure 2.4). Concomitant with this high viremia is a rapid drop in the number of circulating and 
intestinal mucosal CD4+ T cells (Figure 2.4) as a result of HIV induced cell lysis and killing of 
infected CCR5 CD4+ T-cells (85). Despite this high viremia and rapid drop in CD4+ T-cells, some 
individuals acutely infected with HIV show little or no symptoms. Acute infection symptoms may 
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include fever, decreased appetite, headache, rash, malaise, sore throat, muscle aches, and 
swollen lymph nodes, though individuals who experience symptoms often mistake them for the flu 
or other viral illness (85). Thus, most people with acute HIV infection do not know they have been 
infected, resulting in ~15% of people in the United States living with HIV being unaware of their 
seropositive status (86). This primary stage of infection lasts until the immune system creates 
antibodies against HIV (seroconversion) and activation of a partially-effective CD8+ T cell 
response (85), which results in a reduction, but not elimination, of circulating virus and a partial 
rebound in circulating CD4+ T-cells. Although initially partially effective, this immune response 
fails to control the virus resulting in chronic HIV-infection.  
 
Chronic immune activation and inflammation in systemic HIV disease progression   
 
After the initial acute HIV infection in an untreated individual, there is a clinically latent phase of 
the disease, often lasting years. However, continuous HIV replication during this period results in 
further CD4+ T-cell loss and a state of generalized immune activation (Figure 2.4). As a result of 
CD4+ T-cell depletion and eventually immune system failure, untreated individuals eventually 
(over years) progress to Acquired Immunodeficiency Syndrome (AIDS), a condition characterized 
by deficiency in cell-mediated immunity resulting in increased susceptibility to opportunistic 
infections, certain forms of cancer, and neurocognitive impairment. Treating HIV-infected 
individuals with combination antiretroviral therapy (ART), which inhibits multiple HIV enzymes 
simultaneously, reduces viral replication, increases CD4+ T cell counts, and significantly reduces 
HIV-associated morbidity and mortality, especially when initiated early in infection (87, 88) (Figure 
2.4). Today, a 20 year-old individual with HIV infection and starting cART is now expected to live 
into his or her 60s (2). 
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Figure 2.4 Clinical course of HIV-1 infection. Representative clinical course of HIV-1 infection 
in an individual A) never on ART B) and initiating ART after primary infection. Diagrams depict 
plasma HIV RNA (red line), peripheral CD4+ T-lymphocyte count (blue line), the trend of immune 
activation and inflammation (green block), the development of HAND and HIVE, as well as other 
characteristics of clinical HIV infection.  
A 
B 
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However, a growing body of evidence has defined chronic inflammation associated with immune 
activation as a major contributor to systemic and CNS disease progression in HIV-infected 
individuals, even in individuals treated with ART (3, 5, 89-103). Although ART significantly 
reduces viral replication and associated morbidity and mortality in HIV-infected individuals, lower 
life expectancy remains, particularly in individuals beginning ART after becoming 
immunosuppressed (CD4 T-lymphocyte counts < 200 cells/µl) (104-108). Elevated plasma levels 
of the associated biomarkers IL-6, D-dimer, C-reactive protein (CRP), and fibrinogen correlate 
strongly with HIV mortality in such individuals (109, 110). Such chronic immune activation is 
thought to result in large part from increased microbial translocation across the damaged 
gastrointestinal tract, which might harbor more pathogenic bacterial populations than in non-
infected individuals (111, 112). In HIV-infected humans and simian immunodeficiency virus (SIV)-
infected macaques gut microbial translocation results from depletion of mucosal CD4+ T 
lymphocytes, mucosal immune activation and inflammation, damage to mucosal epithelium, and 
transmigration of microbial products into the mesenteric lymph nodes and distal sites through the 
portal and systemic circulation (111). The translocated microbial products include 
lipopolysaccharide (LPS) (91, 97, 111), which associates with LPS-binding protein (LBP) in a 
complex that binds to monocyte CD14 and toll-like receptor 4 (TLR4) on immune cells. These 
LPS/LBP interactions with these receptors can activate monocytes and T-lymphocytes leading to 
induction of NF-κB activation, cytokine production, T-lymphocyte sequestration in lymphoid 
tissues, increased T-lymphocyte turnover, and associated events (113-115). The associated T-
lymphocyte turnover could generate new memory CD4+ T lymphocytes, thus providing additional 
targets for HIV replication (111, 116). Depletion of both CD4+ and CD8+ T-lymphocyte 
populations, which is strongly associated with disease progression (117), occurs in late stages of 
disease and is associated with and proposed to be caused by immune activation (118, 119).  
 
In addition to increasing plasma levels of LPS, HIV can induce immune activation of 
monocyte/macrophages through direct effects of infection or through the release of factors that 
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can interact with bystander uninfected monocyte/macrophages. For example, the HIV envelope 
glycoprotein gp120 is shed from virions and can transduce signals in monocytes when presented 
as a soluble protein or as a component of the virus particle even when presented on non-
infectious virions (as in plasma in vivo).(120, 121) Gp120 interacts with non-infected, bystander 
monocytes/macrophages and activates intracellular pathways that lead to monocyte/macrophage 
immune activation (120, 121). Other factors released from HIV-infected macrophages, such as 
TNFα and other proinflammatory cytokines, can also induce bystander cell immune activation 
(122-124). This monocyte activation is associated with elevated blood levels of soluble CD14 
(sCD14), soluble CD163 (sCD163), and monocyte-associated CD14 and CD16 (37, 96, 125). The 
CD16+ monocyte subset is more permissive for HIV infection than the CD16- subset (126), and 
the level of circulating CD14+/CD16+ monocytes correlates with an increased risk of disease 
progression (125).  
 
Because systemic immune activation is driven by HIV replication, suppression of HIV replication 
with ART suppresses such immune activation; however this suppression is often incomplete (91, 
92, 94, 95, 111, 127-131) (Figure 2.4) The presence of viral ‘blips’, defined as periodic detection 
of viral RNA in plasma which spontaneously returns to undetectable levels in chronically 
‘suppressed’ ART-treated individuals has been associated with increased expression of immune 
activation markers and accelerated disease progression (132). The significance of these ‘blips’ 
remains undetermined, although their association with immune activation in the systemic and 
CNS compartments is receiving intense scrutiny (132-134). Nonetheless, the persistence of 
immune activation despite suppression of HIV replication with our without viral ‘blipping’ remains 
a major obstacle to preventing further disease progression in ART-treated individuals. Successful 
therapeutic targeting of persistent immune activation has now been proposed as a critical goal for 
further improving long-term survival, lowering risk of associated end-organ diseases, and 
improving quality of life in HIV-infected cART-treated individuals (111, 116).  
 
21 
  
Systemic oxidative stress in HIV/AIDS: A target for adjunctive antioxidant therapy 
 
HIV infection can also induce systemic oxidative stress (135-138) through both chronic immune 
activation (139-141) and direct effects of HIV proteins (142-145) (reviewed (4)). Increased 
oxidative stress in HIV-infected individuals was first suggested after confirmation of diminished 
levels of reduced glutathione in plasma, lymphocytes, PBMCs, and monocytes isolated from such 
individuals (146-148). These early findings were supported by later studies demonstrating 
reduced levels of thioredoxin (a thiol antioxidant) in HIV-infected cells (149) and elevated serum 
levels of the lipid peroxidation products malondialdehyde (150, 151) and lipid hydroperoxides 
(152) in HIV-infected individuals. Moreover, the HIV proteins gp120 (142, 145, 153-156), Vpr 
(144, 157), and Tat (143, 145) have been directly implicated in the induction of cellular oxidative 
stress. Oxidative stress in turn can drive NF-κB-driven HIV replication (158-160) and 
inflammatory cytokine release (158, 161-165), thus perpetuating chronic systemic immune 
activation and disease progression in HIV-infected individuals. Furthermore, in vivo markers of 
oxidative stress correlate with systemic disease progression in HIV-infected individuals (166-168). 
One study showed that glutathione deficiency in CD4+ T-lymphocytes from HIV-infected patients 
was associated with markedly increased mortality (169). These findings implicate oxidative stress 
in HIV disease pathogenesis and mortality and highlight the potential for adjunctive antioxidant 
therapies to ameliorate disease progression in ART-treated patients. 
 
2.4 Conclusion 
 
Using CD4 as its primary receptor and either CCR5 or CXCR4 as a co-receptor, HIV-1 
productively infects cells of the human immune system, including CD$+ T-lymphocytes, 
macrophages, and microglia. Upon establishment of clinical infection, HIV replicates rapidly 
resulting in depletion of CD4+ T-lymphocytes. The immune system is unable to effectively control 
viral replication resulting in a chronic infection associated with systemic immune activation, 
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inflammation, and oxidative stress. The resulting dysfunction in cell-mediated immunity, 
monocyte/macrophage activation, and pro-inflammatory state drive the clinical sequela of HIV-
infection. Treatment with ART suppresses HIV replication and associated immune activation; 
however, this suppression is often incomplete and elevated systemic immune activation and 
inflammation persist; this persistence remains a major obstacle to preventing further disease 
progression in ART-treated individuals. Thus, adjunctive therapy that successful targets the 
persistent inflammation and oxidative stress is a critical goal for lowering risk of associated end-
organ diseases and improving quality of life in ART-treated HIV-infected individuals.  
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3.1 Introduction 
 
In addition to systemic disease, HIV infection is also associated with neurological disease 
including neurocognitive impairment in HIV-infected individuals. Early brain infection by HIV is a 
consistent consequence of HIV infection (170) and cerebrospinal fluid (CSF) HIV RNA levels 
correlate with severity of neurocognitive dysfunction in ART-naïve subjects, thus linking central 
nervous system (CNS) dysfunction to CNS HIV replication in those individuals (171, 172). HIV is 
believed to enter the brain through migrating infected monocytes and/or lymphocytes that cross 
the blood brain barrier (BBB) early in infection (173) (Figure 3.1). Once infection is established, 
perivascular macrophages are the major CNS site of productive HIV replication, although 
endogenous brain microglia can also harbor virus (41). Associated with both early and chronic 
brain infection is amplification of pro-inflammatory cascades, production of reactive oxygen 
species, expression of HIV proteins, oxidative stress, and increased production of glutamate and 
other excitotoxins, all of which have been linked directly or indirectly to neuronal injury and 
dysfunction and subsequent neurocognitive impairment (174) (Figure 3.1). These links were 
strongly established in the pre-antiretroviral therapy (ART) era, although the validity of these links 
in individuals on suppressive ART is now being challenged, as detection of CSF HIV RNA is more 
rare and often not correlated with neurocognitive dysfunction in those individuals (reviewed in 
(175)). However, there is no credible evidence that ART can irreversibly suppress or clear HIV 
from or within the CNS and high rates of neurocognitive impairment persist in HIV-infected ART-
treated individuals. Furthermore, interruption of ART can be associated with viral rebound in the 
CSF, neuronal injury, and worsened neurocognitive performance (176-178). With recent studies 
confirming surprisingly high rates of CSF viral escape (blipping) in individuals felt to be in a state 
of HIV suppression, a role for persistent CNS HIV infection and replication, even if intermittent, in 
HIV neuropathogenesis in ART-experienced patients appears likely (179).  
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3.2 HIV-Associated Neurocognitive Disorders (HAND) 
 
HIV infection causes varying degrees of cognitive, motor, and behavioral deficits collectively 
known as HIV-associated neurocognitive disorders (HAND) in up to 50% of ART treated 
individuals (180-184). HAND consists of three sub-classifications (the Frascati criteria (180)) that 
span a neuropsychological spectrum of impairment:  
 
Asymptomatic neurocognitive impairment (ANI): 1.0 standard deviation below the mean for age-
education-appropriate norms on neuropsychological tests in two or more cognitive domains with 
no functional impairment  
Mild neurocognitive disorder (MND): 1.0 standard deviation below the mean for age-education-
appropriate norms on neuropsychological tests in two or more cognitive domains with mild 
functional impairment of daily living   
HIV-Associated Dementia (HAD): 2.0 standard deviations below the mean for age-education-
appropriate norms on neuropsychological tests in two or more cognitive domains with marked 
functional impairment of daily living   
 
At least five cognitive domains must be assessed for a proper diagnosis of HAND. These 
cognitive domains include abstract/executive function, speed of information processing, 
attention/working memory, memory (learning and recall), sensory-perceptual, motor skills, and 
verbal language. Additionally the pattern of cognitive impairment cannot meet criteria for delirium 
and there must be no evidence of another, pre-existing cause for the neurocognitive impairment 
(e.g. substance abuse, CNS infection, cerebrovascular disease, major depression with functional 
limitations, or CNS neoplasm). Screening tools, many of which are simple and brief, are available 
for use in the clinic to screen for further follow-up with a complete neuropsychological 
examination for a concrete diagnosis (185). Unfortunately, despite these tools, HAND, especially 
milder forms, is highly underdiagnosed in the HIV-positive population. 
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Currently, ART is the only treatment for HAND. Effective ART has decreased the prevalence of 
HAD (6, 186, 187), the most severe form of HAND, however, a significant proportion of patients 
on ART (30-50%) continue to develop milder neurocognitive impairments (ANI and MND), despite 
reduced plasma viremia, improved immunological parameters, and decreased progression to 
AIDS (6-17). A recent study even showed a significant increase in the prevalence of the milder 
forms of HAND in the ART era (9). These milder forms of HAND are associated with a decreased 
ability to perform complex daily tasks, poorer quality of life, and difficulty obtaining employment 
(188). One possibility for this persistence is poor ART penetration and availability within the CNS, 
with CSF ART concentrations falling below the concentrations needed to inhibit wild-type virus 
replication for several drugs (189). This led to the hypothesis that ART regimens with high CNS 
penetration would better prevent HAND. However, the evidence that ART regimens that 
effectively penetrate the CNS can better protect from HIV-related neuronal injury and 
neurocognitive dysfunction is controversial (16). The high prevalence of HAND and other 
neurologic manifestations of HIV-infection despite the introduction of ART underscore a critical 
need for adjunctive therapies that target persistent neuropathological processes within the CNS 
compartment (190-195).  
 
3.3 HIV Neuropathology  
 
Neuroinflammation   
 
The neuropathogenesis of HAND has been associated with decreased CNS neuronal synaptic 
and dendritic density (196-198), neuronal apoptosis and necrosis (199-202), and altered neuronal 
physiology (203-211), linked to both systemic and CNS inflammation. Systemically, elevated 
levels of circulating CD16+ monocytes, CD14+ monocyte HIV DNA content, soluble CD14, 
soluble CD163, microbial translocation, and low CD4+ T-cell nadir correlate with an increased 
risk for HAND (212), indicating a central role for systemic monocyte activation and immune 
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dysfunction in pathogenesis. Within the CNS effects of infection are largely driven by HIV 
replication in macrophages/microglia (41), and possibly astrocytes. Productive HIV replication in 
the brain occurs primarily within perivascular monocyte-derived macrophages (MDM) and 
microglia, while restricted, non-productive replication occurs in astrocytes (213-216). Persistent 
CNS HIV infection drives immune activation of resident macrophages/microglia, pervasive 
reactive astrocytosis, perivascular inflammation and infiltration of monocytic cells (217), which 
can result in HIV-encephalitis (HIVE), particularly in individuals not receiving ART (218). The 
introduction of ART has decreased morbidity/mortality of HIV infection, the severity of 
neurocognitive impairment and associated neuroinflammation in HAND, and the prevalence of 
encephalitis (18, 20-23, 219). Despite these beneficial effects of ART, neuroinflammation and 
neuropathological damage persists (18-24), and persistent systemic and CNS markers of 
monocyte/macrophage activation predict neurocognitive impairment (25-33), even in individuals 
with excellent virological suppression (34-40). Moreover, the clinical severity of HAND correlates 
more strongly with monocyte infiltration and MDM/microglia activation than with CNS viral antigen 
load or number of HIV-infected cells in the brain (40, 197, 199, 220, 221). In summary, current 
research highlights the central role of macrophages/microglia and persistent neuroinflammation in 
HAND in individuals receiving ART. 
 
Role of CNS macrophages, microglia, and astrocytes in HIV-mediated neurotoxicity  
 
The neuronal dysfunction in HIV-infected individuals is likely in part a consequence of neurotoxins 
released from HIV-infected MDM (HIV-MDM) and immune activated MDM/microglia and 
astrocytes (222-225) (Figure 3.1). Our laboratory and others have demonstrated that a major 
component of HIV-MDM neurotoxins are small (<3 kDa), heat-stable, protease-resistant 
excitotoxins that act through N-methyl-D-aspartate-receptor (NMDAR) activation, a finding 
supported by studies in animal models of HIV neurotoxicity (226-228). Many candidate 
excitotoxins released from HIV-MDM have been described including glutamate (46, 229), 
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quinolinic acid (230, 231), NTox (232), platelet activating factor (233), TNFα (234), and the viral 
proteins gp120 (235, 236) and Tat (228, 237, 238) among others. HIV-infected individuals 
express increased levels of glutamate (239-241), quinolinic acid (242, 243), platelet activation 
factor (233), TNFα (244), and other neurotoxins in their CSF, which correlate with increased 
severity of HAND and neuroinflammation. Many of these neurotoxins released from HIV-MDM, 
such as the proinflammatory cytokine TNFα also dysregulate astrocyte function, particularly 
glutamate homeostasis (Figure 3.1). 
 
Proper functioning of glutamate uptake and metabolism by astrocytes is vital to prevent 
glutamate-dependent excitotoxicity as astrocytes are the major regulator of glutamate in the brain 
(245, 246). Astrocyte control of extracellular glutamate is regulated through multiple mechanisms 
including direct uptake of glutamate, Ca2+-dependent release of glutamate, and catabolism of 
glutamate by glutamine synthetase (245, 246). Each of these processes can be perturbed 
through the actions of HIV coat protein gp120 (247-250), TNFα (251-254), arachidonic acid (247), 
prostaglandins (255), reactive oxygen species (256), and associated neuroinflammation (246), 
each of which is also associated with HIV replication within CNS macrophages and microglia. 
This further emphasizes the link between inflammation, oxidative stress, and neurodegeneration 
in HIV CNS infection. Accordingly, the identification of endogenous pathways that regulate HIV-
MDM production of neurotoxins and factors that result in astrocyte dysfunction will provide novel 
therapeutic targets for ameliorating neurodegeneration and neurocognitive impairment in HAND. 
 
CNS oxidative stress in HAND  
 
HIV infection can induce CNS oxidative stress (161, 257-259) through chronic immune activation 
(139-141) and direct effects of HIV proteins. The HIV viral proteins gp120 (142, 145, 260), Vpr 
(144, 261), and Tat (143, 145) have been directly implicated in the induction of oxidative stress in 
CNS-relevant cell types. Oxidative stress drives NF-κB-driven HIV replication (158-160), 
inflammatory cytokine release (158, 161-165), and neurotoxin production (162, 259, 262-266). 
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Figure 3.1 Schematic model of HIV Neuropathogenesis. Abbreviations used: arachidonic acid 
(AA), platelet activating factor (PAF), prostaglandins (PGs), quinolinic acid (QUIN), reactive 
oxygen species (ROS).  
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Furthermore, in vivo markers of oxidative stress correlate with neurocognitive impairment (161, 
265, 267) as well as systemic disease progression (166-168) in HIV-infected individuals. The 
ubiquitous antioxidant response pathway provides endogenous protection against cellular 
oxidative stress (see Chapter 5). The antioxidant response is driven by the Nrf2 transcription 
factor, and gp120-induced oxidative stress and inflammation in astrocytes was reported to be 
significantly higher when Nrf2 expression was suppressed by siRNA (162). Finally, in addition to 
its role in HAND, oxidative stress has been implicated in the pathogenesis of other 
neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and 
Huntington’s disease (264, 268-276), which emphasizes the broad potential value of developing 
effective CNS therapies against oxidative stress. 
 
3.4 CNS HIV Tropism and HAND: Challenging Conventional Thinking  
 
Establishing a CNS HIV reservoir within the macrophage and microglial lineages by macrophage-
tropic (M-tropic) strains, conventionally defined as those that infect both T lymphocytes and 
macrophages, has been considered a necessary, but not sufficient precursor to the development 
of HAND. Individuals with the severest form of HAND, HIV-associated dementia (HAD) often 
have genetically distinct M-tropic variants in their CSF that are not found in the plasma (277), 
consistent with a central role for replication of M-tropic strains within the CNS in the pathogenesis 
of HAND. However, recent evidence also suggests that not only M-tropic strains but also ‘T cell-
tropic’ strains, conventionally defined as those that infect T lymphocytes but not macrophages, 
can be isolated from the CNS and that each contributes to the development of HAD (277). 
Schnell et al (277) found genetically compartmentalized T cell- and M-tropic HIV populations 
within the CSF that were distinct from those found in the plasma of eight of eight subjects with 
neurocognitive dysfunction (seven HAD, one milder dysfunction). Three subjects had 
compartmentalized T cell-tropic populations and five had compartmentalized M-tropic 
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populations. This study challenged the established hypothesis that M-tropic strains are primarily 
responsible for driving the pathogenesis of HAND.  
 
More recently, the same group further analyzed genetic and phenotypic characteristics cloned 
env sequences of paired CSF/plasma isolates from five individuals and confirmed that CSF-
derived viruses segregated into two distinct groups: M-tropic and T cell tropic and, based upon 
their relative ability to infect cell lines engineered to express tightly-controlled low- and high-level 
CD4 surface expression respectively (278). This well-defined segregation of naturally-occurring 
HIV phenotypes does not strictly predict the conventional M-tropic and T cell-tropic infection 
patterns in primary monocyte-derived macrophages or primary CD4+ T lymphocytes. 
Furthermore, how this phenotype segregation might apply to infection of CD4-negative cell types, 
such as astrocytes, is unanswered. Thus, the issue of the distribution of HIV strains within 
different cell lineages/reservoirs within the CNS and the relevance of each to HAND 
neuropathogenesis has been re-opened. This is particularly relevant to persistence of HIV within 
the CNS in ART-suppressed patients, the genesis of CSF HIV blips linked to neuroinflammation 
(see 3.5 Role for HIV ‘Blipping’), and for consideration of CNS HIV eradication strategies.  
 
Thus, our understanding of the role for HIV tropism in determining early events leading to CNS 
invasion, establishment of viral reservoirs, and long-term selection pressures within the CNS 
continues to evolve. We are re-examining our long-held belief that macrophage tropism is the 
predominant HIV determinant of neurovirulence driving HAND, although it appears certain that it 
is a common factor in HIV neuropathogenesis. Nonetheless, HIV neuropathogenesis might not be 
an exclusive function of M-tropic strains, and the importance of thoroughly evaluating early events 
and the role of T-cell tropism in CNS infection are critical for optimizing treatment strategies and 
achieving better neuroprotection.    
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3.5 Role for HIV ‘Blipping’  
 
HIV ‘blips’ are thought to represent new rounds of HIV replication that result in increased viral 
loads above the established lowest level of quantifiable HIV RNA. Viral (HIV) blips are defined as 
spontaneous expression of viral RNA copies (plasma, CSF) in individuals on ART with sustained 
antecedent undetectable viral loads with return to undetectable levels (133). CSF discordant 
blipping is generally defined as a higher RNA copy level of > 0.5 log in the CSF in comparison 
with plasma. An overall plasma HIV blip (> 50 HIV RNA copies/ml) frequency of ~25% has been 
demonstrated in an observational cohort study (n=3550 virally suppressed patients) (133). 
Several causes of blipping are proposed, including differences in viral load assay sensitivity (279) 
and factors affecting HIV replication (ART adherence, immune activation, viral resistance, among 
others) (132-134). A role for blips in contributing to increased immune activation and accelerated 
disease progression has been suggested (132), although this has been challenged (280).  
 
The significance of viral blips remains undetermined, and their possible association with HAND is 
under increasing investigation (134, 281, 282). Emerging evidence supports a role for blipping in 
promoting increased immune activation in the systemic circulation and CNS compartment, which 
is linked with development of HAND. A link between plasma HIV blips and systemic immune 
activation has recently been demonstrated in a prospective study of matched blippers and non-
blippers (283). The study involved 82 individuals with plasma viral blips (VL > 50 and <1000 
copies/ml after at least 180 days at undetectable VL on ART) matched with 82 cohort controls 
without blips. The patients with plasma viral blips after suppressive ART showed increased T cell 
activation (CD3+HLA-DR+ T lymphocyte level) compared with patients without blips. This 
suggests that plasma blips might identify those patients at increased risk for immune activation 
associated with disease progression. Additionally, Castro et al (132) retrospectively analyzed 
responses in a ART interruption study and found that subjects with plasma blips above 200 
copies/ml prior to ART interruption had lower CD4+ T cell levels under ART, and poorer CD4+ T 
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cell recovery and increased expression of immune activation markers after ART interruption.  This 
study provided evidence not only that blipping could drive immune activation, but also that the 
magnitude of the blip can determine future virological failure.   
 
Evidence suggesting that blips might merely maintain an established state of immune activation 
rather than increase immune activation has also been presented. Benmarzouk-Hidalgo et al (280) 
studied patients who were switched to simplification treatment of darunavir/ritonavir monotherapy 
for 24 months after a 6 month period of sustained HIV suppression with combination ART. 
Outcome groups were assigned as those with continuous aviremia, blips (one plasma VL > 50 
copies/ml, preceded and followed by undetectable VL) and intermittent viremia (episodes of VL > 
20 copies/ml without blips or failure). Virological failure was defined as two consecutive VL > 200 
copies/ml. Only virological failure and not blipping or intermittent viremia was associated with 
increased immune activation (CD4+ and CD8+ T lymphocyte activation, primarily TCM CD4+ T 
lymphocytes) from the baseline status. In addition, monocyte activation (plasma sCD14 levels) 
remained unchanged in the blipping and intermittent viremia groups, while decreasing in the 
aviremic group. Thus, sustained aviremia associated with significant decreases in activation of 
CD4+ and CD8+ T lymphocytes and monocytes while virological failure associated with increases 
in activation of each T lymphocyte subset. Those individuals with blipping and intermittent viremia 
maintained their previous levels of immune activation. These studies add to the growing evidence 
indicates that suppression of viral blipping could help in controlling and/or suppressing immune 
activation in many HIV-infected individuals and they support the importance of determining these 
associations in the CNS.  
 
Defining the possible associations between blipping in the CNS compartment and increased risk 
for HAND is critical; HAND persists in HIV-suppressed populations and blipping is surprisingly 
common in such populations (133, 284). A study of 200 HIV-infected individuals with sustained 
HIV suppression (median 48 months; range 3.2-136.6) found an overall prevalence of HAND of 
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Figure 3.2 Hypothetical time course of cerebrospinal fluid viral blips, neuroinflammation, 
and neuronal injury. Diagram outlining the postulated temporal associations between CSF HIV 
viral blips, neuroinflammation (CSF neopterin), and neuronal injury (CSF neurofilament light 
chain, NFL). 
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69% including a 19% prevalence of significant functional neurological impairment (17% MND, 2% 
HAD) (8). Although not designed to detect viral blips, this study suggests persistence of 
neurological dysfunction in individuals considered to be appropriately treated (HIV suppression) 
with ART. Given the prevalence of blips in other studies, it raises the question of whether plasma 
and/or CSF viral blips might contribute to this risk for HAND in suppressed populations. 
 
Recently published and ongoing, unpublished studies directly address the relationships between 
CSF HIV blipping, inflammation and HAND risk. Eden et al (281) found that ~10% of 69 
neurologically normal, HIV ‘suppressed’ patients had detectable CSF HIV RNA, consistent with 
ongoing HIV replication in the CNS compartment. Furthermore those with detectable CSF RNA 
had significantly higher CSF expression of markers of monocyte activation (neopterin) and also a 
longer duration of ART treatment. Follow up studies have indicated that the elevated CSF 
neopterin levels are not associated with neuronal injury (elevated CSF neurofilament (NFL) 
levels) at the time of sampling (Figure 3.2), but whether these blips will associate with future risk 
for neuronal injury remains to be determined (285). 
 
Because blips can associate with increased duration of ART and the emergence of ART 
resistance (281, 286), determining the frequency of ART resistance mutations in blippers is 
critical for ART management of HAND risk. Canestri et al (134) found ART resistance mutations 
in 7 of 8 CSF specimens from CSF blippers in a small group (n=11) of HIV suppressed (~18 
months) patients with neurological symptoms. Ten of the patients had CSF pleocytosis, indicating 
a strong association between CSF blipping and inflammation. Notably, however, the patients 
were not evaluated by HAND criteria and so the relationship to HAND is speculative. Additional 
evidence for emergence of ART resistance in CSF blippers is provided by the ongoing UK 
PARTITION STUDY of CNS ART penetration (287). Three of three CSF specimens tested from a 
cohort of 38 CSF blippers showed reverse transcriptase resistance mutations, which supports the 
earlier demonstration and previous reports of a high prevalence of drug resistance in CSF 
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blippers (179). Prospective monitoring for drug resistance in the CSF is necessary to determine 
the risk for developing HAND.  
  
In summary, the argument for a causal relationship between HIV blips, increased immune 
activation, and risk for disease progression in both systemic and CNS compartments is increasing 
in strength. A role for intermittent HIV replication within the CNS in HAND pathogenesis in virally 
‘suppressed’ ART-experienced patients appears likely. As average ART duration increases, the 
risks of recurrent blipping will likely become more apparent, and the challenges of monitoring 
blipping in the CSF as well as plasma will need to be resolved.  
 
3.6 Conclusion  
 
HIV-associated neurocognitive disorders (HAND) remain prevalent despite apparently effective 
suppression of HIV replication by ART in most treated individuals (171, 175, 288). The underlying 
neuropathological processes in the brain that contribute to neurological dysfunction in HAND in 
the era of ART are probably significantly attenuated by such therapy, resulting in a more 
protracted and less severe clinical course of HAND. Although fulminant encephalitis is now 
distinctly uncommon in HIV infection, CSF biomarkers of neuroinflammation and brain 
neuroimaging biomarkers of glial activation and neuronal injury are frequently detected in virally-
suppressed individuals. This persisting neuroinflammation likely leads to persisting production of 
HAND-associated neurotoxins from infected and activated glia, particularly macrophages and 
microglia. Partial protection against HAND by ART confirms a direct and possibly incomplete link 
to HIV replication; however longitudinal studies in ART-experienced cohorts indicate surprisingly 
frequent episodes of CNS viral escape (HIV blipping) in those thought to have complete viral 
suppression. This suggests a persistent link between CNS HIV replication, immune activation, 
inflammation and neurological dysfunction that escapes full suppression by current ART. The 
high prevalence of HAND and other neurologic manifestations of HIV-infection despite the 
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introduction of ART underscore a critical need for adjunctive therapies that target the persistent 
inflammation and oxidative stress within the CNS compartment.  
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Curr HIV/AIDS Rep. 2014; 11(3):325-25. Copyright © 2014 Springer International Publishing 
39 
 
 
4.1 Introduction   
  
HIV-associated neurocognitive disorders (HAND) are a group of syndromes of varying degrees of 
cognitive impairment affecting up to 50 % of HIV-infected individuals. The neuropathogenesis of 
HAND is thought to be driven by HIV invasion and productive replication within brain perivascular 
macrophages and endogenous microglia, and to some degree by restricted infection of 
astrocytes. The persistence of HAND in individuals experiencing suppression of systemic HIV 
viral load with antiretroviral therapy (ART) is incompletely explained, and suggested factors 
include chronic inflammation, persistent HIV replication in brain macrophages, effects of aging on 
brain vulnerability, and comorbid conditions including hepatitis C (HCV) co-infection, substance 
abuse, and neurotoxicity of ART, among other factors. This chapter discusses several of these 
co-morbid conditions: co-infection with HCV, drugs of abuse, aging, and antiretroviral drug 
effects. Effectively managing these co-morbid conditions in individuals with and without HAND is 
critical for improving neurocognitive outcomes and decreasing HIV-associated morbidity. 
 
4.2 Hepatitis C Co-Infection. 
 
Detection of HCV genomes and active HCV replication within the central nervous system (CNS) 
has prompted great interest in HCV infection as a contributor to neurocognitive impairment in 
HIV-infected individuals (289-292) (293-295). One recent estimate of the prevalence of HCV 
infection across all populations within the US at 2% (296) and other studies estimate that 20-30% 
of HIV+ individuals worldwide are co-infected with HCV (297, 298). These high rates of co-
infection emphasize the potentially high risk of HCV increasing the morbidity associated with 
HAND when both viruses infect the brain. Indeed, replicating HCV has been detected in 
autopsied brain tissue predominantly in CD68+ macrophages/microglia, and to a lesser degree in 
astrocytes, which suggests a shared HCV/HIV reservoir within the brain (289, 299). Furthermore, 
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brain macrophage HCV infection is associated with increased macrophage expression of pro-
inflammatory cytokines (300), which is also a feature shared with HIV infection of macrophages 
that can contribute to neurodegeneration (Figure 4.1).  
 
The prevalence of neurocognitive dysfunction attributable to HCV infection alone is difficult to 
determine and probably highly variable, with estimates ranging from ~10-49% (reviewed in (290)), 
while the prevalence of neurocognitive dysfunction in HIV/HCV co-infection has been estimated 
as high as ~63% (301). Individuals seropositive for HCV are twice as likely to have global 
neuropsychological impairment than seronegative individuals, independent of HIV infection (302). 
Such impairment is commonly associated with metabolic and structural brain abnormalities, as 
detected in magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) 
studies. Several MRS studies have found metabolic alterations consistent with neuronal injury 
and gliosis (decreased N-acetyl-aspartate/creatine and increased choline/creatine ratios) in the 
brains of HCV+/HIV- individuals with cognitive impairment but without hepatic failure (290, 294, 
295) (303). Furthermore, hyperperfusion in the basal ganglia, suggestive of neuroinflammation, 
has been detected in HCV+ individuals by brain perfusion-weighted neuroimaging (303). An MRS 
study of 15 HCV+/HIV- individuals treated with pegylated interferon/ribavirin demonstrated 
decreased brain choline/creatine and myoinositol/creatine ratios in individuals with sustained 
HCV suppression, suggesting a potential brain neuroprotective/anti-inflammatory response with 
anti-HCV treatment (293). One structural brain MRI analysis of 251 HIV+ individuals without 
significant co-morbidities for cognitive impairment other than HIV infection demonstrated a 
greater loss of white matter volume in HCV+/HIV+ individuals in comparison with HCV-/HIV+ 
individuals (304). Notably, a significant correlation between plasma lipopolysaccharide levels and 
HAND was demonstrated in and HIV/HCV co-infected cohort, despite no significant correlation in 
HIV- or HCV- monoinfected sub-cohorts (305). These studies clearly demonstrate that HCV 
infection is associated with functionally significant injury to the brain that can potentially 
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Figure 4.1 CNS inflammatory effects of HIV and HCV infection on monocytes, 
macrophages, and microglia. CD14+/CD16+ monocytes can be infected by HCV and HIV and 
migrate across the endothelial barrier into the brain. Macrophages and microglia within the brain 
can support productive infection with HIV and HCV, resulting in the production of pro-
inflammatory cytokines and neurotoxins. Those associated with HCV infection are depicted in the 
left-most macrophage image, and those associated with HIV infection are depicted in the right-
most macrophage image. Such pro-inflammatory cytokines and neurotoxins have been shown to 
induce neuronal injury through directed and indirect (astrocyte-mediated) mechanisms. 
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exacerbate the injurious effects of HIV infection, and they further suggest that induced 
neuroinflammation is a shared major contributor.    
 
Although the association between HIV and HCV co-infection and worsened neurocognitive 
functioning has been observed in numerous studies, the relationship between active HCV 
replication (as indicated by detectable plasma HCV RNA) and worsening neurocognitive function 
has been questioned. A study of 24 HCV+ individuals with newly detectable plasma HCV RNA 
within 12 months of study showed worse neurocognitive performance in comparison with 57 
individuals with HIV monoinfection (306). This was associated with MRS evidence of glial 
activation/inflammation in the basal ganglia. Contrasting results were seen when The AIDS 
Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) study examined 
the relationship between HCV replication and neurocognitive performance in 517 HIV-infected 
individuals, of which 172 demonstrated detectable plasma HCV RNA (345 individuals had no 
detectable plasma HCV RNA). Although both groups performed below norms, there was no 
discordance in neurocognitive function between the two groups (307, 308), suggesting that active 
HCV replication, at least that outside of the CNS, does not drive neurocognitive dysfunction.  
Nonetheless, consistent with other studies of HCV seropositive (HCV+) patients, an earlier ACTG 
study confirmed that HCV infection, as indicated by HCV antibody detection (HCV seropositive) in 
HIV+ individuals is correlated with worse neurocognitive performance than that in HIV+ 
individuals not co-infected with HCV (309). 
 
Thus, considerable evidence supports a significant negative impact of HCV infection on HAND 
and the high prevalence of HAND and HIV/HCV co-infection requires that effective suppression of 
both HIV and HCV be a high priority.  The recent FDA approval (December 16, 2013) of the anti-
HCV drug, Sofosbuvir, a nucleotide polymerase inhibitor, for HCV monoinfection and HCV/HIV 
co-infection represents a major step in the struggle to cure HCV infection (310). This approval 
could potentially represent a highly effective means of preventing neurocognitive deterioration in 
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HIV+ patients newly infected with HCV and it also raises the question of the possibility of 
improving cognitive performance in HAND individuals with co-infection. A therapeutic trial of 
Sofosbuvir as treatment for or prevention of neurocognitive impairment in HIV+/HCV+ individuals 
is clearly indicated.  
 
4.3 Drugs of Abuse 
    
Substance abuse often represents a co-morbid condition with HIV infection, and evidence 
supports additive or synergistic effects of substance abuse on the persistence and severity of 
neurocognitive dysfunction in patients with HAND (311) (summarized in Table 4.1). Under strict 
diagnostic criteria, a diagnosis of HAND requires the exclusion of other co-morbid conditions that 
may contribute to neurocognitive impairment, including drug abuse (180). However, drug abuse is 
common in HIV infected populations and is a major co-morbidity risk for neurocognitive 
impairment in HIV+ individuals (312-315). In the United States approximately one in four HIV+ 
individuals studied from 2005 to 2009 required treatment for alcohol or drug abuse (316). Thus, 
studying the interactions between drug abuse, HIV infection, and neurocognitive function is of 
high clinical importance. Although, the potential direct neurotoxic effects of drugs of abuse are not 
the focus of this section, we will focus on drug effects that may synergize with HIV-mediated 
neurocognitive impairment. 
 
Numerous studies have implicated cocaine, methamphetamine (meth), and opioid use in 
exacerbating the risk for neuronal injury and neurocognitive impairment in HIV+ patients (311, 
317-322). However, a recent large cohort study by Byrd et al. (2011) found that participants with 
histories of substance use (alcohol, cocaine, cannabis, opiates, methamphetamine) did not have 
higher rates of neurocognitive impairment or functional impairment in everyday life (321). Most of 
these participants were not current users and less than a third reported using illicit substances 
within the last year. The authors propose that sustained periods of drug abstinence may be 
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sufficient for full or partial reversal of substance use effects on neurocognition. These findings are 
consistent with another longitudinal study demonstrating improvement in neurocognitive function 
in long-term abstinent meth users (average of 13 months) compared to non-abstinent meth users 
(323). These results suggest that drugs of abuse may have a limited legacy effect on 
neurocognitive impairment in HIV+ individuals and that current and recent substance use may be 
more relevant to modulating HIV neuropathogenesis.  
 
Cocaine, meth, and opioids have been shown to increase HIV infection/replication in primary 
human macrophages in vitro (312, 324-330), likely due at least in part to increases in HIV co-
receptor (CCR5 and CXCR4) expression (331-333). Cocaine and opioids also increase HIV 
infection and replication in T-lymphocytes in vitro (334-337). The effects of meth on T-lymphocyte 
HIV replication remain controversial due to variations in models, viral strains, exposure time, and 
drug concentrations used (338, 339). Some studies suggest that dopamine, which is elevated 
within the CNS in response to these drugs of abuse, can enhance macrophage HIV infection and 
replication as well as alter macrophage cytokine production (340, 341). These findings are 
consistent with studies demonstrating that treatment of SIV-infected rhesus macaques with 
selegiline, an inhibitor of dopamine catabolism through inhibition of MAO activity, or L-DOPA, the 
precursor of dopamine, resulted in elevated brain viral loads (342, 343). In the SIV-macaque 
model, methamphetamine and opioid exposure increased both CSF/brain viral loads and 
macrophage influx into the CNS (344-346). In contrast, cocaine exposed SIV-infected macaques 
did not show elevated CNS viral replication or alterations in inflammatory markers; notably, the 
low dose cocaine-treated animals had significantly lower CSF viral RNA (347). The relative 
contribution of the direct drug effects or indirect dopamine effects on CNS viral loads and 
macrophage influx is not known. Taken together these data suggest that some drugs of abuse 
may increase HIV replication within CNS macrophage/microglia, which likely results in enhanced 
neuroinflammation, HIV-infected macrophage/microglia neurotoxin production, and associated 
neuronal dysfunction (42, 46, 312).   
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 Cocaine Meth Opioids Dopamine 
Risk of neurocognitive impairment in HIV+ individuals 
with current/recent use of selected drug ↑ ↑ ↑ N/A 
HIV replication in human macrophages ↑/- ↑ ↑ ↑ 
Monocyte/macrophage CCR5 expression ↑ ↑ ↑ ? 
Monocyte/macrophage CXCR4 expression  ↑ ↑ ↑/- ? 
HIV replication in human T-lymphocytes ↑↑ ↑/- ↑ ↑ 
CSF/brain SIV viral load in macaque model ↓/- ↑ ↑ ↑ 
Pro-inflammatory cytokine release from 
macrophages/monocytes/microglia/astrocytes ↑ ↑ ↑ 
some ↑ 
some ↓ 
Anti-inflammatory cytokine release from 
macrophages/microglia/astrocytes ↑/- ? ↓/- ↓ 
Blood brain barrier breakdown following exposure in 
rodent models ↑ ↑ 
↑ during 
withdrawal ? 
 
 
Table 4.1 Effects of cocaine, methamphetamine (meth), opioids, and dopamine on HIV, SIV, 
and neuroinflammation. Symbols used: ↑ increased; ↓ decreased; ↑/- increased reported in 
some studies, but not others; ↓/- decrease reported in some studies, but not others: ? no current 
data; N/A not applicable.  
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Further supporting a role for drugs of abuse increasing neuroinflammation and associated 
neurodegeneration, the pathological diagnosis of HIV-encephalitis is more common in HIV+ 
individuals who abuse drugs compared to HIV+ controls (348-350). The relative additive and 
synergistic effects of drugs of abuse on neuroinflammation in HIV+ individuals is not known. Both 
in vitro and in vivo data suggest that cocaine, meth, and opioids promote increased 
proinflammatory cytokine release and activation of microglia, perivascular macrophages, and 
astrocytes (312, 351-354). Increased activation of these glial cells within the CNS drives oxidative 
stress, excitotoxicity, and inflammatory neuronal injury (355). Furthermore, distinct mechanisms 
have been identified for augmenting neurotoxin production by astrocytes. Exposure to opioids 
(morphine) or meth has been shown to inhibit astrocyte regulation of extracellular glutamate (356, 
357), an excitotoxin strongly implicated in HAND (46, 358). Cocaine may potentiate astrocyte 
toxicity through apoptotic pathways involving reactive oxygen species generation, mitochondrial 
membrane potential loss, and activation of the inflammatory NF-κB pathway (359). In conclusion, 
drugs of abuse may induce neuronal injury through potentiation of glia pro-inflammatory signaling 
and through perturbation of astrocyte homeostatic functioning; additionally, these insults may be 
further promoted through drug-induced increases in CNS HIV replication.  
 
During HIV infection, both viral and host factors alter the stability and function of the blood brain 
barrier (BBB) and this is believed to be a critical driver of HIV neuroinflammation and 
neuropathogenesis (360). This effect can be exacerbated by drugs of abuse. Such drugs have 
been proposed to exacerbate neurocognitive impairment in HIV-infection through further 
disruption of the BBB, resulting in enhanced immune cell infiltration, elevated CNS inflammation, 
and alteration in cellular homeostasis. In rodent models, cocaine and meth exposure increase 
BBB breakdown (361-364). Cocaine and meth also alter tight junction and cell adhesion molecule 
expression, permeability, and immune cell migration across brain microvascular endothelial cells 
(BMECs) in vitro (365-370). These effects on BBB integrity may be synergistic, as co-treatment 
with the HIV envelope glycoprotein gp120 and meth increased permeability across BMECs and 
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decreased the expression of tight junction proteins (ZO-1, JAM-2, claudin-3, claudin-5) more than 
treatment with gp120 or methamphetamine alone (365). In contrast, chronic opioid (morphine) 
exposure did not significantly alter BBB integrity in rats (371); however, another study suggests 
that spontaneous morphine withdrawal in rats results in significant BBB breakdown in multiple 
brain regions, including the cerebral cortex, hypothalamus, hippocampus, and cerebellum (372). 
The HIV and drug-mediated BBB dysfunction promotes immune cell infiltration (HIV-infected and 
non-infected) into the CNS and promotes neuroinflammation, which in turn may drive further loss 
of BBB integrity.  
 
Lastly, the treatment of drug abuse is likely to improve drug adherence to ART treatment, which 
remains the best currently available intervention for limiting the severity of neurocognitive 
impairment and associated neuroinflammation in HAND. Current drug use and alcohol abuse are 
associated with poorer adherence to ART regimens as well as a decreased or absent access 
and/or use of HIV care (373-376). These obstacles are an important barrier to appropriate 
treatment of HIV-infection and associated comorbidities, including neurocognitive impairment, in 
HIV+ drug users. Treating opioid addiction with methadone maintenance or buprenorphine has 
been shown to increase adherence to ART therapy and improve patient outcomes in HIV+ 
individuals with opioid abuse history (377). Another study observed a similar associative increase 
in ART adherence among drug users who were enrolled in non-medication drug abuse treatment 
programs (378), suggesting multiple modalities of drug abuse treatment may improve ART 
adherence in HIV+ individuals. The poor ART adherence among this vulnerable group of HIV+ 
drug abusers likely contributes to poor clinical outcomes. However, a review of 20 studies 
examining the effect of substance use on HIV disease progression found that drug use 
associated with more rapid HIV disease progression, even after controlling for ART adherence 
(379). Thus beyond the effects of drug abuse on ART adherence, drug abuse may affect HIV 
systemic and CNS disease progression, in part through the mechanisms outlined above.   
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Thus, drugs of abuse are strongly associated with worsening neuronal injury and neurocognitive 
impairment in HIV+ individuals. These drugs of abuse likely act through multiple mechanisms to 
promote neuronal dysfunction including i) increasing HIV infection and replication, ii) reducing 
BBB integrity, iii) stimulating neuroinflammation, iv) augmenting neurotoxin production and 
handling by astrocytes and macrophages, and v) decreasing ART regimen adherence. Effective 
treatment of neurological complications in the HIV+ population will require special clinical 
attention to drug use and abuse.  
 
4.4 Aging 
 
By 2015 more than 50% of the HIV+ population in the United States will be older than 50 years of 
age (380) and therefore at increased risk for neurocognitive dysfunction when compared with 
age-matched seronegative populations (288). As ART-treated patients age, they are at risk for 
associated CNS diseases and systemic diseases that can contribute to cognitive dysfunction, 
including renal failure and cardiovascular/atherosclerotic disease. Among the CNS diseases 
prevalent in aging, Alzheimer’s disease (AD) and Parkinson’s disease express some pathological 
features that have been seen in HIV+ brain tissue (380, 381). Thus, the brain in aging HIV+ 
individuals might be particularly vulnerable because of the combined effects of age-associated 
systemic diseases that indirectly affect the brain, and/or direct brain effects of HIV infection and 
aging (reviewed in (5)).  
 
Neuropathological and biochemical changes in the aging HIV-infected brain   
 
The neuropathological changes in the aging HIV+ brain and the relationship to neurocognitive 
dysfunction have received considerable attention but a consistent picture has not emerged. 
Demonstrations of AD- and PD-like brain neuropathology in ART-treated individuals (382, 383) 
include elevated levels of hyperphosphorylated Tau (p-Tau) in the hippocampus, elevated intra- 
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and extracellular beta-amyloid (Aβ) in the frontal cortex and hippocampus (219, 384-386), and 
elevated levels of alpha-synuclein in the substantia nigra (387) (383). Other studies have 
demonstrated elevated levels of amyloid precursor protein in damaged axons in brain specimens 
from ART-naive patients without elevated levels of p-Tau or neuritic plaque formation (388, 389). 
An association between the apolipoprotein E (APOE) e4 allele and increased diffuse b-amyloid 
plaques in HIV-infected brain was recently demonstrated in a study of 160 brains from HIV+ 
individuals (age range 27-67 years) (390). This study further demonstrated that age increased 
age also independently increased the likelihood of plaque deposition. A recent and much smaller 
brain autopsy study of ten ART-treated individuals (and ten seronegative controls; all patients 
between 28-58 years of age) showed that brain b-amyloid deposition was increased in HIV+ 
intravenous drug users, but this did not correlate with brain viral load (391). Correlations among 
lower expression of markers of autophagy, increased expression of markers of brain 
inflammation, reduction of the Beclin 1 protein that forms a critical core for the autophagosome, 
and older age in individuals with HIVE was demonstrated in a recent neuropathological study 
(392). Although b-amyloid deposition was not studied in those cases, the known association 
between Beclin 1 deficiency, low expression of autophagy markers, and increased risk for b-
amyloid deposition in AD brain (393) suggests the possibility of similar associations in HIVE brain, 
but whether such associations exist in non-encephalitic HAND cases is not yet reported.  Thus, 
the issue of aberrant processing of amyloid, synuclein, and tau proteins in the HIV-infected brain 
and the relationship to aging in ART-treated individuals remains unresolved and additional 
studies are needed to address the potential roles for such aberrant protein processing in HIV 
neuropathogenesis.  
 
Neurocognitive testing in aging HIV+ cohorts  
 
Determining whether effects of HIV and aging on neurocognitive functioning are truly independent 
or additive has been an priority of recent longitudinal neuropsychological and neuroimaging 
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studies. A study of 54 HIV+ and 30 HIV- individuals (40 – 74 years of age) assessed 
longitudinally over one year for performance on tests of verbal and visuospatial learning and 
memory (394). There were significant effect of age group and HIV x age group interactions on 
learning and memory performance between baseline and one year-follow up examination. The 
investigators concluded that a decline in performance in HIV+ individuals when compared with 
HIV- controls was enhanced through an additive age effect. Recently summarized data from the 
HIV Neurobehavioral Research Center in San Diego showed that global neurocognitive 
performance declined more rapidly with age in HIV+ individuals than in HIV- matched controls 
(288).  The difference in rate of decline of performance vs. age (slope of regression line) indicated 
that the effects of aging on neurocognitive performance are amplified by HIV infection. The 
domains of performance that are particularly vulnerable include the speed of information 
processing and executive functioning.  
 
Application of neuroimaging to brain effects of HIV and aging   
 
Neuroimaging studies, including MRI, fMRI, MRS and DTI (Diffusion Tensor Imaging), have 
provided additional definitive evidence of enhanced vulnerability of the brain in HIV-infected 
individuals as they age (reviewed in (395)). The distinct advantages of applied neuroimaging are 
that individuals can be examined repeatedly under different conditions and compared in cross-
sectional cohorts or in longitudinally-followed cohorts with complementary neuropsychological 
and biomarker testing.  
 
Numerous neuroimaging studies of HIV+ individuals have demonstrated regional and global brain 
atrophy injury (grey and white matter), altered expression of cellular markers of neuronal integrity 
(N-acetyl aspartate) and glial activation (myoinositol), altered cerebral blood flow and 
physiological activation states, and microstructural white matter changes that can be attributed to 
HIV infection as well as aging.  Furthermore, a recent CSF metabolomics analysis demonstrated 
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elevated levels of products of metabolic waste (phenyacetylglutamine, lactate, 3-
hydroxybutyrate), glutamate, glial activation markers, and mitochondrial metabolites in HAND 
patients on ART, which suggests similar biochemical brain disturbances in both aging and HAND 
(396). Therefore, one can evaluate the natural history of HIV CNS infection, correlations between 
structural and functional brain disturbances and clinical performance, responses to therapy, and 
validity of biomarkers with neuroimaging techniques applied cross-sectionally and longitudinally in 
selected cohorts. Such studies can effectively complement neuropathological analyses to identify 
critical pathways of cellular injury and response that could potentially be targeted for therapeutics.  
 
The effects of brain aging on functional physiological responses in HIV-infected brain have been 
recently explored with functional MRI (fMRI) techniques. Impairment of normal recruitment of 
brain regions for functional responses that can compensate for local brain dysfunction has been 
demonstrated in HIV infected individuals.   Functional MRI was used in study of 122 individuals 
(59 seronegative, 29 HIV+/HAND, 37 HIV+/neurocognitive normal) to determine whether subject 
age affected brain activation during attention-requiring tasks independently from HIV infection 
(397). Strict HAND diagnostic criteria were used, and normalized NP data derived from a 
seronegative cohort of 342 individuals were adjusted for age and education. The study 
demonstrated that HAND patients demonstrate an age-dependent decline in functional brain 
activation in response to certain neuropsychological test demands, which indicates an inability to 
compensate for declining brain functioning. Another recent study of 52 HIV+ and 52 HIV- 
individuals using resting-state functional connectivity MRI showed that deficits in functional 
connectivity between different brain regions in HIV+ individuals resemble those affected in normal 
aging (398). These HIV and age effects were independent, which was interpreted as consistent 
with a premature brain aging effect of HIV.  
 
These and other studies utilizing neuropsychological performance testing, neuroimaging, and 
neuropathological analyses strongly support a strong correlation between accelerated 
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neurocognitive decline driven by HIV infection in aging individuals, even those with what is 
considered ‘effective’ suppression of systemic HIV replication. These studies also further 
emphasize the need for developing new strategies, involving current ART and possibly adjunctive 
therapies, for protecting the brain against injury in the aging HIV+ population.  
 
4.5 ART Neurotoxicity    
 
Whether CNS-targeted therapy based upon putative level of CNS ART-penetrance (CNS 
Penetration-Effectiveness/CPE), antiviral activity, or even neurotoxicity of a particular drug class 
will prove effective in limiting HAND is unclear.  Early studies of ART effects on neurocognitive 
test performance suggested that ART regimens containing drugs with relatively higher CPE could 
have increased benefit in protection against neurocognitive impairment (399, 400). Other studies 
have either no benefit to selected ‘neuroactive’ ART regimens or even neurotoxic effects. Two 
multi-center clinical trials (ACTG 5170, ACTG 736) have suggested possible neurotoxicity of 
ART, as reflected in improvement in neuropsychological test performance after ART interruption 
(ACTG 5170(401)) and poorer performance in patients on ART regimens with a higher CPE 
(ACTG 736) (402). A recent study showed that virologically suppressed patients (> one year on a 
stable regimen, undetectable viral loads) receiving protease-inhibitors (PIs) as ‘boosted 
monotherapy’ or as triple therapy with two nucleoside reverse transcriptase inhibitors showed 
similar patterns of neuropsychological test performance in 14 measures (403). These results 
were interpreted as evidence against the number of neuroactive drugs used in a regimen, rather 
than effective systemic viral load suppression, as an indicator or predictor of neuroprotection. 
Nonetheless, the issue of chronic ART neurotoxicity as a co-factor for exacerbating HAND 
remains as a critical and unsettled question in long-term management of HIV infection.  
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4.6 Conclusion 
 
HIV associated neurocognitive disorders remain enigmatic despite intensive research aimed at 
understanding the factors and processes that contribute to their persistence in ART-treated 
individuals. Among the more significant discoveries in the last several years are the correlations 
between chronic, persistent inflammation and oxidative stress, systemic disease progression and 
HAND. These associations of inflammation, immune activation, and oxidative stress with disease 
progression in different body compartments suggests that shared immune-modulating and anti-
oxidative processes should be therapeutically targeted to fully protect the individual from disease 
progression. Identifying such targets and testing currently available drugs, as well as continuing 
to develop new drugs, are worthy goals. However, full protection against neurocognitive decline in 
HIV+ ART-treated patients will also require effective targeting of the common co-morbid 
conditions that also affect such patients:  co-infection with HCV, substance abuse, potential ART 
toxicity, and aging.  
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5.1 Introduction 
 
The human genome encodes for a large number of inducible genes to protect against cellular and 
tissue injury. Many of these cytoprotective genes have a common promoter element, the 
antioxidant response element (ARE), which is regulated through the Keap1-Nrf2 pathway. 
Induction of the ARE induces the transcription and expression of a collation of more than 200 
cytoprotective and detoxifying effector proteins (404). These Nrf2 target gene products are 
involved in numerous protective functions including metabolism, phase II detoxification, export of 
endo- and xenobiotics, glutathione biosynthesis (the principle endogenous small molecule 
antioxidant), peroxidation, heat shock protein responses, modulation of immune and inflammatory 
signaling, mitochondrial biogenesis, and tissue repair (reviewed in (405)).  
 
One of the Nrf2/ARE driven genes is the highly inducible phase II detoxifying enzyme heme 
oxygenase-1 (protein HO-1; gene HMOX1). HO-1 is a sentinel cytoprotective enzyme that has 
emerged as a critical effector for limiting oxidative stress, inflammation, and cellular injury within 
the central nervous system (CNS) and other tissues in several disease states. The protective 
functions of HO-1 have been linked to its degradation of heme and the subsequent generation of 
carbon monoxide, biliverdin, and bilirubin, which have immunomodulatory and anti-oxidative 
properties (44). HO-1 is upregulated by multiple stimuli, including heme, oxidative stress 
(hydrogen peroxide, reactive oxygen species), nitric oxide, cytokines, endotoxin, heavy metals, 
ultraviolet radiation, shear stress, hyperoxia, and hypoxia (44). HO-1 is a type II transmembrane 
protein anchored to the endoplasmic reticulum (ER) by a hydrophobic C-terminus transmembrane 
domain with the enzymatically active portion facing the cytosol (406, 407). HO-1 can also be 
found anchored to the plasma membrane in caveolae as well as the mitochondrial inner 
membrane (408, 409), suggesting it may serve specific functions within particular cellular 
compartments. Additionally, upon certain cellular stressors HO-1 can be cleaved from its 
transmembrane domain and translocate to the nucleus, where it may have non-enzymatic 
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cytoprotective functions through activation of transcription factors (410, 411). A constitutively 
expressed heme oxygenase isoform, HO-2, catabolizes the same enzymatic reaction, although it 
is not regulated by the ARE, and, unlike HO-1, HO-2 is not considered to be a critical mediator of 
acute cellular injury responses. Likely due to these anti-inflammatory and cytoprotective roles of 
HO-1, numerous studies have demonstrated that inducing the HO-1 pathway and its products 
protects against a variety of conditions that are characterized by oxidative stress and 
inflammation (412-415). This identification of HO-1 as a drug target has led to fervent study of 
pharmacologic inducers of HO-1 for their potential as therapeutics (416-418).  
 
5.2 Regulation of the Endogenous Antioxidant Response and HO-1 
 
Keap1-Nrf2 pathway 
 
All genes of the endogenous antioxidant response, including HO-1, have a common promoter 
element, the ARE, which is regulated by the Keap1-Nrf2 pathway. Keap1 (Kelch-like ECH 
associated protein 1) is a cysteine-rich protein that is the chemical sensor responsible for Nrf2 
(nuclear factor erythroid 2-realted factor 2) activation (405). Under baseline conditions, Keap1 
forms a dimer and binds cytoplasmic actin and Nrf2 and targets Nrf2 for ubiquitination, thus both 
physically sequestering Nrf2 in the cytoplasm and targeting it for proteolytic degradation (405). 
These effects of Keap1 robustly prevent Nrf2 from entering the nucleus, binding the ARE, and 
driving transcription of target genes. In response to numerous cellular insults, particularly 
oxidative stress, Keap1 releases Nrf2, allowing Nrf2 to translocate to the nucleus, heterodimerize 
with other transcription factors including small Maf proteins, bind the ARE, and turn on the 
expression of target antioxidant response genes (405). Multiple mechanisms for the release of 
Nrf2 by Keap1 have been demonstrated; these include Keap1 conformational changes as a result 
Keap1 cysteine residues changing redox state in response to an oxidizing environment (419) and 
ubiquitination of Keap1 (420). Additionally there is strong evidence of Keap1-independent 
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mechanisms of Nrf2 activation, including the ability of Nrf2 to sense inducers directly (421), 
increased Nrf2 mRNA transcription (422), translational control through redox-sensitive internal 
ribosomal entry site in the 5’-UTR of Nrf2 mRNA (423), and phosphorylation of Nrf2 (424).  
 
The multiple pathways for activation allow the Nrf2-driven ARE to respond to a broad range of 
cellular insults. There is strong evidence that different cell stressors and inducers of the Nrf2-
dependent ARE utilize different combinations of these mechanisms described above to ultimately 
induce the transcription of antioxidant response genes. Endogenously the Nrf2/ARE pathway can 
be upregulated by oxidative stress (e.g. reactive oxygen species, electrophiles), shear stress, 
endoplasmic reticulum stress, infection, inflammation, mitochondrial dysfunction, etc. (405). 
Additionally, exogenous compounds from up to ten distinct chemical classes have been reported 
to induce the Nrf2/ARE (405), highlighting the potential for therapeutic targeting of the Nrf2/ARE 
pathway.  
 
Transcriptional regulation of HO-1 
 
In addition to Nrf2, several transcription factors bind the upstream promoter region and regulate 
expression of the HO-1 gene including hypoxia-inducible factor-1 (425), nuclear factor-kappa B 
(NF-κB) (426), activator protein-1 (427), signal transducer and activator of transcription 3 (428, 
429), and broad complex-tramtrack-bric-a-brac-domain (BTB) and cap’n’collar (CNC) homology 1 
(BACH1) (430) (reviewed in (418)). The best studied of these regulatory transcription factors is 
BACH1, a potent transcriptional repressor of HO-1 in addition to some other, but not all, ARE 
genes (e.g. NQO1) (431). Under baseline conditions, BACH1 forms a heterodimer with small Maf 
proteins and can bind certain ARE promoter elements thus preventing Nrf2 binding and 
repressing transcription. In the presence of elevated intracellular heme levels or oxidative stress, 
BACH1 undergoes a conformation change and dissociates from the HO-1 promoter, allowing Nrf2 
to bind and activate HO-1 gene expression (432, 433). Other pathways that have been implicated 
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in regulating HO-1 gene expression include p28 MAPK (434), phosphatidylinositol-3 kinase/Akt 
pathway (429, 435), and the IL-10 pathway (429, 436). The multiple identified transcription factors 
and signaling pathways that regulate HO-1 gene expression are one reason why HO-1 protein 
expression is induced in response to such a wide array of cellular insults (oxidative stress, heavy 
metals, ultraviolet light, inflammation, etc.) and other signals.  
 
Micro-RNA regulation of HO-1  
 
In addition to the multiple mechanisms of transcriptional control of HO-1, there is considerable 
research implicating an important role for microRNA (miR) regulation of HO-1 mRNA. MicroRNAs 
are small non-coding RNA molecules (~22 nucleotides) that post-transcriptionally silence specific 
mRNAs through base-pairing with complementary sequences in the 3’ untranslated region. As a 
result of this complementary binding, mRNAs can be silenced through i) mRNA cleavage and 
degradation, ii) mRNA destabilization through shortening the poly(A) tail, and iii) less efficient 
translation (reviewed in (437)). Multiple miRs have been identified that downregulate HO-1 
expression. These HO-1-downregulating miRs include those that target HO-1 mRNA directly (e.g. 
miR-155 (438, 439), miR-24-3p (440), miR-377 (441), miR-217 (441), miR-122 (442), miR-16-5p 
(443)) and those that target other genes involved in promoting HO-1 expression (e.g. miR-34a 
(444)). Additionally multiple miRs have been implicated in increasing HO-1 through targeting 
genes involved in repressing HO-1, such as BACH1 (miR196 (445), let7 (446), and miR-155 
(447)). Thus, the multifaceted transcriptional regulation of HO-1 mRNA is further nuanced through 
microRNA mediated regulation directly of HO-1 mRNA and indirectly through associated genes.  
 
Posttranslational regulation of HO-1  
 
A few studies have also examined the posttranslational regulation of HO-1. HO-1 has been 
shown to be ubiquitinated and subsequently degraded in a proteasome-dependent manner 
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through the ER-associated degradation pathway (448). The E3-ubiquitin ligase, TRC8, has been 
demonstrated to target HO-1 for ubiquitination and subsequent degradation (449). Whether HO-1 
is regulated significantly through changes in rate of degradation is currently unknown. In addition 
to changes in HO-1 protein levels, HO-1 activity reportedly can be regulated through post-
translational phosphorylation. Specifically, HO-1 activity can be increased, albeit modestly, 
through phosphorylation at serine 188 by Akt/PKB (450). In summary, HO-1 expression and 
activity is tightly regulated through multiple mechanisms, which is likely responsible for HO-1’s 
ability to be upregulated by a wide array of cellular signals and insults.  
 
5.3 HO-1 and Heme/Hemoglobin Scavenging  
 
As a degrader of heme, the major source of iron in the body, HO-1 plays a key role in iron 
recycling and homeostasis. Heme is a major component of a group of intracellular hemoproteins 
that include cytochromes, oxidase (e.g. NADPH oxidase), peroxidases, catalases, and synthases 
(e.g. nitric oxide synthase). HO-1 (and HO-2) degrades and thereby recycles free intracellular 
heme that is released when these hemoproteins are degraded. Additionally, heme has a 
significant and important role in binding and transporting oxygen from the respiratory organs to 
the rest of the body for aerobic respiration. Hemoglobin is the heme-containing oxygen-transport 
metalloprotein found abundantly in red blood cells. Intravascular hemolysis as a result of injury, 
disease (e.g. infections, autoimmune disorders, etc.), or toxins/drugs results in elevated plasma 
hemoglobin. Due to its heme moieties, free hemoglobin (or free heme itself) has damaging 
oxidative effects on tissues, relating in particular to the formation of oxygen radicals and the 
scavenging of nitric oxide (451).  
 
To combat the potential hemoglobin toxicity during hemolysis, a potent hemoglobin scavenging 
system detoxifies and removes extracellular hemoglobin. The hemoglobin-binding protein 
haptoglobin is the first line of defense against hemoglobin toxicity. Haptoglobin, which is secreted 
60 
  
by hepatocytes, monocytes/macrophages, and other cell types (452), binds hemoglobin in an 
almost irreversible interaction and stabilizes the oxidative intermediate, thus preventing 
subsequent oxygen radical formation (453). This binding of haptoglobin to hemoglobin promotes 
CD163-mediated uptake of hemoglobin by cells of the macrophage/monocyte cell lineage (e.g. 
Kupffer cells, red pulp macrophages, alveolar macrophages, etc.) and the subsequent proteolytic 
degradation of hemoglobin and catabolism of the toxic heme moiety via the HO-1 (and HO-2) 
pathway (453). The presence of increased intracellular heme as a result of this CD163-mediated 
uptake of hemoglobin results in a potent and swift upregulation of HO-1 expression in order to 
rapidly detoxify the free heme. An additional back-up system exists to scavenge free extracellular 
heme that has disassociated from hemoglobin. The receptor CD91, which is abundant on 
macrophages and hepatocytes, can uptake heme when it is bound to the heme-scavenging 
protein hemopexin, where heme is again degraded through the heme oxygenase pathway (453). 
Thus, HO-1 plays a central and conserved role in protecting tissues from hemoglobin/heme 
oxidative damage as a result of intravascular hemolysis.  
 
5.4 HO-1 as an Anti-Inflammatory and Anti-Oxidative Enzyme   
 
Anti-oxidative and cytoprotective functions of HO-1  
  
Despite HO-1’s conserved and central role in detoxifying heme, numerous other cytoprotective 
roles for HO-1, have been described. HO-1 has been shown to be important in limiting cellular 
and tissue injury in response to non-heme oxidative stress. Adult HO-1 deficient mice have been 
shown to have elevated markers of oxidative stress, including oxidized proteins and lipid 
peroxidation (454, 455) and HO-1-/- embryonic fibroblasts derived from these mice demonstrated 
elevated levels of reactive oxygen species (456). Multiple primary cell lineages (e.g. fibroblasts, 
vascular smooth muscle, astrocytes) derived from HO-1-deficient mice are more susceptible to 
oxidant-induced cell injury and death (456-458). Moreover, induction of HO-1 in vitro has been 
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demonstrated repeatedly to protect numerous cell types from oxidative stress (459-462), 
including cells of the CNS such as astrocytes (463, 464) and neurons (465, 466). These data 
identify HO-1 as a critical component of the cellular response to oxidative stress that protects 
against subsequent cellular and tissue injury.  
 
Anti-inflammatory functions of HO-1 
 
In addition to its role in limiting oxidative stress, HO-1 has been identified as a critical mediator of 
immune activation and inflammation. HO-1 deficient mice show signs of a progressive chronic 
inflammatory disease, as demonstrated by high peripheral white blood cell count, enlarged 
spleens and lymph nodes (extramedullary hematopoiesis and follicular hyperplasia), high 
CD4+:CD8+ T-lymphocyte ratios, elevated activated CD4+ T-lymphocytes, increased monocyte 
adhesion to vessel walls, increased baseline serum IgM, inflammatory cell tissue infiltrates 
(particularly in the liver), and elevated splenocyte secretion of pro-inflammatory cytokines in 
response to endotoxin or anti-CD3/anti-CD28 stimulation  (455, 467). Consistent with this anti-
inflammatory role of HO-1, the first identified human patient with HO-1 deficiency demonstrated 
enhanced systemic inflammatory reactions in addition to asplenia, intravascular hemolysis, and 
systemic vascular endothelial disturbance, among other symptoms (468, 469). 
 
The anti-inflammatory and immunomodulatory functions of HO-1 have been shown to be 
particularly important within cells of the myeloid lineage (monocytes, macrophages, and dendritic 
cells). Induction of HO-1 has been shown to limit the expression of various pro-inflammatory 
factors including IL-6, TNFα, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-
2) in macrophages and alter surface antigen expression in monocytes with reduction in human 
leukocyte antigen-DR, CD36, and CD11B (467, 470). Moreover, mice with genetic HO-1 
deficiency restricted to cell of the myeloid lineage exhibited altered innate immune function in 
response to infections and experimental autoimmune encephalitis, potentially as a result of a 
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defect in the interferon-β signaling pathway (471). Additionally, human HO-1 deficiency has been 
associated with a disturbance in macrophage phagocytic function (468, 469). Further highlighting 
the importance of macrophage HO-1, transplant of wild-type macrophages into HO-1-deficient 
mice reversed many systemic disease parameters (anemia, blood chemistries, iron metabolism, 
renal damage) (472). HO-1 also regulates the maturation and proper functioning of dendritic cells 
(473). HO-1 has also been shown to have immunomodulatory effects on other cell lineages of the 
immune system, including T-lymphocytes. For example, HO-1 has been demonstrated to play an 
integral role in modulating T lymphocyte-mediated immunity (474), particularly with respect to the 
suppressive capacity of regulatory T cells (475). These data highlight the central role of HO-1 in 
downregulating and modulating inflammatory responses, particularly within the myeloid lineage.  
 
Potential mechanism for anti-inflammatory and anti-oxidative effects of HO-1 
 
The mechanisms by which HO-1 mediates its anti-inflammatory and anti-oxidative effects are not 
completely understood. However, these immunomodulatory and protective functions of HO-1 
have been linked to both its degradation of free heme and the subsequent generation of the anti-
inflammatory compounds carbon monoxide (CO), biliverdin, and bilirubin (44). Numerous 
cytoprotective and anti-inflammatory effects of HO-1 can be mimicked when CO or bilirubin are 
exogenously applied (454, 470, 476-478). HO-1 induction or inhaled CO have been shown to 
protect against lung ischemia/reperfusion injury, interstitial lung disease (fibrosis), acute lung 
injury, and pulmonary hypertension (479). Similarly, HO-1 induction or exogenous treatment with 
bilirubin can reduce i) superoxide production in vascular smooth muscle cells, ii) decrease 
reactive oxygen species in embryonic cells, iii) and lessen activation and dysfunction of vascular 
endothelial cells in response to proinflammatory stresses (457, 480, 481). One reported 
mechanism by which HO-1, perhaps through signaling by its enzymatic products, may 
downregulate inflammatory responses is by inhibiting the NF-κB pathway. While HO-1 does not 
inhibit NF-κB translocation to the nucleus or DNA binding, HO-1 reportedly inhibits the activating 
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phosphorylation of Ser276 on p65/RelA. Additionally, there is evidence that HO-1 may be cleaved 
from its transmembrane domain and translocate to the nucleus where it can alter transcription of 
other protective cellular genes (410). Thus, the cytoprotective effects of HO-1 in many model 
systems may be a result of protective effects and signaling through cleaved HO-1 and HO-1’s 
enzymatic products CO, biliverdin, and bilirubin.  
 
5.5 HO-1 in Diseases of Inflammation and Oxidative stress 
 
HO-1 polymorphisms  
 
Polymorphisms that exist at the human HO-1 locus have been associated with altered incidence 
and/or progression of various diseases (reviewed in (45)). There are currently three described 
polymorphism in the 5’ flanking region of the HO-1 gene: two single nucleotide polymorphisms 
(SNP), G(-1135)A and T(-413)A, and a (GT)n dinucleotide repeat polymorphism (482-484). The 
best characterized of these polymorphisms is the HO-1 promoter region (GT)n dinucleotide 
repeat polymorphism. The length of the GT repeat varies from 12 to 40 repeats with a bimodal 
distribution with the most common alleles having 23 and 30 repeats in multiple populations 
studied (482, 483, 485-487). Using luciferase promoter constructs in cell lines, the length of the 
(GT)n repeat has been demonstrated to modulate HO-1 transcription (485, 486). Specifically, 
shorter HO-1 promoter region (GT)n repeat lengths increased HO-1 basal promoter activity and 
increased HO-1 induction in response to various stimuli. Additional studies have confirmed these 
findings using primary cells and lymphoblastoid cell lines established from subjects with known 
GT repeat lengths (488, 489). Furthermore, cells with short repeats are more resistant to 
oxidative stress induced apoptosis (488). Given the anti-inflammatory and cytoprotective 
functions of HO-1, a multitude of clinical studies have examined the HO-1 promoter region (GT)n 
dinucleotide repeat polymorphism in patients with various diseases and medical conditions. 
Longer (GT)n repeats, associated with lower HO-1 expression, have been associated with worse 
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Diseases with worse clinical outcome  
associated with longer HO-1 promoter  
region (GT)n repeats  
Sample Size Reference 
   
Pulmonary disease   
Emphysema in smokers 201 (485) 
Acute Chest Syndrome in Sickle Cell 
Disease 
942 (502) 
Lung function in smokers 749 (503) 
   
Cardiovascular disease    
Coronary artery disease 577; 796; 259; 328; 2,298; 
472 
(504); (486); 
(483); (505); 
(506); (507) 
Abdominal aortic aneurysms  271 (508) 
Inflammation after balloon angioplasty 317 (509) 
Restenosis after stenting or angioplasty 323; 381 (510);(511) 
   
Transplant disease    
Kidney allograft function 101; 384 (487); (512) 
   
   
Obstetrics   
Idiopathic recurrent miscarriage 291 (513) 
   
Gastrointestinal disease    
Necrotizing acute pancreatitis 239 (514) 
   
Infectious disease   
Sepsis 136 (515) 
Pneumonia  200 (516) 
   
Neurological disease   
Ischemic stroke 347 (517) 
Cerebral aneurysm  69 (518) 
   
Immune disease   
Rheumatoid arthritis  325; 1582 (519); (520) 
 
 
Table 5.1 Studies that identified longer HO-1 promoter region (GT)n microsatellite 
polymorphisms as a risk factor for worse clinical outcomes in various disease states.  
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clinical disease in multiple disease states, many of which have inflammation and oxidative stress 
as a core component of the underlying pathology (see Table 5.1). The association of HO-1 
promoter polymorphisms with the progression of these clinical diseases further highlights the 
broad role of HO-1 in modulating inflammation and oxidative stress across a variety of 
pathological conditions.  
 
HO-1 and modulating disease outcomes 
 
Using genetic approaches, several studies have demonstrated the ability of HO-1 to alter the 
pathologic outcome in experimental mouse models of disease. HO-1 knockout mice demonstrate 
exacerbation of disease in multiple animal models, including myocardial infarction and ischemia-
reperfusion injury (490, 491), severe sepsis and endotoxin shock (456, 492, 493), autoimmune 
neuroinflammation (494), atherosclerosis (495), steatohepatitis (496), and mycobacterium 
infection (497). In support of the protective role of HO-1 in some of these diseases, BACH1 
knockout mice (which have high levels of HO-1 expression) have reduced disease pathology in 
models of atherosclerosis (498), steatohepatitis (499), secondary injury after spinal cord injury 
(500), and colitis (501). These complimentary mouse genetic studies, similar to the clinical HO-1 
promoter polymorphism studies in human disease populations, underscore the broad role of HO-
1 in modulating pathological conditions, particularly those with inflammatory and oxidative stress 
pathology.  
 
5.6 Conclusion 
 
HO-1 is a critical member of a coalition of effector proteins of the Nrf2-driven antioxidant 
response. In addition to regulation by the ARE, HO-1 expression and activity is further modulated 
at the transcription level by multiple other transcription factors, at the mRNA level by various 
microRNAs, and at the post-translational level through phosphorylation and proteasome-
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mediated degradation. Beyond its conserved role in the degradation of the pro-oxidant heme, 
HO-1 serves a vital and seemingly ubiquitous role in limiting oxidative stress, inflammation, and 
cellular injury within the CNS and other tissues. At least some of these protective effects of HO-1 
can be linked to the enzyme’s generation of the anti-inflammatory and anti-oxidative products, CO 
and bilirubin. Inducing and inhibiting HO-1 in animal disease models and studying HO-1 promoter 
polymorphisms in human disease cohorts have identified HO-1 as a modulator of disease 
progression and severity in multiple inflammatory and pro-oxidative disease states. The 
consistent ability of HO-1 induction to limit inflammation and oxidative stress in various disease 
models has spurred much study of potentially therapeutic HO-1 inducers and their ability to limit 
inflammation, oxidative stress, and disease pathology across multiple disciplines (416, 417, 521). 
Given these well-described protective functions of HO-1, the studies within this thesis explore the 
role for and the potential therapeutic targeting of HO-1 in HIV neuropathogenesis.   
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6.1 Material and Methods for Chapter 7 
 
Study design and setting 
 
We performed a retrospective cross-sectional study using data and biological samples (plasma, 
CSF) from 48 HIV-infected adults enrolled in the CNS HIV Anti-Retroviral Therapy Effects 
Research (CHARTER) cohort of the NIMH/NINDS/NIH. Characteristics of the CHARTER cohort 
are described elsewhere (10). CHARTER is an ongoing, observational cohort study of HIV-
infected persons enrolled between 2003-2007 from six United States university-affiliated HIV 
treatment centers. Enrolling 1561 HIV+ subjects at baseline, the study was designed to assess 
the frequency and severity of HAND, and the specific contributions of HIV versus HIV-associated 
comorbidities to neurocognitive impairment. Inclusion criteria for the CHARTER study were 
broad, but individuals with severe comorbid psychiatric, medical, or neurological disorders 
deemed likely to adversely affect cognitive functioning were excluded, as were HIV-negative 
subjects. Our study used data and samples from 48 CHARTER subjects (15 each from ANI, and 
MND sub-groups, 3 HAD subjects, and 15 neurocognitively normal HIV-infected subjects). The 
cohort included men and women aged 18-65 years who were ART naïve or currently off of ART, 
and who underwent successful lumbar puncture, venipuncture, and neuropsychological testing. 
See Table 6.1 for cohort demographics. Subjects with a history of CNS opportunistic infection, 
trauma, epilepsy, MS, known causes of mental retardation, dementia, or active psychotic illness 
were excluded.  
 
Data collection  
 
Original data collection for the CHARTER cohort was approved by the Human Subjects 
Protection Committees of each participating institution. All subjects provided written consent to 
participate in the CHARTER study. Data were originally obtained through comprehensive 
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neuromedical, neurocognitive, psychiatric, and functional evaluations, and collection of blood and 
urine samples. Collection of CSF was through lumbar puncture (10). The de-identified data and 
biological samples for this substudy were obtained with permission of the CHARTER steering 
committee. Because the dataset and samples were de-identified and because our substudy did 
not involve patient contact, The Children’s Hospital of Philadelphia institutional review board 
determined (November 21, 2012) that this study did not qualify as human subjects research. 
 
Laboratory assessments  
 
HIV infection was diagnosed by ELISA with Western blot confirmation. Clinical laboratory 
assessments, including complete blood counts, chemistry panels, rapid plasma regain (RPR), 
hepatitis C virus (HCV) antibody, and flow cytometry for CD4+ T-lymphocyte count) were 
performed at each CHARTER site’s Clinical Laboratory Improvement Amendments (CLIA)-
certified, or CLIA equivalent, medical center laboratory. Plasma HIV loads (viral loads) were 
quantified by real-time PCR ultrasensitive assay (nominal lower quantitation limit 50 copies per 
mL; Amplicor®, Roche Diagnostic Systems, Indianapolis, IN) in a central lab. (10).  
 
Biomarkers were measured in triplicate by validated, commercially available 96-well plate ELISAs 
on stored, frozen samples (-80C). Paired CSF/plasma samples were assayed for NFL (Uman 
Diagnostics AB, limit of detection 31 ng/mL) and pNFH (Biovendor catalog number RD 
191138300R, limit of detection 23.5 pg/mL); NFL and pNFH were detected only in CSF samples. 
sCD14 and sCD163 were assayed in paired CSF/plasma samples (R&D Systems, catalog 
number DC140, limit of detection 125 pg/mL sCD14 and  Trillium Diagnostics, IQP-383, , limit of 
detection 0.23 ng/mL sCD163).  
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Characteristic All, n=48 NCN, n=15 ANI, n=15 MND, n=15 HAD, n=3 pb 
Male sex 36 (75) 12 (80) 9 (60) 12 (809 3 (100) 0.362 
Black race 25 (53) 8 (57) 7 (47) 9 (60) 1 (33) 0.777 
Age (years) 39.5 (36-47.5) 44 (36-49) 38 (31-40) 40 (25-48) 47 (38-50) 0.392 
Duration of HIV (months) 98 (29-157) 131 (81-186) 99 (11-122) 98 (23-162) 34 (2-234) 0.616 
Education (years) 12 (11-13) 13 (12-15) 11 (10-12) 12 (9-14) 12 (12-14) 0.102 
HCV Positive 14 (31) 5 (33) 6 (40) 3 (20) 0 (0) 0.420 
RPR Positive 5 (10) 1 (7) 1 (7)  3 (21) 0 (0) 0.538 
CD4 nadir ≤200 14 (29) 5 (33) 3 (20) 4 (27) 2 (67) 0.420 
Plasma CD4 <50 5 (10) 1 (7) 1 (7) 1 (7) 2 (67) 0.046 
    50-199 5 (10) 1 (7) 2 (13) 2 (13) 0 (0) - 
    200-349 7 (15) 0 (0) 3 (20) 3 (20) 1 (33) - 
    ≥ 350 31 (65) 13 (87) 9 (60) 9 (60) 0 (0) - 
Plasma HIV-1 RNA 
(log10 copies/mL) 
4.34  
(3.66-4.87) 
3,83 ( 
3.15-4.06) 
4.68  
(3.97-5.04) 
4.54 
(3.93-5.08) 
5.53 
(3.12-6.16) 
0.038 
CSF HIV-1 RNA 
(log10 copies/mL) 
2.45 
(1.70-3.20) 
1.83  
(1.70-3.20) 
2.84 
(1.70-3.20) 
2.86 
(2.01-3.41) 
1.70 
(1.70-2.35) 
0.330 
 
 
Table 6.1 Demographic and clinical characteristics of HIV autopsy cohort for study entitled 
"Central and Peripheral Markers of Neurodegeneration and Monocyte Activation in HAND" 
(Chapter 7). 
a Categorical variables are described using n (%). Continuous variables are described using 
median (IQR).  
b p values to compare characteristics among different subgroups of HAND were calculated using 
chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables.  
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Neurocognitive assessments 
 
All CHARTER study subjects completed a comprehensive neuropsychological test battery 
assessing seven cognitive domains commonly affected in HIV infection (verbal fluency, executive 
functioning, speed of information processing, learning, recall, working memory, and motor skills). 
Raw test scores were converted to demographically adjusted T-scores using the best available 
normative data accounting for age, sex, ethnicity, and education. Functional impairment was 
assessed using the Patient’s Assessment of Own Functioning Inventory (PAOFI) and an 
instrumental activities of daily living (IADL) questionnaire. (10). A global performance score was 
determined as previously described (522, 523). HAND status was classified according to Frascati 
criteria (180). 
 
Data analysis and statistical methods 
 
Data were analyzed using Stata version 12.1 (StataCorp, College Station, Texas, 2011). 
Continuous variables were described using median and interquartile range (IQR), and intergroup 
differences were evaluated using Kruskal-Wallis tests and Wilcoxan rank-sum tests. Categorical 
variables were described using counts and percents, and intergroup differences were compared 
using the Chi-square test. Spearman’s correlation coefficients were used for correlations between 
biomarkers. Statistical significance was determined a prior as a two-tailed P-value < 0.05. 
 
6.2 Material and Methods for Chapter 8 
 
Subjects in DLPFC cohort  
 
A cohort of 90 HIV-positive (HIV+) and 66 HIV-negative (HIV-) subjects was selected from the 
National NeuroAIDS Tissue Consortium (NNTC) (524) autopsy cohort for analysis of protein 
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expression within DLPFC tissue. This cohort was assembled by the Texas NeuroAIDS Research 
Center and has been described in a prior report (525). The 90 HIV+ cases included subjects who 
had pathologically confirmed encephalitis (HIVE+; n=14) and subjects who did not have HIVE 
(HIV+/HIVE-; n=76). Among the 76 HIV+/HIVE- individuals were 37 confirmed cases of HAND, 6 
cases confirmed as neurocognitively normal, and 33 cases with either no associated 
neurocognitive diagnosis or neurocognitive dysfunction in which factors other than HIV infection 
were not ruled out. Among the 14 HIVE+ cases, 9 were confirmed to have HAND (the other 5 had 
either no associated neurocognitive diagnosis or neurocognitive dysfunction in which factors 
other than HIV infection were not ruled out). Following administration of the neurocognitive test 
battery implemented by the NNTC (523), the neurocognitive diagnosis of HAND was assigned by 
the supervising neuropsychologist according to the Frascati Criteria (180) as reviewed by an 
experienced neurologist. NNTC site neuropathologists rendered nosological diagnoses of HIVE 
as guided by the criteria of Budka et al (526). Sixty-three percent of HIV+ subjects were ART-
experienced. HIV− subjects were significantly older than HIV+ subjects on average by 6.6 years, 
but did not significantly differ from HIV+ subjects in gender, ethnicity, race, or post-mortem 
interval. See Table 6.2 for summarized demographic and clinical data. Further details on the 
demographic and clinical data of this cohort were described previously (525).  
 
Neurocognitive testing 
 
The neurocognitive test battery implemented by the NNTC (Table 6.3 (523)) was used to evaluate 
7 domains of cognitive functioning and to assign a diagnosis of HAND. Most HIV+ subjects (78%) 
underwent neurocognitive testing at 6-month intervals prior to death. Neurocognitive domain test 
results were assigned a T-score normalized for age, gender, ethnicity, and education-adjusted 
norms. A composite (Global) T-score for overall performance across all domains was calculated 
for subjects who completed at least 10 of 14 tests.  
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Characteristic HIV- HIV+ (no HIVE) 
HIV+ 
HIVE p-value 
Number of subjects 66 76 14 - 
Age at death 50.6 ± 16.6 44.4 ± 9.1 41.6 ± 7.1 0.005a 
Hours postmortem 14.8 ± 11.2 13.1 ± 14.1 19.7 ± 20.7 0.143a 
Male n (%) 49 (74%) 59 (78%) 14 (100%) 0.104b 
Race     
    White  43 (65%) 48 (63%) 12 (86%) 
0.143b     Black 16 (24%) 22 (29%) 1 (7%) 
    Other/Unknown  7 (10%) 6 (8%) 1 (7%) 
Hispanic 19 (29%) 12 (17%) 2 (14%) 0.195b 
Disease parameters     
    Log10 plasma HIV RNA copies/mL - 4.3 ± 1.4 5.2 ± 0.9 0.450c 
    Log10 CSF HIV RNA copies/ml - 3.8 ± 0.8 5.9 ± 1.4 <0.001c 
    Log10  Brain HIV RNA copies/gram - 2.8 ± 1.1 5.3 ± 1.5 < 0.001c 
    CD4+ lymphocytes/mm3 - 116 ± 169 49 ± 49 0.158c 
Neurocognitive impairment      
    HAND - 37 (49%) 9 (64%) 
0.591b 
    Neuropsych impairment other origin - 22 (29%) 3 (21%) 
    Neurocognitive normal - 6 (8%) 0 (0%) 
    No neurocognitive data  - 11 (14%) 2 (14%) 
ART treatment status  -    
    ART-experienced  - 49 (65%) 8 (57%) 
0.079b     ART-naive - 10 (13%) 5 (36%) 
    Unknown ART - 17 (22%) 1 (7%) 
 
 
Table 6.2 Demographic, clinical, and antiretroviral therapy data for DLPFC cohort for 
studies entitled Brain Heme Oxygenase-1 Deficiency Accompanies Neuropathogenesis of 
HIV-Associated Neurocognitive Disorders” (Chapter 8) and “HO-1 (GT)n Promoter 
Polymorphism Associates with HIV-Encephalitis” (Chapter 9). Categorical variables are 
described using n (%). Continuous variables are described using mean ± standard deviation. 
Abbreviations used: HIV encephalitis (HIVE), HIV-associated neurocognitive disorders (HAND), 
antiretroviral therapy (ART). Sample sizes of subgroups may be smaller than the overall group 
sample size due to the availability of demographic and clinical data.  
aAnalysis of variance p-value 
bChi-square test p value 
cStudent’s t-test p-value.  
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Domain Primary Neuropsychological Test 
Executive 
Trail Making Test (TMT), Part B 
Wisconsin Card Sorting Test - 64 Card Version (WCST-64), Perseverative 
Responses 
Speed of  
Information Processing 
Trail Making Test (TMT), Part A 
Wechsler Adult Intelligence Scale - Third Edition (WAIS-III), Digit Symbol 
Wechsler Adult Intelligence Scale - Third Edition (WAIS-III), Symbol Search 
Attention &  
Working Memory 
Paced Auditory Serial Addition Test - 50 item version (PASAT-50) 
Wechsler Adult Intelligence Scale - Third Edition (WAIS-III), Letter-Number 
Sequencing 
Learning 
Brief Visuospatial Memory Test - Revised (BVMT-R), total (trials 1-3) 
Hopkins Verbal Learning Test - Revised (HVMT-R), total (trials 1-3) 
Memory 
Brief Visuospatial Memory Test - Revised (BVMT-R), Delayed Recall 
Hopkins Verbal Learning Test - Revised (HVMT-R), Delayed Recall 
Verbal Fluency Controlled Oral Word Association Test (COWAT-FAS) 
Motor Grooved Pegboard (most impaired hand) 
 
Table 6.3 Primary neurocognitive test scores used to establish domain clinical T-scores. A 
Global T-score for overall performance across all domains was calculated for subjects who 
completed at least of 10 of 14 tests. See (523) for more details.  
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Subjects in regional analysis cohort   
 
A cohort of 12 HIV-negative (HIV-), 12 HIV-positive with a diagnosis of HAND (HIV+/HAND), and 
10 HIV-positive with HIVE (HIVE+) subjects was selected from the NNTC (524) for a regional 
brain analysis of protein expression within the striatum (head of caudate), occipital cortex, and 
cerebellum (anterior cerebellar cortex). This cohort was matched for age, post mortem interval, 
sex, race, and ethnicity (Table 6.4). Of the 34 cases in this regional analysis cohort, 16 were 
represented in the larger DLPFC cohort.  
 
Brain dissection and extraction of protein and RNA 
  
DLPFC was dissected from Brodmann areas 9 or 10. For protein extraction, fresh-frozen brain 
(30-500 mg) was homogenized by silica bead beating, sonicated, and solubilized (0.03% TX-100, 
0.5 mM DTT, 5 mM MgCl2, Tris 10 mM, pH 7.8). RNA was prepared using the RNeasy Lipid 
Tissue Mini Kit (Qiagen) as previously described (525, 527). Briefly, 100 mg of brain tissue from 
an adjacent region of protein extraction was dissected on dry ice and homogenized in a minibead 
beater. RNA was extracted with chloroform and centrifuged in RNeasy mini spin columns, 
washed, and eluted.  
 
Quantification of viral loads and CD4 count 
  
In the majority of cases, blood and CSF samples were obtained within 6 months of subject death 
and on the same day that neurocognitive domains were assessed. Plasma and CSF viral loads 
were determined with the Amplicor HIV-1 Monitor test v1.1 through v1.5 (Roche). Brain 
parenchyma HIV RNA was quantified from brain extracted RNA as previously described (525, 
527). Briefly, 1µg microgram of brain RNA and 1µM of antisense primer 84R were used in 20µl 
reaction (iScript cDNA Synthesis Kit, Bio-Rad Laboratories). Four microliters of cDNA was used  
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Characteristic HIV- HIV+/HAND (no HIVE) 
HIV+ 
HIVE p-value 
Number of subjects 12 12 10 - 
Age at death 43.0 ± 4.5 41.9 ± 7.6 40.0 ± 5.7 0.518a 
Hours postmortem 24.4 ± 7.2 22.2 ± 17.7 26.2 ± 24.9 0.869a 
Male n (%) 9 (75%) 10 (83%) 9 (90%) 0.652b 
Race     
    White  9 (75%) 9 (75%) 8 (80%) 
0.938b     Black 2 (17%) 1 (8%) 1 (10% 
    Other/Unknown  1 (8%) 2 (17%) 1 (10%) 
Hispanic 3 (25%) 1 (8%) 1 (10%) 0.454b 
Disease parameters     
    Log10 plasma HIV RNA copies/mL - 4.5 ± 1.5 5.2 ± 0.9 0.213c 
    Log10 CSF HIV RNA copies/ml - 2.8 ± 1.4 5.5 ± 1.4 <0.001c 
    CD4+ lymphocytes/mm3 - 50 ± 106 46 ± 30 0.158c 
Neurocognitive impairment      
    HAND - 12 (100%) 6 (60%) 
0.052b     Neuropsych impairment other origin - 0 (0%) 3 (30%) 
    No neurocognitive data  - 0 (0%) 1 (10%) 
 
Table 6.4  Demographic, clinical, and antiretroviral therapy data for brain regional analysis 
cohort for studies entitled Brain Heme Oxygenase-1 Deficiency Accompanies 
Neuropathogenesis of HIV-Associated Neurocognitive Disorders” (Chapter 8). Categorical 
variables are described using n (%). Continuous variables are described using mean ± standard 
deviation. Abbreviations used: HIV encephalitis (HIVE), HIV-associated neurocognitive disorders 
(HAND), antiretroviral therapy (ART). Sample sizes of subgroups may be smaller than the overall 
group sample size due to the availability of demographic and clinical data.  
aAnalysis of variance p-value 
 bChi-square test p value 
cStudent’s t-test p-value.  
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for 25µl quantitative real-time PCR (qPCR) by using JumpStart Taq ReadyMix for Quantitative 
PCR (Sigma) and SmartCycler (Cepheid). Results were standardized against a known brain 
secondary standard. CD4+ T-lymphocyte counts were determined by flow cytometry and 
performed at each NNTC site’s Clinical Laboratory Improvement Amendments (CLIA)–certified, 
or CLIA equivalent, medical center laboratory. 
 
Quantification of brain mRNAs 
 
Expression of brain mRNAs was quantified after cDNA synthesis from mRNA samples using Taq-
Man Universal PCR Master Mix (Applied Biosystems) by qPCR as previously described (527). 
Duplicate qPCR reactions were run and relative mRNA expression was calculated using the ΔΔCt 
method (compared to GAPDH mRNA expression) using the primer and probe mixes listed in 
Table 6.5.  
 
Western blot analysis 
 
Cell cultures were rinsed with ice-cold PBS, lysed in 75mM Tris-HCL (pH 6.8) containing 15% 
glycerol, 3.75mM EDTA, and 3% SDS, and supplemented with Complete Protease Inhibitor 
Cocktail (Roche) and PhosSTOP phosphatase inhibitor mixture (Roche). Cell and DLPFC protein 
lysates were subjected to SDS-PAGE as previously described (46) using primary and secondary 
antibodies listed in Tables 6.6 and 6.7. For all autopsy cases, protein expression as determined 
by Western blotting was normalized to both β-tubulin and GAPDH expression.  
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Human Gene Company Primer and Probe Set Catalog # 
CD163 Applied Biosystems Hs01016661_m1 
CD68 Applied Biosystems Hs00154355_m1 
CD8A Applied Biosystems Hs01555600_m1 
GAPDH Applied Biosystems Hs99999905_m1 
IRF1 Applied Biosystems Hs00971959_m1 
ISG15 Applied Biosystems Hs00192713_m1 
MX1 Applied Biosystems Hs00182073_m1 
 
Table 6.5 Quantitative real-time PCR primer and probe sets.  
 
 
 
 
Protein 
Target 
Host 
Species 
Mono- or 
Polyclonal 
Provider Catalog 
# 
Antibody 
Concentration 
Band 
Size 
β-tubulin rabbit monoclonal Cell Signaling 2128 0.014 µg/ml 55 kDa 
FTH1 rabbit polyclonal Cell Signaling 3998 0.071 µg/ml 21 kDa 
GAPDH mouse monoclonal Advanced 
Immunochemical 
Mab 6C5 0.260 µg/ml 35 kDa 
GPX1 rabbit monoclonal Cell Signaling 3286 0.110 µg/ml 21 kDa 
GSTP1 mouse monoclonal Cell Signaling 3369 0.400 µg/ml 23 kDa 
HO-1* rabbit polyclonal Enzo Life Sciences SPA-895 2.0-4.0 µg/ml 29 kDa 
HO-1# rabbit polyclonal Enzo Life Sciences SPA-896 2.0-4.0 µg/ml 29 kDa 
HO-2 rabbit polyclonal Enzo Life Sciences SPA-897 2.0-4.0 µg/ml 35 kDa 
NQO1 mouse monoclonal Abcam ab28947 1.0 µg/ml 28 kDa 
PRDX1 rabbit polyclonal Cell Signaling 8732 0.097 µg/ml 21 kDa 
SOD1 mouse monoclonal  Cell Signaling 4266 0.250 µg/ml 18 kDa 
TRXR1 rabbit polyclonal Cell Signaling 6925 0.025 ug/ml 55 kDa 
 
Table 6.6 Primary antibodies for Western blotting.  
*Antibody used for Western blot detection of HO-1 in human brain tissue.  
#Antibody used for Western blot detection of HO-1 in all in vitro studies using primary cells.  
79 
  
 
 
 
 
 
 
Secondary 
Antibody 
Host 
Species 
Provider Catalog # 
Antibody 
Concentration 
IRDye 680RD Goat Anti-Mouse IgG goat Licor 926-68070 0.050 µg/ml 
IRDye 680RD Goat Anti-Rabbit IgG goat Licor 926-68071 0.050 µg/ml 
IRDye 800RD Goat Anti-Mouse IgG goat Licor 926-32210 0.067 µg/ml 
IRDye 800RD Goat Anti-Rabbit IgG goat Licor 926-32211 0.067 µg/ml 
HRP-conjugated AffiniPure Goat Anti-
Mouse IgG (H+L) 
goat Jackson 
Immunoresearch 
115-035-
003 
0.160 µg/ml 
HRP-conjugated AffiniPure Goat Anti-
Rabbit IgG (H+L) 
goat Jackson 
Immunoresearch 
111-035-
003 0.160 µg/ml 
HRP-conjugated Goat Anti-Rabbit IgG 
(H+L) 
goat Cell Signaling 7074 0.071 µg/ml 
HRP-conjugated Goat Anti-Mouse IgG 
(H+L) 
horse Cell Signaling 7076 0.071 µg/ml 
 
Table 6.7 Secondary antibodies for Western blotting. Signal intensity was analyzed using 
ImageJ for HRP-conjugated secondary antibodies and Image Studio (LiCor) for fluorescent 
secondary antibodies.  
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Statistics 
 
All quantifications are expressed as mean ± SEM. One-way ANOVA followed by a Holm-Sidak 
post-test were performed on indicated comparisons. Analyses of linear trends were performed by 
multivariate linear regression analysis where b is the slope of the line of association and p is the p-
value versus the null hypothesis (b = 0). α = 0.05 unless otherwise noted in order to correct for 
multiple comparisons. Statistical input support was provided by the Biostatics and Data 
Management Core, Center for AIDS Research, Perelman School of Medicine, University of 
Pennsylvania.  
 
Study approval 
 
All animal studies and protocols were carried out in accordance with the NIH Guidelines for the 
Care and Use of Laboratory Animals and approved by the University of Pennsylvania IACUC. All 
NNTC studies were conducted in accordance with human subject protection protocols at 
participating institutions. Written consent was obtained for subjects at four collection sites in the 
USA. The following offices maintained the IRBs that provided oversight for the protection of 
human subjects: 1) The University of Texas Medical Branch Office of Research Subject 
Protections; 2) Mount Sinai Medical Center Program for the Protection of Human Subjects; 3) 
University of California, San Diego Human Research Protections Program; 4) University of 
California, Los Angeles Office of the Human Research Protection Program. 
 
6.3 Material and Methods for Chapter 9 
 
Subjects in DLPFC cohort, Brain dissection and extraction of protein and RNA; Quantification of 
viral loads and CD4 count; Quantification of brain mRNAs; Western blot analysis; Neurocognitive 
testing 
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See section 6.2 
 
DNA isolation and HO-1 promoter genotyping   
 
DNA was isolated from the dorsolateral prefrontal cortex (DLPFC) using the DNA Extraction kit 
(Agilent Technologies, catalog #200600) according to the manufacturer’s instruction, and each 
sample was standardized to a 20 ng/µl concentration. HO-1 microsatellite (GT repeat) genotyping 
was performed by the Penn Genomics Analysis Core (PGAC) in the Perelman School of 
Medicine at the University of Pennsylvania (Philadelphia, PA). The sequences of the primers 
were taken from Seu et al. (2011). The forward primer sequence, ‘MS-Primer1’ (as named in Seu 
et al., 2011), was labeled at the 5’ end with 6-FAM: 5’-FAM-CCAGCTTTCTGGAACCTTCTG-3’. 
The reverse primer sequence, ‘MS-Primer2,’ was unlabeled: 5’-
GAAACAAAGTCTGGCCATAGGA-3’. The samples were amplified using the Roche PCR Core 
Kit (Roche) on an thermocycler (GeneAmp PCR System 9700, Applied Biosystems) using a 
touchdown PCR protocol. Samples were initially heated to 95*C for 10 minutes, then cycled 
between 95*C (20 sec) for denaturing, 62*C (20 sec) for annealing, and 72*C (45 sec) for 
elongating. The touchdown protocol started the annealing temperature at 62*C and dropped 
0.5*C during each subsequent cycle for the first 15 cycles. The remaining 35 cycles maintained 
the annealing temperature at 55*C, followed by a final hold of 72*C for 10 minutes. Two 
microliters (2 µl or approximately 40 ng) of DNA was used for each sample, and a final primer 
concentration of 250 nM for both forward and reverse primers was used. PCR products were run 
on a 2% agarose gel to ensure quality control of amplification of the target sequence. The 
resulting products were run on the 3130XL Capillary Sequencer (Applied Biosystems). Sizing was 
analyzed with GeneMapper (Applied Biosystems) and gated for products 200-300 basepairs in 
length. All samples were run twice independently to ensure accurate and reproducible sizing, and 
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were determined to be accurate within +/- 2 GT repeats, with a less than 5% chance of error 
based on reproducibility.  
 
Statistics 
 
Analyses of linear trends were performed by Spearman correlation where r is the Spearman’s 
correlation coefficient and p is the p-value versus the null hypothesis (slope = 0). We used a statistical 
significant cut-off of α = 0.05.  
 
Study approval 
 
All protocols were carried out in accordance with the NIH Guidelines for the Care and Use of 
Laboratory Animals and approved by the University of Pennsylvania IACUC. All human studies 
and protocols for monocyte isolation were reviewed and approved by the University of 
Pennsylvania and University of Texas IRBs and all participants provided written informed 
consent.  
 
6.4 Material and Methods for Chapter 10 
 
Isolation and culture of human monocyte-derived macrophages (MDM) 
 
Human monocytes were isolated from healthy donors by Ficoll density gradient centrifugation as 
previously described (42). Monocytes were plated at 10.5 × 103 cells/cm2 in Cell-Bind plates 
(Corning) and cultured in DMEM supplemented with 10% FBS (Thermo Scientific), 10% horse 
serum (Invitrogen), 1% nonessential amino acids (Invitrogen), 2mM glutamine (Invitrogen), and 
50U/ml penicillin/streptomycin at 37oC, 6% CO2. Cells were cultured for 7 days in vitro (DIV) and 
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visually inspected for MDM differentiation before use in HIV-infection experiments. MDM were 
cultured for 7-10 DIV before use in noninfectious experiments.  
 
HIV infection of MDM 
 
Differentiated MDM were exposed to 0.2-50ng of p24 of HIV per 106 cells for 24 hours. All HIV-1 
virus stocks were prepared by the University of Pennsylvania Center for AIDS Research Virology 
Core (Table 6.8) through transfection of 293T cells for molecularly cloned viruses or by 
amplification in primary human peripheral blood mononuclear cells. HIV-1 89.6 accessory gene 
mutants have been described previously (528). HIV-2 CBL-20 virus stock was obtained from Dr. 
Robin Weiss through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH. 
Supernatants from HIV-infected or noninfected (Mock) MDM were collected every 3 days through 
12 days post-infection and stored at -80oC. Supernatants were monitored for HIV replication by 
quantifying cell associated HIV-1 p24 content, as analyzed by Western blot, or by viral reverse 
transcriptase (RT) activity, as analyzed by the amount of radiolabeled deoxythymidine 
incorporation (529). Briefly, 10µl of MDM supernatant is incubated with 50µl of RT cocktail (50µM 
Tris pH 7.8, 75µM KCl, 5µM MgCl2, 0.05% NP-40, 2µM DTT, 5µg/ml, 1.6 mU poly(rA)·p(dT)12-18, 
and 10µCi/ml dTTP [α-32P]) at 37oC overnight. 30µl of sample is dotted onto DE81 Whatman ion 
exchange cellular chromatography paper (Fisher) and air dried for 30 minutes, washed four times 
with 2X UltraPure SCC (Invitrogen), washed once in absolute ethanol, and dried at 80-100oC for 
30 minutes. Whatman paper is then placed in scintillation vial with 5ml of Scintiverse BD cocktail 
(Fisher) and counted for 32P in a scintillation counter. 
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Donor/ 
Sourcea 
Strain 
Isolate 
Type 
Co-receptor 
Usage 
Tissue 
Isolated 
From 
Clinical Diagnoses Reference 
A Jago Swarm CCR5 CSF AIDS Dementia  
Complex Stage 0.5 
(530) 
B Doge Swarm CCR5 CSF AIDS Dementia  
Complex Stage 1 
(530) 
C TYBE Swarm CXCR4 CSF CMV Encephalitis (530, 531) 
D BR-2 Swarm CCR5 Brain  Progressive  
Dementia  
(532, 533) 
D CSF-2 Swarm CCR5 CSF Progressive  
Dementia 
(532, 533) 
E BL-3 Swarm CXCR4 PBMC  (534) 
F SF162 Swarm CCR5 CSF Toxopplasmosis,  
Acute Meningitis 
(535, 536) 
G JR-FL Swarm CCR5 Frontal Lobe AIDS Encephalopathy,  
Kaposi's Sarcoma 
(537, 538) 
G JR-CSF Swarm CCR5 CSF AIDS Encephalopathy,  
Kaposi's Sarcoma 
(537, 538) 
H 89.6 Clone CCR5/ CXCR4 Blood AIDS with no  
neurological disease 
(538, 539) 
I NL43 Clone CXCR4 Blood/  
bone marrow 
AIDS and non-AIDS (540) 
J 3B Swarm CXCR4 Blood/  
bone marrow 
AIDS and non-AIDS (541, 542) 
K YU2 Clone CCR5 Brain HIV-1 Associated  
Encephalopathy 
(543) 
L Bal-1 Swarm CCR5 Lung Pediatric patient  
with AIDS 
(544) 
M ADA Swarm CCR5 Blood Kaposi's Sarcoma (545) 
 
Table 6.8 Characteristics of select HIV-1 clade B strains prepared by the Center for AIDS 
Research Virology Core at the Perelman School of Medicine at the University of Pennsylvania, 
Philadelphia, PA, USA.  
aStrains with the same donor/source identifiers were isolated from the same individual 
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Western blot analysis 
MDM cultures were rinsed with ice-cold PBS, lysed in 75mM Tris-HCL (pH 6.8) containing 15% 
glycerol, 3.75mM EDTA, and 3% SDS, and supplemented with Complete Protease Inhibitor 
Cocktail (Roche) and PhosSTOP phosphatase inhibitor mixture (Roche). MDM protein lysates 
were subjected to SDS-PAGE as previously described (46) using primary and secondary 
antibodies listed in Tables 6.6 and 6.7 Protein expression as determined by Western blotting was 
normalized to GAPDH expression. 
 
RNA quantification and qPCR analysis 
 
Cell cultures were rinsed in ice-cold PBS and RNA was isolated using RNeasy Kit (Qiagen) per 
manufactures instructions. RNA concentration and quality was analyzed by NanoDrop 2000c 
(Thermo Scientific). Following cDNA generation using Reverse Transcriptase Kit (Applied 
Biosciences), quantitative real-time PCR (qPCR) was performed using RealMasterMix (5Prime) 
on a MasterCycler RealPlex 2 (Eppendorf) with the primer sets listed in Table S4 in the 
supplemental material.  
 
MDM-mediated neurotoxicity and MDM extracellular glutamate 
 
Rat cerebrocortical mixed neuroglial cultures (~80% neurons, 20% glia) were prepared from E17 
embryos of Sprague-Dawley rats, as previously described (46). Cells were plated in tissue-culture 
plates pre-coated with poly-L-lysine (Peptides International) and maintained in neurobasal media 
plus B27 supplement (Invitrogen) at 37oC and 5% CO2. After 7 DIV, approximately one-half 
volume of fresh media was added to the cells to replace evaporation losses. All cultures were 
used between days 14 and 17 DIV. Cell-based MAP2 ELISAs were performed on primary rat 
cerebrocortical cells plated at a density of 1x104 cells/well in 96-well plates as previously 
described (42, 46). Following a 24 hour exposure to HIV-MDM supernatant (n = 6 technical 
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replicates), neuronal cultures were fixed and fluorescently labeled using the following reagents: 
mouse anti-MAP2 (Covance), goat anti-mouse β-lactamase TEM-1 conjugate (Invitrogen), and 
Fluorocillin Green substrate (Invitrogen). Fluorescence intensity was measured using a flour 
metric plate reader with a 480/520-nm filter set. MDM supernatant was applied at 1:10-1:60 
dilution; the dilution that gave values within the linear range of the assay is presented. For 
uninfected MDM experiments pure neuronal cultures (~97-99% neurons, 5x104 cells/well) were 
used in order to detect lower levels of neurotoxicity. To obtain pure neuronal cultures cells were 
treated with 10µM arabinosylcytosine 48 hours after plating and otherwise handled as described 
above. Neuronal survival was expressed as a percentage of untreated (UT) cultures. In previous 
publications we have demonstrated that this MAP-2 ELISA quantification robustly correlates with 
neuronal death as determined by hand counts of surviving MAP-2 stained neurons in this culture 
system (546, 547). 
 
MDM extracellular glutamate 
  
Glutamate concentration in MDM supernatant was assayed in triplicate using the Amplex Red 
Glutamic Acid/Glutamate Oxidase Assay Kit (Invitrogen) according to the manufacturer’s 
directions.  
 
ART preparation  
 
Stock solutions of Tenofovir disoproxil fumarate, Efavirenz, Atazanavir sulfate, Ritonavir, and 
Raltegravir were prepared in DMSO and stock solution of Emtricitabine was prepared in H2O and 
stored at -20oC until use. All ART drugs were provided by the NIH AIDS Research and Reference 
Reagent Program. 
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Statistics 
 
All quantifications are expressed as mean ± SEM. Two-tailed student’s t-test or one-way ANOVA 
followed by a Holm-Sidak post-test were performed on indicated comparisons. α = 0.05 unless 
otherwise noted in order to correct for multiple comparisons. Statistical input support was 
provided by the Biostatics and Data Management Core, Center for AIDS Research, Perelman 
School of Medicine, University of Pennsylvania.  
 
Study approval 
 
All animal studies and protocols were carried out in accordance with the NIH Guidelines for the 
Care and Use of Laboratory Animals and approved by the University of Pennsylvania IACUC. All 
human studies and protocols for monocyte isolation were reviewed and approved by the 
University of Pennsylvania IRB and all participants provided written informed consent. 
 
6.5 Material and Methods for Chapter 11  
 
Isolation and culture of MDM; Western blot analysis; MDM-mediated neurotoxicity; MDM 
extracellular glutamate 
 
See section 6.4 
 
HIV infection of MDM 
 
Differentiated MDM were exposed to 50-100ng of p24 of HIV-1 89.6 (R5/X4 strain) or Jago (R5 
strain) per 106 cells for 24 hours. HIV-Jago is a macrophage-tropic CSF isolate from a patient 
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with confirmed HIV-associated dementia (530). Virus stocks were prepared by the University of 
Pennsylvania Center for AIDS Research Virology Core. Supernatants from HIV-infected or 
noninfected (mock) MDM were collected every 3 days and stored at -80oC. Supernatants were 
monitored for HIV replication by quantifying viral reverse transcriptase (RT) activity, as previously 
described (see section 6.4; (43)).  
 
siRNA knockdown 
 
Silencer® Select siRNAs (Ambion; Table 6.9) were transfected at a final concentration of 50nM 
using Lipofectamine RNAiMax (Invitrogen). Lipofectamine and siRNA were pre-incubated for 10 
minutes in 50µl of Opti-Mem (Invitrogen) prior to treatment of MDM. All knockdown experiments 
were verified by Western blot. Transfection efficiency was evaluated using the BLOCK-IT™ Alexa 
Fluor® Red Fluorescent Oligo (Invitrogen).  
 
Drugs and chemical preparations 
  
Stock solutions of DMF, MMF, tBHQ, and camptothecin (Sigma-Aldrich) were prepared in DMSO 
and stored at -20oC until use. CoPP and SnMP (Frontier Scientific) were prepared in 1N NaOH 
and stored at -20oC until use. Stock solutions of mercaptosuccinic acid and dicoumarol (Sigma-
Aldrich) and IFNγ, TNFα, and LPS (Peprotech) were prepared in PBS and stored at -20oC until 
use. Stock solutions of efavirenz (NIH AIDS Research and Reference Reagent Program) were 
prepared in DMSO and frozen at -80oC until use.  
All human studies and protocols for monocyte isolation were reviewed and approved by the 
University of Pennsylvania IRB and all participants provided written informed consent. 
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Human Gene 
mRNA Targeted 
Company Product Line siRNA ID 
Number 
BACH1 
Ambion  
(Life Technologies) 
Silencer® Select s1859 
BACH1 
Ambion  
(Life Technologies) 
Silencer® Select s1860 
HO-1 
Ambion  
(Life Technologies) 
Silencer® Select s6673* 
HO-1 
Ambion  
(Life Technologies) 
Silencer® Select s6674 
HO-2 
Ambion  
(Life Technologies) 
Silencer® Select s6675* 
HO-2 
Ambion  
(Life Technologies) 
Silencer® Select s6677 
Scramble 
Ambion  
(Life Technologies) 
Silencer® Select 
Catalog #: 
4390846* 
 
 
Table 6.9 Small interfering RNAs (siRNAs) used for knockdown experiments.  
*siRNAs used in HIV-MDM experiments.  
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Statistics 
 
All quantifications are expressed as mean ± SEM. Two-tailed student’s t-test or one-way ANOVA 
followed by a Holm-Sidak post-test were performed on indicated comparisons. α = 0.05 unless 
otherwise noted in order to correct for multiple comparisons. Statistical input support was 
provided by the Biostatics and Data Management Core, Center for AIDS Research, Perelman 
School of Medicine, University of Pennsylvania.  
 
Study approval 
 
All animal studies and protocols were carried out in accordance with the NIH Guidelines for the 
Care and Use of Laboratory Animals and approved by the University of Pennsylvania IACUC. All 
human studies and protocols for monocyte isolation were reviewed and approved by the 
University of Pennsylvania IRB and all participants provided written informed consent. 
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7.1 Abstract 
 
HIV-associated neurocognitive disorders (HAND) affect up to 50% of HIV-infected adults, 
independently predict HIV morbidity/mortality, and are associated with neuronal damage and 
monocyte activation. Cerebrospinal fluid (CSF) neurofilament subunits (NFL, pNFH) are sensitive 
surrogate markers of neuronal damage in several neurodegenerative diseases. In HIV, CSF NFL 
is elevated in individuals with and without cognitive impairment, suggesting early/persistent 
neuronal injury during HIV infection. Although individuals with severe cognitive impairment (HIV-
associated dementia (HAD)) express higher CSF NFL levels than cognitively normal HIV-infected 
individuals, the relationships between severity of cognitive impairment, monocyte activation, 
neurofilament expression, and systemic infection are unclear. We performed a retrospective 
cross-sectional study of 48 HIV-infected adults with varying levels of cognitive impairment, not 
receiving anti-retroviral therapy (ART), enrolled in the CNS Anti-Retroviral Therapy Effects 
Research (CHARTER) study. We quantified NFL, pNFH, and monocyte activation markers 
(sCD14/sCD163) in paired CSF/plasma samples. By examining subjects off ART, these 
correlations are not confounded by possible effects of ART on inflammation and 
neurodegeneration. We found that CSF NFL levels were elevated in individuals with HAD 
compared to cognitively normal or mildly impaired individuals with CD4+ T-lymphocyte nadirs 
≤200. In addition, CSF NFL levels were significantly positively correlated to plasma HIV-1 RNA 
viral load, and negatively correlated to plasma CD4+ T-lymphocyte count, suggesting a link 
between neuronal injury and systemic HIV infection. Finally, CSF NFL was significantly positively 
correlated with CSF pNFH, sCD163 and sCD14, demonstrating that monocyte activation within 
the CNS compartment is directly associated with neuronal injury at all stages of HAND.  
 
7.2 Introduction  
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HIV-associated neurocognitive disorders (HAND) are a common complication of HIV infection in 
the era of combined antiretroviral therapy (cART) that independently predicts overall morbidity 
and mortality (548-551). The clinical sub-syndromes of HAND vary in severity of cognitive 
impairment and associated functioning, and include asymptomatic neurocognitive impairment 
(ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD) (180). Although 
HIV does not infect neurons, cognitive impairment in HIV is associated with pathological evidence 
of neuronal damage (synaptic loss, dendritic simplification), as well as infection and activation of 
central nervous system (CNS) infiltrating monocyte-derived macrophages (197, 548, 552). Up to 
30% of HIV-infected individuals qualify for a diagnosis of ANI, 10-30% for MND, and 2-8% for 
HAD (548, 553); each diagnosis is based on neurocognitive testing and assessments of daily 
functioning in the absence of pre-existing or confounding diagnoses that may independently 
result in cognitive impairment. The temporal progression among these subtypes of HAND is not 
consistently linear, although they appear to be clinically and pathologically related (548, 553, 
554). Individuals with ANI have an increased risk of progression to functional decline compared to 
neurocognitively normal HIV-infected individuals (548, 553, 555-557). In addition, mild, moderate, 
and severe cognitive impairment have been associated with synaptodendritic injury (197, 548, 
553, 554), although the relationship between pathological abnormalities and severity of cognitive 
impairment has not been fully defined (558). 
 
Neurofilaments (NFs) are structural proteins specific to neurons that are released into the 
cerebrospinal fluid (CSF) and blood following axonal disruption or degeneration (559-561). The 
neurofilament core chains are of low, medium or high molecular weight (NFL, NFM, NFH, 
respectively) with varying degrees of phosphorylation; these proteins are expressed in a 
stereotypic and phylogenetically conserved manner throughout neuronal development (562, 563). 
Elevations in CSF NFL are a sensitive surrogate marker of neuronal damage, as evidenced by 
pathological white matter changes, in several neurodegenerative diseases, including Alzheimer’s 
disease, subcortical vascular dementia (564), amyotrophic lateral sclerosis (ALS) and multiple 
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sclerosis (MS) (565, 566). In HIV infection, CSF NFL levels are elevated both in early and later 
infection, in individuals with and without neurocognitive impairment (567, 568), although levels 
are highest in HAD (563, 569, 570). Moreover, CSF NFL levels increase with cART interruption, 
and decrease with cART initiation (569); neurocognitive performance improves in HAD in parallel 
with CSF NFL drop (563). Phosphorylated NFH (pNFH), a more protease resistant NF, has also 
been examined in multiple pathologies involving neuronal injury. Specifically, serum pNFH is 
elevated in amyotrophic lateral sclerosis (ALS) (571), optic neuritis (560) and following acute 
ischemic stroke (572). In addition, CSF and serum NFH concentrations correlate with each other 
in ALS (571). Neither CSF nor serum/plasma pNFH levels have been examined in HIV infection. 
In multiple sclerosis, CSF pNFH but not CSF NFL levels are higher in progressive patients 
compared with relapsing remitting patients. However, CSF NFL but not CSF pNFH levels predict 
early clinical disease progression from a first time demyelinating attack to relapsing/remitting 
disease (559, 573). Therefore, elevations in CSF NFL and pNFH, while both reflecting axonal 
damage, might have different associations with disease subtypes and/or disease progression, 
thus supporting separate investigation of each neurofilament subunit in HIV-infected individuals. 
 
Positive correlations between CSF NFL and CSF neopterin (a marker of intrathecal 
monocyte/macrophage activation) have been described in individuals with HAD (563, 569), 
supporting previous evidence that axonal degeneration is associated with such activation (574). 
Although plasma sCD163 has been correlated with HAND subtype (575), the relationship 
between plasma monocyte activation markers, CSF NF isoforms, and HAND subtype has not 
been defined. Among the monocyte activation markers is membrane-bound CD14, a receptor for 
lipopolysaccharide. Activation of CD14 is associated with CD14 cleavage and release from the 
cell membrane in a soluble form (sCD14). Notably, plasma sCD14 levels independently predict 
mortality (574, 576) and impaired neurocognitive test performance in HIV-infected subjects (33). 
In addition, plasma sCD14 is elevated in HIV-infected subjects with cerebral atrophy compared to 
those without cerebral atrophy (574). Thus, sCD14 is an excellent candidate biomarker of 
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monocyte/macrophage activation associated with HIV-induced neurodegeneration. Similar to 
CD14, CD163, a monocyte-associated hemoglobin/haptoglobin complex scavenger receptor, is 
cleaved and shed from activated monocyte/macrophages in a soluble form, sCD163 in 
inflammatory states (577). Plasma sCD163 levels are elevated HIV-infected subjects, particularly 
those with cognitive impairment (35, 575), and plasma levels decrease with cART in parallel with 
HIV RNA (35). In addition, CD163+ monocyte/macrophages accumulate in perivascular brain 
regions in individuals with HIV encephalitis (101, 578). The number of perivascular CD163+ 
monocyte/macrophages is positively correlated with plasma HIV load (102), suggesting trafficking 
of peripherally activated monocytes to perivascular areas in the brain. Finally, elevated plasma 
sCD163 levels have been demonstrated in cognitively impaired HIV-infected individuals 
compared with non-impaired individuals (575), although whether such levels are correlated with 
expression of markers of neurodegeneration is not known.  
 
To determine the relationship between neurodegeneration and monocyte/macrophage activation 
in HAND, as assessed by soluble biomarkers, we determined the correlations among levels of 
CSF neurofilament isoforms (NFL, pNFH), sCD14, and sCD163 across different stages of HAND 
and cognitively normal HIV-infected adult controls. We then examined associations of soluble 
biomarker levels with markers of systemic infection (plasma HIV-1 RNA viral load, CD4+ T-
lymphocyte count), and with global and domain-specific cognitive impairment and HAND stage. 
 
7.4 Results  
 
To avoid any potential confounding effects of ART on expression of selected biomarkers of 
inflammation and neuronal injury, we selected a study cohort of individuals currently not receiving 
ART. Cohort demographics, medical, and laboratory characteristics are summarized in Table 6.1. 
Among the 48 subjects examined 75% were male, and 53% were African American. The median 
age was 39.5 (IQR 36-47.5, range 19-62). Only plasma CD4+ T-lymphocyte count and plasma 
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HIV-1 RNA differed across HAND subtypes: CD4+ T-lymphocyte count was lower and plasma 
HIV-1 RNA was higher in HAD when compared with ANI, MND and neurocognitively normal 
controls (p=0.046, p=0.038, respectively). Thus, as expected, our subjects with HAD 
demonstrated greater immune deficiency and poorer systemic viral control, than those without 
HAD as has been previously demonstrated in ART-naïve patients (553, 557). Finally, only one 
subject (ANI) was actively using illicit drugs (marijuana, opioids) during this study. 
 
To determine the associations between neuronal injury, monocyte/macrophage activation and the 
severity of HAND, we first examined expression of neurofilament isoforms NFL and pNFH in CSF 
and expression of sCD163 and sCD14 in both CSF and plasma across the different sub-types of 
HAND. Among individuals with CD4+ T-lymphocyte nadirs ≤200, CSF NFL levels were 
significantly elevated in individuals with HAD compared with neurocognitively normal subjects and 
those with MND (Figure 7.1A). There were no differences among HAND subtypes in levels of 
CSF NFL across all CD4+ T-lymphocyte nadirs (Figure 7.1B), CSF pNFH (Figure 7.1, C and D), 
CSF/plasma sCD14, or CSF/plasma CD163 (data not shown). In addition, CSF NFL levels did not 
significantly differ across HAND subtypes by current CD4+ T-lymphocyte count among 
neurocognitively normal subjects in contrast to another recent study (579). Finally, because our 
cohort did not include HIV-negative individuals, we compared absolute NFL levels with historical 
age-specific controls using the same NFL ELISA assay (Uman Diagnostics, AB) (567). Using 
these historical controls, we found that 10/15 neurocognitively normal, 11/15 ANI, 11/15 MND, 
and 2/3 HAD subjects demonstrated elevated CSF NFL levels, suggesting ongoing subclinical 
neuronal injury in HIV-infected individuals regardless of neurocognitive status.  
 
Both CSF and plasma expression of sCD163 and sCD14 correlated within compartments (Figure 
7.2, A and B), as did CSF NFL and pNFH (data not shown). These strong intra-compartment 
correlations among similar mechanistic biomarkers support the conclusion that these markers are 
predictably detecting monocyte/macrophage activation and neuronal injury in these subjects. 
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Figure 7.1 CSF NFL is elevated in individuals with HAD and a history of 
immunosuppression. NFL concentrations in the CSF of HIV+ (A) individuals with CD4 count 
nadir ≤200 and (B) individuals with any CD4 count nadir. pNFH concentrations in the CSF of 
HIV+ (C) individuals with CD4 count nadir ≤200 and (D) individuals with any CD4 count nadir. 
Data is presented as median and IQR  with differences between groups evaluated using Kruskal-
Wallis tests. 
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Figure 7.2 Monocyte activation markers intra-compartmentally correlate within the CSF 
and plasma. Correlations between the monocyte markers sCD163 and sCD14 within the (A) 
CSF and (B) plasma across all HIV-infected individuals with and without HAND. Correlations 
were analyzed using Spearman’s correlation coefficients. 
 
 
 
 
Figure 7.3 CSF NFL correlates negatively with plasma CD4+ T-lymphocyte count and 
positively with HIV-1 RNA load. Correlations between CSF NFL concentrations and plasma (A) 
CD4+ T-lymphocyte count and (B) HIV-1 RNA load in all HIV-infected individuals with and without 
HAND. Correlations were analyzed using Spearman’s correlation coefficients. 
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Next, to assess the relationship between CSF markers of neurodegeneration, monocyte 
activation, and systemic HIV infection, and to determine whether markers of 
monocyte/macrophage activation correlate with neuronal injury in HAND, each of the above 
candidate biomarkers was examined in association with each other and with plasma HIV-1 RNA 
viral load and CD4+ T-lymphocyte count in all subjects, regardless of cognitive impairment. Here, 
CSF NFL was negatively correlated with CD4+ T-lymphocyte count (Figure 7.3A) and positively 
correlated with plasma HIV-1 RNA viral load (Figure 7.3B), suggesting a relationship between 
neuronal damage and systemic HIV infection. CSF pNFH did not demonstrate the same 
correlations with markers of systemic HIV infection. Additionally, CSF NFL and pNFH levels 
correlated strongly and positively with CSF sCD163 (Figure 7.4, A and B) and CSF sCD14 
(Figure 7.4, C and D), thus indicating that monocyte/macrophage activation within the CNS 
compartment is tightly linked to neuronal injury. In contrast to CSF expression, plasma expression 
of sCD14 and sCD163 did not correlate with CSF NFL or CSF pNFH. This suggests either no 
association between systemic monocyte/macrophage activation and CNS neuronal injury in this 
untreated cohort or a low level of sensitivity of plasma sCD14 and sCD163 detection as 
biomarkers for CNS neuronal injury in comparison with CSF sCD14 and sCD163.  
 
Examination of biomarker associations with cognitive testing subdomain and global cognitive 
scores demonstrated that CSF pNFH was significantly higher in subjects with impaired speed of 
information processing (median CSF pNFH 103 pg/mL in unimpaired compared to 371 pg/mL in 
impaired subjects, total CSF pNFH range 96-1144 pg/mL, p=0.018) and memory (median CSF 
pNFH 103 pg/mL in unimpaired compared to 220 pg/mL in impaired subjects, p=0.021) compared 
to unimpaired subjects, although the magnitude of this effect was small. There were no significant 
correlations among NFL, plasma/CSF sCD14 or sCD163 and subdomain global deficit scores or 
impairment (data not shown).  
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Figure 7.4 Neurofilament concentrations positively correlate with monocyte activation markers 
within the CSF Correlations between sCD163 and (A) NFL and (B) pNFH and between sCD14 
and C) NFL and D) pNFH within the CSF of all HIV-infected individuals with and without HAND. 
Correlations were analyzed using Spearman’s correlation coefficients. 
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Finally, to investigate whether Hepatitis C virus (HCV) serostatus affected the relationships 
described above between the neurofilament isoforms, monocyte activation markers, and HAND 
subtypes, we performed an exploratory analysis examining concentrations of each of these 
markers across HAND for HCV+ and HCV- subjects separately. No statistically significant 
differences were found (data not shown). To determine whether a differential level of peripheral or 
central monocyte activation was present in HCV+ versus HCV- subjects, we then compared 
monocyte activation marker concentrations between these populations. After removing outlier 
values, none of the markers examined was significantly different between HCV+ and HCV- 
subjects (data not shown). 
 
6.5 Discussion  
 
We have demonstrated a strong correlation between CSF markers of neuronal damage (NFL, 
pNFH) and monocyte/macrophage activation (sCD14 and sCD163) in an unselected cohort of 
viremic HIV-infected individuals not receiving ART. No correlations between CSF NFL/pNFH and 
plasma sCD14 and sCD163 were demonstrated. In addition, plasma sCD163 did not vary 
significantly across different HAND subtypes, in contrast with a previous study of virologically-
suppressed individuals on ART (575). However, plasma sCD163 levels in our cohort were higher 
than those observed in the previous study, which could reflect other factors contributing to 
monocyte/macrophage activation in this cohort, including perhaps uncontrolled peripheral HIV 
infection, co-infection with HCV, or syphilis in some individuals (Table 6.1). Nonetheless, our 
study clearly demonstrates that CNS monocyte/macrophage activation, as measured by CSF 
sCD163 and sCD14 is strongly correlated with neuronal injury, and based on our current 
understanding of HIV neuropathophysiology, this likely represents a causal association. 
 
The possible association between CSF neurofilaments and severity of cognitive impairment in 
HIV infected individuals has not been fully described and involves complex and numerous 
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variables. Similar to others (563, 569, 570), we found that CSF NFL was significantly elevated in 
HAD subjects compared with those with milder (MND) or no cognitive dysfunction; this 
relationship was observed only in individuals with CD4 count nadirs ≤200, which is strongly 
associated with an increased risk for HAND (10, 553, 557). Recent studies have demonstrated 
significant elevations in CSF NFL in individuals with acute HIV infection and in HIV-infected 
individuals without cognitive impairment (567, 568), although higher levels are observed in 
individuals with HAD, the most severe form of HAND. Elevated CSF NFL in acute HIV infection 
has also been associated with low N-acetylaspartate/creatine ratios (another indicator of neuronal 
injury) in cortex and white matter, as measured by brain magnetic resonance spectroscopy (568). 
In contrast, our study failed to demonstrate significant elevations of CSF NFL in ANI and MND 
individuals when compared with neurocognitively normal HIV-infected individuals, although we do 
not have a seronegative control group to determine whether CSF NFL is elevated in our 
seropositive neurocognitively normal control group. In examining previously published age-
specific normative data from 107 HIV-uninfected subjects using the same ELISA platform (567), it 
does indeed appear that a significant proportion of our neurocognitively normal, ANI, and MND 
subjects had NFL elevations compared to uninfected controls. These data imply that many of our 
untreated subjects have ongoing subclinical CNS injury. But this conclusion is inherently limited 
by the use of historical controls. Thus, although CSF NFL can be considered to be sensitive 
marker of neuronal injury in the CNS in HIV infection, whether it reliably predicts or correlates with 
the severity of neuronal injury and neurocognitive impairment remains undefined.  This is clearly 
an important gap in our understanding of the significance of the relative degree of neuronal injury 
in determining the presence and/or severity symptoms of cognitive dysfunction in HIV infection. 
 
Our data suggest that CSF pNFH levels in individuals with HAND differ in comparison with CSF 
NFL levels. While CSF pNFH did not vary significantly across the different HAND sub-types, on 
cognitive testing subdomain assessment, we demonstrated significant associations with CSF 
pNFH and impaired speed of information processing and memory. However, the magnitude of 
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effect was small. Speed of information processing is dependent on multiple neurologic pathways, 
and therefore may be non-specifically affected compared to other, more localizable subdomains. 
In addition, CSF pNFH had an even stronger correlation with CSF markers of monocyte activation 
compared to CSF NFL, suggesting that these different neurofilament isoforms may represent 
distinct neuronal injury pathways with ultimately different clinical implications. 
 
Our study showed no significant correlation between CSF NFL level and current CD4 count 
among neurocognitively normal HIV-infected subjects as demonstrated in previous studies (569, 
579), perhaps reflecting a sample size too small to stratify into CD4 subgroup ranges. However, 
our data was significant for a negative correlation between CSF NFL and plasma CD4+ T-
lymphocyte count across all strata of cognitive impairment, as well as a positive correlation 
between CSF NFL and plasma HIV-1 RNA viral load. Taken together, these data suggest more 
neuronal injury in more advanced (or poorly controlled) systemic infection, and may suggest a 
part of a mechanistic link to the clinical observation that low CD4+ T-lymphocyte count and high 
viral load are risk factors for HAD in untreated HIV infection. Notably, there was not a similar 
correlation between CSF pNFH and the same plasma markers of systemic HIV infection. 
 
Because identifying a valid plasma biomarker for neuronal injury and/or HAND in HIV-infected 
individuals is still an unmet need, we considered the potential usefulness of neurofilament 
isoforms as such biomarkers. Published studies indicate that NFL is quickly proteolytically 
degraded in blood specimens, while pNFH is more protease-resistant (559). Based on prior 
investigations demonstrating serum pNFH elevation in other neurodegenerative diseases (560, 
571, 572), serum pNFH could serve as a biomarker for neurodegeneration in the brain and/or 
spinal cord, each of which is affected in many individuals with HIV infection. Analyses of serum 
neurofilament isoforms in HIV infection have not been reported. However, despite demonstrating 
pNFH in CSF samples from our cohort, we failed to detect pNFH in matched plasma samples. 
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About one-third of our overall study population was Hepatitis C virus (HCV) positive, consistent 
with other estimates in adult HIV-infected populations (297, 302). However, HCV was not present 
in any subject with HAD. Prior literature suggests that individuals co-infected with both HIV and 
HCV have worsened cognitive impairment compared to HIV infection alone (306, 309). 
Mechanistically, HCV replicates in CD68+ macrophages of autopsied HIV-infected brain tissue 
(299), and is associated with increased macrophage expression of pro-inflammatory cytokines 
(300). Co-infection with HCV and HIV may therefore affect neurocognitive status via its effects on 
monocyte/macrophage activation (580). However, in this study we did not observe a difference in 
monocyte activation marker concentrations between all HCV+ and HCV- subjects, nor did we 
observe a difference in neurofilament isoforms concentrations or monocyte activation marker 
concentrations in HCV+ and HCV= subjects when analyzed across the spectrum of HAND. 
Whether these findings are truly representative of HIV/HCV co-infection neuropathology, or if they 
were limited by our sample size or other confounding factor not accounted for in these 
associations is unclear. 
 
Our study had several limitations. First, because ART is now widely distributed, recruiting ART-
free individuals is particularly difficult; our study therefore included a small cohort size (n=48) with 
few HAD subjects (n=3). Thus, sub-analyses with even smaller numbers (e.g. the relationship 
between HAND and CSF NFL among patients with CD4 count <200) may have limited potential 
biological significance. However, these data are consistent with other prior reports, and the 
possible effect of a history of profound immunosuppression on these relationships is thought 
provoking. Second, because this was a cross sectional correlation study, factors confounding the 
relationship between monocyte/macrophage activation and HAND status are not accounted for in 
statistical associations. However, relevant covariates were equivalent across the different 
subtypes of HAND, except for CD4+ T-lymphocyte count and viral load, which are known risk 
factors for HAD. In addition, causality cannot be inferred in a cross sectional study. Finally, by 
including only HIV-infected viremic subjects not receiving ART, we might obscure relevant 
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associations between plasma monocyte/macrophage activation and neurodegeneration because 
of high levels of plasma monocyte/macrophage activation in untreated, viremic subjects. 
Nonetheless, we have eliminated the possibility of unanticipated effects of ART on inflammation 
and neurodegeneration. 
 
In summary, we have demonstrated a positive correlation between expression of CSF 
neurofilament isoforms and CSF sCD14 and sCD163 in viremic HIV-infected individuals not 
receiving ART, thus directly linking CNS monocyte/macrophage activation with neuronal injury. 
Future studies may examine if this relationship is specific to HIV neuropathogenesis, or if it is 
observed in other neuroinflammatory disorders as well. Furthermore, sCD14 and sCD163 levels 
are highly correlated in CSF and plasma, suggested that monocyte/macrophage activation can 
reliably be detected by ELISA in such stored tissue specimens. We have also confirmed that 
severe CD4 depletion (a risk factor for HAD) is associated with elevated CSF NFL levels at the 
time of diagnosis of HAD, and that elevated CSF NFL levels are highly correlated with low CD4+ 
T-lymphocyte counts and high plasma HIV-1 RNA viral load, suggesting a link between neuronal 
injury and systemic HIV infection. A previous study has suggested that CSF NFL can serve as a 
predictive biomarker for HAD in individuals not receiving ART (570). Whether CSF NFL is a 
sensitive predictor of risk for HAND subtypes, and whether sCD14 and sCD163 might also have 
predictive value on later development/progression of HAND in viremic versus aviremic ART-
experienced individuals remains to be determined. Finally, we have demonstrated somewhat 
different correlations of NFL and pNFH with respect to cognitive measurements, suggesting that 
the different neurofilament isoforms may represent distinct neuronal injury pathways in HIV 
neuropathophysiology.
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8.1 Abstract 
 
Heme oxygenase-1 (HO-1) is a highly inducible, detoxifying enzyme critical for limiting oxidative 
stress, inflammation, and cellular injury within the central nervous system (CNS) and other 
tissues. In several neurodegenerative diseases brain HO-1 expression is increased, presumably 
to protect against concurrent insults. Our analysis of HO-1 expression in the brain prefrontal 
cortex of HIV-infected individuals demonstrated a significant HO-1 protein deficiency, even in 
HIV-infected subjects treated with antiretroviral therapy (ART). This HO-1 deficiency was 
particularly striking in individuals with the pathological diagnosis of HIV-encephalitis (HIVE). This 
loss of HO-1 protein expression within the prefrontal cortex associated with cognitive dysfunction, 
CNS HIV replication, type I interferon responses, and macrophage activation. Additionally, we 
observed a reduction of HO-1 protein expression in the striatum of subjects with HIVE, although 
no alterations in HO-1 protein expression were seen in the occipital or cerebellar cortex. These 
findings identify HO-1 as a host factor that is deficient in the brains of HIV-infected individuals and 
suggest that loss of HO-1 and its protective functions may contribute to such HIV 
neuropathogenesis. Rescue of this deficiency through induction HO-1 in the CNS of HIV-infected 
antiretroviral therapy-treated patients could provide a novel approach for protection against 
neurodegeneration and associated cognitive dysfunction. 
 
8.2 Introduction  
 
HO-1 is a sentinel, detoxifying enzyme that is induced in response to numerous insults including 
inflammation and oxidative stress (581-583). The potent anti-inflammatory and cytoprotective 
actions of HO-1 have identified it as a potential therapeutic target in CNS inflammatory and 
neurodegenerative diseases (584, 585). Among these diseases, HIV infection is associated with 
neurodegeneration that is thought to result from effects of persistent inflammation and oxidative 
stress in both systemic and CNS compartments that persists in individuals on ART (93, 161, 258, 
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574). Within the CNS, such effects are driven by HIV infection of macrophages and microglia and 
contribute to the continued prevalence of cognitive, motor, and behavioral deficits collectively 
known as HIV-associated neurocognitive disorders (HAND) (180, 586), which affect up to 50% of 
HIV-infected ART-treated individuals (8, 10). This high prevalence of HAND strongly underscores 
the need for adjunctive therapies that target the neuropathological processes associated with 
persistent inflammation and oxidative stress in HIV-infected individuals. We have identified HO-1 
as a potential targetable host factor that may contribute to HIV-associated neuropathological 
processes using human brain specimens from a large cohort of HIV-infected individuals.  
 
Two heme oxygenase isoforms (HO-1 and HO-2) are expressed to varying levels in nearly all cell 
lineages, but only HO-1, the rapidly inducible isoform, is considered to be a critical mediator of 
the cellular response to injury (44). Elevated HO-1 expression has been observed in brain tissue 
from individuals with Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, perhaps 
reflecting a limited host protective response against ongoing injury (587-589). The protective 
functions of HO-1 have been linked to the enzyme’s degradation of heme, a strong pro-oxidant, 
and the subsequent generation of the anti-inflammatory and anti-oxidative products, carbon 
monoxide, biliverdin, and bilirubin (44), although non-enzymatic cytoprotective functions of HO-1 
through activation of oxidant-responsive transcription factors have also been proposed (410, 
411). HO-1 catabolism of heme also releases free iron, which can contribute to cellular oxidative 
damage and toxicity. However, free iron rapidly induces expression of ferritin, a ubiquitous 
intracellular protein that binds and stores iron in a non-toxic form. Expression of HO-1 is regulated 
through the Nrf2-dependent antioxidant response element (ARE), which regulates the induction of 
a coalition of antioxidant and detoxifying effector proteins (404).  
 
Through analysis of post-mortem brain tissue specimens from 156 individuals, we have 
demonstrated that HO-1 protein expression is deficient in the dorsolateral prefrontal cortex 
(DLPFC) of HIV-infected subjects and that this HO-1 deficiency is correlated with CNS viral load 
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and markers of immune activation. Additionally, we have shown that HIV-associated HO-1 
deficiency also occurs within the striatum, but not in the occipital cortex or cerebellum. These 
findings suggest that HO-1 deficiency may contribute to HAND neuropathogenesis and that 
restoring CNS HO-1 expression may attenuate neurodegenerative processes and thereby reduce 
the persistent risk of HAND in ART-treated individuals 
 
8.3 Results  
 
HO-1 protein expression is reduced in the prefrontal cortex of HIV-infected subjects 
 
To determine the expression of HO-1 in the brains of HIV-infected individuals, we used Western 
blotting to analyze the expression of HO-1, other canonical ARE effector proteins, and HO-2 in 
fresh-frozen autopsy specimens of DLPFC tissue from subjects enrolled in the National 
NeuroAIDS Tissue Consortium (NNTC). These included samples from HIV-negative subjects 
(HIV-, n=66), and HIV-positive subjects with and without HIV encephalitis (HIVE) (HIVE+, n=14 
and HIV+/HIVE-, n=76, respectively) (see Table 6.2 for summary of cohort demographics and 
clinical data). To normalize the protein data, we quantified both β-tubulin and GAPDH expression 
and herein present all brain protein expression data normalized independently to both of these 
protein loading controls in consecutive figures. Using either loading control, there was a 
significant reduction in HO-1 protein expression in the DLPFC of HIV+/HIVE- individuals in 
comparison with HIV- controls, with the HIVE+ subgroup showing even greater HO-1 deficiency 
(Figure 8.1, A and B; Figure 8.2A). HO-1 expression did not correlate significantly with age or 
post-mortem autopsy interval within the full cohort or within the HIV-, HIV+/HIVE-, or HIVE+ 
subgroups (data not shown).  
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Figure 8.1 HO-1 protein expression is deficient in the DLPFC of HIV-infected subjects (β-
tubulin). Protein expression in the DLPFC was assessed by Western blot in 66 HIV-negative (HIV-
), 76 HIV-positive without HIVE (HIV+/HIVE-), and 14 HIV-positive with HIVE (HIVE+) post-mortem 
brain tissue samples. Of the 76 HIV+/HIVE- subjects, 6 were neurocognitively normal (NCN) and 
37 were diagnosed with HAND. (A) Representative Western blot of ARE and HO-2 proteins in the 
DLPFC of HIV-, HIV+/HIVE-, and HIVE+ subjects. Protein expression levels were quantified by 
densitometry analysis, normalized to β-tubulin, and log transformed for comparison between 
groups for (B-C) HO-1, (D) HO-2, (E) NQO1, and (F) GPX1. The mean HIV- group protein 
expression was set to 0 (dotted line). Red lines indicate mean ± SEM. Groups were analyzed by 
ANOVA with post hoc Holm-Sidak test. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
HO-1
NQO1
GPX1
β-tubulin
GAPDH
29kD
28kD
21kD
35kD
55kD
-3
-2
-1
0
1
2
log
10
  N
QO
1 
Pr
ot
ein
 
   
   
  β
-tu
bu
lin
HIV- HIV+/
HIVE-
HIVE
n.s.
-3
-2
-1
0
1
2
log
10
  G
PX
1 
Pr
ot
ein
   
   
   
β-
tu
bu
lin
 
HIV- HIV+/
HIVE-
HIVE
n.s.
-3
-2
-1
0
1
2
log
10
  H
O-
1 
Pr
ot
ein
  
   
   
   
β-
tu
bu
lin
 **
*** ***
HIV- HIV+/
HIVE-
HIVE
-3
-2
-1
0
1
2
log
10
  H
O-
1 
Pr
ot
ein
  
   
   
   
β-
tu
bu
lin
***
HIV- NCN HAND
w/HIVE
HAND
***
****
**
HIV+
C
E F
B
A
β-tubulin
GAPDH
HIV- HIV+/HIVE- HIVE+
HO-2
-3
-2
-1
0
1
2
log
10
  H
O-
2 
Pr
ot
ein
  
   
   
   
β-
tu
bu
lin
 
HIV- HIV+/
HIVE-
HIVE
n.s.
D
35kD
35kD
55kD
HIV- HIV+/HIVE- HIVE+
111 
  
 
 
 
 
Figure 8.2 HO-1 protein expression is deficient in the DLPFC of HIV-infected subjects 
(GAPDH). ARE protein expression was assessed by Western blot in 66 HIV-negative (HIV-), 76 
HIV-positive without HIVE (HIV+/HIVE-), and 14 HIV-positive with HIVE (HIVE+) post-mortem 
DLPFC tissue samples. Of the 76 HIV+/HIVE- subjects, 6 were confirmed to be neurocognitively 
normal (NCN) and 37 were diagnosed with HAND. (A) Representative Western blot of ARE 
proteins in the DLPFC of HIV-, HIV+/HIVE-, and HIVE+ subjects. Protein expression levels were 
quantified by densitometry analysis, normalized to GAPDH, and log transformed for comparison 
between groups for (B-C) HO-1, (D) NQO1, and (E) GPX1. The mean HIV- group protein 
expression was set to 0 (dotted line). Red lines indicate mean ± SEM. Groups were analyzed by 
ANOVA with post hoc Holm-Sidak test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Further subgroup analysis revealed that HO-1 expression was reduced in HIV+/HIVE-subjects 
diagnosed with HAND compared to those diagnosed as neurocognitively normal when 
normalized to β-tubulin (Figure 8.1C), although this comparison was not significant when GAPDH 
expression was used to normalize (Figure 8.2B). Notably, the two HIVE+ subjects who did not 
demonstrate HO-1 deficiency (Figure 8.1B; Figure 8.2A) had neurocognitive impairment attributed 
to causes other than HAND. Use of ART was not associated with a significant difference in HO-1 
expression levels in either HIV+/HIVE- or HIVE+ subjects (Figure 8.3). 
 
There were no significant differences in expression of either heme oxygenase-2 (HO-2), a 
ubiquitously-expressed heme oxygenase isoform (47% homology with HO-1) that is not regulated 
through the ARE, or the ARE effector protein NAD(P)H quinone oxidoreductase 1 (NQO1) among 
the HIV-, HIV+/HIVE-, and HIVE+ subgroups (Figure 8.1, D-E ; Figure 8.2, C-D). Similarly, 
expression of the ARE effector protein glutathione peroxidase 1 (GPX1) did not significantly differ 
among these groups when normalized to β-tubulin (Figure 8.1F), although GPX1 expression 
showed a significant decrease in HIVE+ subjects compared with HIV+/HIVE- and HIV- subjects 
when normalized to GAPDH (Figure 8.2E). We attempted to analyze Nrf2 (the major ARE 
transcriptional regulator) by Western blot in the DLPFC. Using an extended panel of commercially 
available Nrf2 antibodies, we were unable to reliably detect immunoreactivity consistent with Nrf2 
protein expression, despite detecting transfected Nrf2 gene products in HEK cells (data not 
shown). We therefore cannot confirm Nrf2 protein expression levels in brain tissue; however, the 
lack of significant differences in the expression of the ARE proteins NQO1 and GPX1 in the 
DLPFC suggests that Nrf2-dependent ARE activity is not altered by HIV-infection.  
 
Brain HO-1 protein deficiency in HIV-infection varies regionally  
 
To determine whether brain HO-1 deficiency in HIV-infection is restricted to the DLPFC, we 
similarly analyzed HO-1 protein expression in the striatum (head of the caudate), occipital cortex 
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Figure 8.3 ART exposure is not associated with DLPFC HO-1 deficiency in HIV+ subjects 
with or without HIVE. HO-1 protein expression was assessed by Western blot and densitometry 
signal was normalized to (A) β-tubulin and (B) GAPDH in 10 ART-naive HIV+ subjects without 
HIVE, 49 ART-experienced HIV+ subjects without HIVE, 5 ART-naive subjects with HIVE, and 8 
ART-experienced subjects with HIVE. No significant difference was observed in DLPFC HO-1 
expression in ART-naive or ART experienced subjects in HIV+ subjects with or without HIVE. 
DLPFC HO-1 expression was significantly reduced in HIVE subjects compared with HIV+ subjects 
without HIVE in both the ART-naive and ART-experienced groups. The mean HIV- protein 
expression was set to 0 (dotted line). Red lines indicate mean ± SEM. Groups were analyzed by 
ANOVA with post hoc Holm-Sidak test. *p < 0.05, ***p < 0.001. 
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and cerebellum (anterior cerebellar cortex) in 12 HIV-, 12 HIV+/HIVE-, and 10 HIVE cases. This 
regional analysis cohort was matched for age, post mortem interval, sex, race, and ethnicity. We 
observed a significant reduction in HO-1 protein expression in the striatum of HIVE+ subjects 
compared to HIV- and HIV+/HIVE- subjects (Figure 8.4A; Figure 8.4A). However, we did not find 
any significant changes in HO-1 protein expression in the occipital cortex or cerebellum (Figure 
8.4, B and C; Figure 8.5, B and C). In each of these regions, the expression of HO-2, NQO1, and 
GPX1 proteins in the HIV- group did not significantly differ from either the HIV+/HIVE- or HIVE+ 
groups. (Figure 8.4, D-F; Figure 8.5, D-F), a finding consistent with that in the DLPFC.  
 
HO-1 deficiency in the prefrontal cortex of HIV-infected subjects correlates with neurocognitive 
dysfunction 
 
The deficiency in prefrontal cortex HO-1 expression in HIV+/HIVE- subjects with HAND compared 
with neurocognitively normal HIV+/HIVE- subjects (Figure 8.1C) suggests that HO-1 deficiency 
may play a role in neurocognitive impairment in HAND. To determine whether specific deficits in 
neurocognitive functioning associate with HO-1 deficiency, we correlated HO-1 expression with 
normalized neurocognitive test T-scores covering 7 cognitive domains. Individual domain T-
scores (and a Global T-score) were determined through a verified NNTC battery of 
neurocognitive tests (Table 6.3; (523)) in 69 HIV+ subjects who had undergone testing.  
 
Although we did not detect any significant correlation between prefrontal cortex HO-1 expression 
and neurocognitive performance when all subjects were grouped as one group, significant 
correlations were observed when subjects were grouped as either self-identified white/Caucasian 
or black/African-American (Table 8.1). HO-1 expression in the white/Caucasian population was 
correlated positively with performance in the Speed of Information Processing and Executive 
Function domains, which are considered to be performance functions that are driven by output 
from the prefrontal cortex (590, 591). In contrast, within the black/African-American population, 
115 
  
  
 
 
 
 
 
 
Figure 8.4 HO-1 is deficient in the striatum of HIV-infected subjects with HIVE (β-tubulin). 
HO-1 protein expression as determined by Western blot in the (A) striatum (head of caudate), (B) 
occipital cortex, and (C) anterior cerebellum of 12 HIV–, 12 HIV+/HIVE–, and 10 HIVE subjects. 
In the same cohort, HO-2, NQO1, and GPX1 protein expression was determined by Western blot 
in the (D) striatum, (E) occipital cortex, and (F) cerebellum. Protein expression levels were 
quantified by densitometry analysis, normalized to β-tubulin, and log transformed for comparison 
between groups. The mean HIV– group protein expression was set to 0 (dotted line). Red lines 
indicate mean ± SEM. Groups were analyzed by ANOVA with post hoc Holm-Sidak test. *P < 
0.05; ***P < 0.001. 
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Figure 8.5 HO-1 is deficient in the striatum of HIV-infected subjects with HIVE (GAPDH). 
HO-1 protein expression as determined by Western blot in the (A) striatum (head of caudate), (B) 
occipital cortex, and (C) anterior cerebellum of 12 HIV–, 12 HIV+/HIVE–, and 10 HIVE subjects. 
In the same cohort, HO-2, NQO1, and GPX1 protein expression was determined by Western blot 
in the (D) striatum, (E) occipital cortex, and (F) cerebellum. Protein expression levels were 
quantified by densitometry analysis, normalized to GAPDH, and log transformed for comparison 
between groups. The mean HIV– group protein expression was set to 0 (dotted line). Red lines 
indicate mean ± SEM. Groups were analyzed by ANOVA with post hoc Holm-Sidak test. *P < 
0.05; ***P < 0.001. 
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 HO-1/β-tubulin HO-1/GAPDH 
Standardized  
Cogntive 
Domain  
T-Score 
All White Black All White Black 
n = 63-69 n = 43-49 n = 15-16 n = 63-69 n = 43-49 n = 15-16 
b p b p b p b p b p b p 
Global 0.79 0.63 3.68 0.05 -8.97 0.04# 2.65 0.10 5.29 0.004# -7.55 0.099 
Executive 2.15 0.30 6.52 0.01† -13.62 0.001# 4.71 0.02† 8.61 <0.001# -12.10 0.009# 
Speed of  
Processing 1.98 0.29 5.60 0.007
# -10.95 0.11 3.47 0.06 6.37 0.002# -6.89 0.34 
Attention  
Working  
Memory 
-0.12 0.95 2.47 0.31 -11.73 0.03† 2.13 0.30 4.53 0.06 -10.91 0.05 
Learning 0.11 0.96 2.63 0.24 -4.08 0.28 2.14 0.25 4.77 0.03† -5.51 0.14 
Memory 2.07 0.32 4.35 0.09 -1.71 0.75 3.78 0.07 6.21 0.01† -3.74 0.49 
Verbal  
Fluency 1.28 0.48 2.02 0.15 -1.37 0.86 1.91 0.30 3.33 0.11 0.24 0.98 
Motor 0.62 0.77 4.59 0.05† 13.26 0.04† 2.16 0.31 5.38 0.02† -8.48 0.23 
 
 
Table 8.1 DLPFC HO-1 expression in HIV+ subjects correlates differentially with neurocognitive 
domain T-scores in racial subpopulations. Correlations were determined between HO-1 
expression as measured by Western blot (normalized to β-tubulin or GAPDH) in all HIV+ subjects 
with neurocognitive testing performed and in the self-identified White/Caucasian and 
Black/African American subpopulations. Correlations were determined from a multivariate linear 
regression where b is the slope of the line of association and p is the p-value versus the null 
hypothesis (b = 0). Analysis was corrected for years of education and age at time of 
neurocognitive testing as covariants. Sample size variations are due to availability of data; not all 
subjects completed the full battery of neurocognitive tests. To correct for multiple comparisons, 
domain T-scores α = 0.01; Global T-score does not require correction, α = 0.05.  
#p < 0.05 and significant after adjusting for multiple comparisons  
†p < 0.05 and not significant after adjusting for multiple comparisons  
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HO-1 expression was negatively correlated with performance in the Executive Function domain. 
HO-1 expression levels did not differ between these two populations, however (data not shown). 
Thus, these results suggest complex associations between brain HO-1 deficiency and cognitive 
performance that could be modulated by host factors differentially expressed in white/Caucasian 
and black/African American populations. Larger cohort studies are clearly needed to further 
define these relationships.       
 
HO-1 prefrontal cortex deficiency correlates with CNS viral load, type I interferon response, and 
macrophage activation  
 
We further sought to determine the relationships among HIV replication and associated markers 
of immune activation and HO-1 expression. In HIV+ subjects, prefrontal cortex HO-1 expression 
correlated negatively with both cerebrospinal fluid (CSF) and prefrontal cortex parenchyma HIV 
RNA load, but not with plasma viral load or CD4+ T-lymphocyte counts (Figure 8.6, A-D; Figure 
8.7, A-D). This suggests that CNS HO-1 deficiency associates with ongoing HIV replication within 
the CNS compartment, but not with HIV replication in the periphery. As increased levels of 
markers of immune activation and the inflammatory type I interferon pathway are associated with 
the presence of HAND and high levels of brain parenchyma HIV RNA (527, 558), we assessed 
the mRNA expression of several markers of immune activation within our entire cohort. 
Expression of mRNA of the type I interferon-inducible genes ISG15 and MX1 correlated 
negatively with HO-1 expression (Figure 8.8, A and B; Figure 8.9, A and B), while no significant 
correlation with mRNA expression of IRF1, a predominantly type II interferon response gene 
(592), was observed (Figure 8.8C; Figure 8.9C). Expression of mRNA of the 
macrophage/microglia activation marker and haptoglobin-hemoglobin scavenging receptor 
CD163 (593) correlated negatively with HO-1 expression (Figure 8.8D; Figure 8.9D). The link to 
CD163, which is expressed by perivascular macrophages as well as a unique subset of ramified 
grey matter microglia in HIVE (101, 594), was relatively specific as the macrophage activation 
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marker CD68 and the cytotoxic T-lymphocyte marker CD8A were not correlated significantly with 
HO-1 (Figure 8.8, E and F; Figure 8.9, E and F). These results suggest that prefrontal cortex HO-
1 deficiency in HIV-infected individuals may be induced by CNS HIV replication and/or the 
associated innate immune activation of macrophages/microglia.  
 
7.4 Discussion 
 
The high prevalence of HAND in ART-treated HIV-infected individuals strongly emphasizes the 
need for adjunctive therapies that target the neuropathological processes that persist within the 
CNS despite the substantial benefit provided by ART (8, 10). These processes include 
inflammation and oxidative stress, which persist not only within the CNS but also within the 
systemic compartment in such individuals (93, 161, 258, 574). In our attempts to identify host 
factors that contribute to these processes, we have demonstrated a significant deficiency of the 
phase II detoxifying enzyme HO-1 in the prefrontal cortex of HIV-infected individuals with HAND 
and we have further shown that this deficiency is particularly severe in those subjects who also 
have HIVE. This protein deficiency appears to be specific for HO-1 relative to other members of 
the ARE-driven gene family, as we saw no consistent changes in other ARE proteins or in the 
heme oxygenase isoform HO-2 in brain tissue. Prefrontal cortex HO-1 deficiency correlated with 
higher brain and CSF viral load and markers of immune activation and was associated with a 
clinical diagnosis of HAND. Notably, we observed no significant difference in the severity of brain 
HO-1 deficiency between ART-naïve and ART-experienced subpopulations, suggesting that 
conventional ART may not prevent or reverse this brain HO-1 deficiency and its associated 
cognitive dysfunction. However, we cannot rule out an influence of ART as ART-experienced 
decedents are often discontinued from therapy regimens near to the time of autopsy. We have 
thus linked brain HO-1 deficiency to HIV replication, immune activation, and clinically significant 
cognitive dysfunction (HAND) in ART-treated and non-treated subjects.  
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Figure 8.6 DLPFC HO-1 protein expression correlates with CSF and brain HIV RNA levels 
(β-tubulin). Samples were derived from the HIV+ cohort for all subjects with detectable viral loads. 
Correlations were determined between DLPFC HO-1 protein expression, as determined by 
Western blot and densitometry analysis normalized to β-tubulin, and HIV RNA in (A) CSF, (B) 
brain parenchyma, and (C) plasma, and (D) plasma CD4 T lymphocyte count in HIV+ subjects. 
Associations were determined by multivariate linear regression with α = 0.01. Red regression 
regression lines denote significant trends.  
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Figure 8.7 DLPFC HO-1 protein expression correlates with CSF and brain HIV RNA levels 
(GAPDH). Samples were derived from the HIV+ cohort for all subjects with detectable viral loads. 
Correlations were determined between DLPFC HO-1 protein expression, as determined by 
Western blot and densitometry analysis normalized to GAPDH, and HIV RNA in (A) CSF, (B) 
brain parenchyma, and (C) plasma, and (D) plasma CD4 T lymphocyte count in HIV+ subjects. 
Associations were determined by multivariate linear regression with α = 0.01. Red regression 
lines denote significant trends. 
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Figure 8.8 DLPFC HO-1 protein expression correlates with brain innate immune responses 
and macrophage markers (β-tubulin). Expression of mRNA within the DLPFC was determined 
by qPCR (see Methods). Correlations were determined between DLPFC HO-1 protein 
expression, as determined by Western blot and densitometry analysis normalized to β-tubulin, 
and (A) ISG15, (B) MX1, (C) IRF1, (D) CD163, (E) CD68, and (F) CD8A mRNA. Associations 
were determined by multivariate linear regression with α = 0.01. Red regression lines denote 
significant trends. 
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Figure 8.9 DLPFC HO-1 protein expression correlates with brain innate immune responses 
and macrophage markers (GAPDH). Expression of mRNA within the DLPFC was determined 
by qPCR (see Methods). Correlations were determined between DLPFC HO-1 protein 
expression, as determined by Western blot and densitometry analysis normalized to GAPDH, and 
(A) ISG15, (B) MX1, (C) IRF1, (D) CD163, (E) CD68, and (F) CD8A mRNA. Associations were 
determined by multivariate linear regression with α = 0.01. Red regression lines denote significant 
trends. 
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In addition to demonstrating HO-1 deficiency in the prefrontal cortex of HIV+ patients with HAND, 
we also observed a significant reduction in HO-1 protein expression in the striatum of subjects 
with HIVE compared with HIV- and HIV+/HIVE- subjects in a smaller cohort. This finding provides 
evidence that HIV-associated HO-1 deficiency within the CNS is not restricted to the prefrontal 
cortex, but occurs in other brain regions. However, we did not observe altered HO-1 protein 
expression in the occipital or cerebellar cortex, indicating that the reduction of HO-1 in HIV-
infection is not a global HIV effect in the brain. The pathological mechanism underlying the 
regional distribution of HO-1 protein deficiency in HIV-infected individuals is unclear. Notably, 
structural and functional imaging studies as well as neuropsychological testing studies suggest 
that the fronto-striatal circuitry may be particularly vulnerable to injury and dysfunction in HIV 
infection (595). Further analysis of regional expression of immune activation markers, viral load, 
and other proteins may elucidate common or unique associations with HO-1 expression.   
 
Previous studies have associated CNS HIV replication with neurodegeneration, immune 
activation, and cognitive dysfunction, and have further shown that persistence of immune 
activation and oxidative stress in both systemic and CNS compartments are associated with 
disease progression within those compartments (93, 161, 258, 574). We demonstrated that 
prefrontal cortex HO-1 deficiency in HIV-infected subjects correlates significantly with increased 
brain parenchyma and CSF viral loads, but not with plasma viral load or CD4 T-cell count. This 
implicates the CNS viral reservoir as a driver of brain HO-1 deficiency independent of systemic 
HIV reservoirs, and it could identify one mechanism, loss of HO-1 enzymatic function, that 
contributes to persistent oxidative stress in HIV-infected brain. In addition to correlating with CNS 
viral replication, prefrontal cortex HO-1 deficiency also correlated with markers of innate immunity 
(type I interferon response genes ISG15 and MX1) and macrophage and microglia activation 
(CD163). These data implicate the potential role for macrophage and microglia 
activation/infiltration in mediating brain HO-1 deficiency, although how this occurs is as yet 
unclear.  
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We believe that the deficiency of HO-1 expression in HAND brain might be unique among 
neurodegenerative diseases associated with CNS inflammation and oxidative stress. Alzheimer’s 
disease, Parkinson’s disease, and multiple sclerosis are also associated with CNS inflammation 
and oxidative stress (596), yet are not associated with decreased brain HO-1 expression. In 
contrast, these neurodegenerative diseases are all associated with increased brain HO-1 (587-
589). For such CNS diseases, HO-1 induction in response to injury is considered to be a limited 
endogenous protective response and a potential therapeutic target for further protection against 
inflammation and oxidative stress (584). Why HO-1 expression is reduced in HIV infection of the 
brain, which is also associated with inflammation and oxidative stress, is unclear. Our preliminary 
studies of HO-1 mRNA expression in HIV-infected brain do not indicate transcriptional 
suppression of HO-1 (See section 11.4). Furthermore, other ARE-driven gene products, such as 
NQO1, GPX1 and others are expressed at normal levels in HIV-infected brain and in HIV-infected 
macrophages, which argues against transcriptional suppression of the ARE promoter as an 
explanation for HO-1 deficiency. The deficiency of HO-1 expression in both systems appears 
relatively specific for HO-1 among ARE proteins, and we suspect accelerated HO-1 degradation 
as the likely cause. We are currently investigating this enhanced HO-1 degradation hypothesis in 
various HIV-relevant models.  
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9.1 Abstract 
 
Heme oxygenase-1 (HO-1) is a ubiquitously expressed detoxifying enzyme with potent anti-
oxidant, anti-inflammatory, and cytoprotective functions, and it is rapidly induced in response to 
cellular injury. Polymorphisms ((GT)n dinucleotide repeat length variations) in the HO-1 promoter 
modulate the level of HO-1 expression, and greater promoter (GT)n repeat length associates with 
poorer outcomes in individuals with certain cardiovascular, pulmonary, renal, infectious, and 
neurological diseases associated with oxidative stress and inflammation.  In HIV-infected 
individuals, greater additive (GT)n repeats associate with lower PBMC HO-1 expression, greater 
levels of systemic inflammation, and poorer control of HIV replication, suggesting a direct link 
between HO-1 expression and HIV disease progression.  Furthermore, reduced brain expression 
of HO-1 in HIV-infected individuals is associated with HIV-associated neurocognitive disorders 
(HAND), HIV-encephalitis (HIVE), and elevated brain markers of macrophage activation. We 
therefore hypothesized that HO-1 promoter (GT)n repeat length is a risk factor for HAND and/or 
HIVE and associated macrophage activation.  Within an autopsy cohort of 68 HIV-infected 
subjects, homozygosity for a long (GT)n repeat length (>30 repeats) strongly correlated with a 
pathological diagnosis of HIVE.  In HIV-negative subjects (n = 55) (GT)n repeat length correlated 
with brain expression of the macrophage activation marker CD163.     These data extend 
previous reports of an association between HO-1 promoter (GT)n repeat length and systemic 
inflammation-associated diseases to an association with inflammation in the central nervous 
system, and a specific role in increasing risk for encephalitis in HIV infected individuals.    
 
9.2 Introduction  
 
Heme oxygenase-1 (HO-1) is a highly inducible, Nrf2-driven, detoxifying enzyme that is critical for 
limiting cellular injury from numerous insults, including inflammation and oxidative stress. 
Protective functions of HO-1 are linked to its rapid degradation of free heme, a major intra- and 
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extracellular byproduct of hemoglobin/myogloblin metabolism and a critical co-factor in various 
enzymatic pathways. The HO-1-mediated catabolism of free heme results in generation of the 
anti-inflammatory and antioxidation products, carbon monoxide, biliverdin, and bilirubin (44). We 
previously demonstrated that expression of HO-1 is reduced in brain prefrontal cortex of HIV-
infected individuals with HIV-associated neurocognitive disorders (HAND), and that this 
deficiency associates with central nervous system (CNS) (489) viral load and markers of 
neuroinflammation, suggesting that HO-1 deficiency represents not only a potential biomarker for 
HAND but also a mediator of HIV Neuropathogenesis (43). We also demonstrated that HIV 
replication in macrophages, a major CNS HIV reservoir, markedly reduces HO-1 expression and 
that this triggers the release of neurotoxic levels of glutamate. Furthermore, correcting this HIV-
induced macrophage HO-1 deficiency greatly attenuates glutamate release and associated 
neurotoxicity. Thus, regulating HO-1 expression in HIV-infected individuals could have a major 
beneficial impact on preventing or attenuating HIV-mediated neurodegeneration and HAND.     
 
Transcriptional regulation of HO-1 expression is determined through sequence variation in the 5’-
flanking region of the HO-1 promoter, which is driven by the transcriptional activator, Nrf2, and 
which contains a (GT)n repeat sequence of varying length. Although estimated HO-1 promoter 
(GT)n repeat lengths vary between 12 and 40, a bimodal distribution of short (23 repeats) and 
long (30 repeats) allele prevalence has been seen in several population studies (45). A long 
(GT)n repeat length is associated with lower promoter responsiveness in transfected cell HO-1 
promoter assays (485, 486, 517, 520, 597). Conversely, a shorter repeat length is associated with 
more robust HO-1 transcriptional induction. In line with the potent anti-inflammatory and anti-
oxidative effects of HO-1 induction, many candidate gene studies have detected associations 
between the short HO-1 (GT)n microsatellite variant and control of inflammatory and pro-oxidative 
disease states (485, 486, 517, 520, 597). A recent study of HIV-infected individuals demonstrated 
that a longer HO-1 promoter (GT)n repeat length correlated with increased plasma sCD14 and 
viral load in HIV-infected African Americans, suggesting a promoter effect on systemic HIV 
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disease progression (489). Moreover, this study also demonstrated that primary immune cells 
(PBMC and CD14+ monocytes) derived from infected individuals having fewer (GT)n repeats 
associated with greater HO-1 RNA and protein expression.    
 
These observations, in conjunction with our previous observation of a correlation between HO-1 
brain deficiency and HAND, with or without HIVE, prompted us to examine the association 
between the HO-1 promoter (GT)n repeat length, the diagnosis of HAND, and the presence of 
HIVE in our autopsy cohort of HIV-infected  and non-infected decedents. We found that i) HO-1 
promoter (GT)n repeat lengths in our cohort ranged from 20 to 36 with a bimodal peak distribution 
of 23 (short) and 30 (long) alleles, consistent with other cohort studies; ii) homozygosity for long 
(>30 (GT)n repeats) alleles correlated strongly with a post-mortem diagnosis of HIVE; and iii) total 
allele (GT)n  repeat length correlated strongly with brain CD163 mRNA expression level. These 
results suggest that HO-1 promoter (GT)n repeat length is a determinant of an individual’s 
vulnerability to developing HIV encephalitis. They further suggest that, even in the absence of 
HIV infection, a long repeat length associates with brain macrophage/monocyte activation, which 
might pre-dispose a newly-infected individual to develop HIV encephalitis. Identifying such host 
risk factors could guide the identification and application specifically-targeted therapies for 
neuroprotection against HIV.  
 
9.3 Results  
 
The distribution of the HO-1 promoter allele (GT)n repeat lengths is bimodal (short allele, 23 
repeats;  long allele, 30 repeats) in our autopsy cohort study, similar to other cohorts studied 
 
Previous studies have demonstrated a bimodal distribution of HO-1 allele promoter (GT)n repeat 
lengths in cohorts of Caucasian individuals and a trimodal distribution in cohorts of African-
American individuals (489).  Our cohort consisted of decedent individuals enrolled in the National 
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NeuroAIDS Tissue Consortium (NNTC), which provided not only tissue-derived specimens (brain 
tissue) and genomic DNA, but also clinical, diagnostic and pathological data collected either pre- 
or post-mortem (43, 525) (Table 6.2). These data include assessments of neurocognitive status, 
markers of macrophage activation, and HIV RNA levels.  Additionally, we determined HO-1 
expression levels within brain tissue derived from the dorsolateral prefrontal cortex (DLPFC) and 
HO-1 promoter (GT)n repeat lengths from banked genomic DNA samples in 55 HIV-negative 
subjects (HIV-) and 91 HIV-positive subjects (HIV+), including some with and without HIV-
encephalitis (HIVE), as follows: (HIVE+, n = 14; HIV+/HIVE-, n = 77, respectively).  
 
Within our cohort we observed an HO-1 promoter (GT)n repeat length distribution with a range of 
20 – 36 (GT)n repeats and bimodal peaks at 23 and 30 (GT)n repeats, with population peak 
frequencies of 19.9% and 65.1%, respectively, (Figure 9.1A), which is consistent with previous 
reports (489). In contrast with this previous report, we did not observe a significant difference in 
the allelic distribution between self-identifying Caucasians and African Americans in our cohort 
(Figure 9.1B; p = 0.0937). The distribution of total allele (diploid allele) (GT)n repeat length per 
subject maintained a bimodal pattern with modes at 53 and 60 (GT)n repeats (Figure 9.1C). Thus 
our cohort demonstrates a range and bimodal distribution of HO-1 promoter (GT)n repeat lengths 
identified in other cohort studies, although we clearly cannot apply conclusions specifically to 
populations outside of the common bimodal distribution.  
HO-1 promote region (GT)n polymorphism repeat length does not correlate with HO-1 mRNA or 
protein expression within the prefrontal cortex 
 
We observed no correlation between total HO-1 (GT)n polymorphism length and DLPFC HO-1 
mRNA or protein expression within the whole cohort (Figure 9.2, A and B) or within the HIV- and 
HIV+ cohort separately (data not shown). Our previous study (43) had demonstrated a significant 
deficiency of HO-1 protein expression and increased HO-1 mRNA expression in the brains of 
HIV-infected individuals, including those represented in this current study, The lack of correlation 
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Figure 9.1 HO-1 promoter region (GT)n polymorphism allele repeat length has a bimodal 
distribution. The allele repeat length of the HO-1 (GT)n polymorphism was determined in 55-HIV 
negative and 91 HIV-positive subjects within our cohort. (A) Relative allele frequency of GT 
repeat lengths within the entire population, demonstrating a bimodal distribution with modes at 23 
and 30. (B) Relative allele frequency of GT repeat lengths in self-identified Caucasians and 
African Americans demonstrating no significant difference in allele distribution between racial 
subpopulations (p = 0.0937, Kolmogorov-Smirnov test). (C) Relative frequency of total GT repeat 
length (allele 1 + allele 2) by individual subject, demonstrating a bimodal distribution with modes 
at 53 and 60.  
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Figure 9.2 HO-1 (GT)n polymorphism repeat length does not correlate with prefrontal 
cortex HO1 mRNA nor protein. HO-1 RNA and protein expression in the DLPFC were 
quantified by qPCR and Western blot, respectively, in 55-HIV negative and 91 HIV-positive 
subjects within our cohort. Correlation between total HO-1 (GT)n polymorphism repeat length and 
DLPFC HO-1 (A) RNA and (B) protein expression. Correlations were assessed by Spearman’s 
correlation with line of best fit determined by linear regression. 
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to post-mortem HO-1 expression is not wholly unexpected as HO-1 is a rapidly and highly 
inducible gene. Thus, potential inherent differences in CNS HO-1 inducibility between subjects as 
a result of the (GT)n promoter polymorphism may be masked by more acute responses that 
regulate HO-1, particularly within the HIV+ cohort where we know viral replication and 
inflammation associate with altered HO-1 expression (43). 
 
The HO-1 promoter allele (GT)n repeat length correlates with brain CD163 expression in HIV-
negative subjects. 
 
To determine the relationship between brain macrophage activation and HO-1 promoter (GT)n 
repeat length, we correlated levels of CD163 and CD68 mRNA expression with HO-1 promoter 
(GT)n repeat length. Within the HIV-negative group (GT)n repeat length significantly correlated 
(p=0.0091) with brain CD163 mRNA levels (Figure 9.3A), suggesting an association between 
lower HO-1 promoter inducibility (greater HO-1 promoter (GT)n repeat length) and greater brain 
macrophage activation. We did not observe a significant correlation between HO-1 (GT)n 
polymorphism length and CD68 (p=0.12), although the trend was in the same direction as CD163 
(Figure 9.3B). 
 
HO-1 promote region (GT)n polymorphism repeat length did not correlate with CNS viral 
replication or markers of macrophage activation within the brain of HIV+ subjects  
 
Within the HIV+ cohort, we did not observe a significant association between total HO-1(GT)n 
polymorphism repeat length and HIV-1 RNA in plasma (data not shown; p = 0.26) or CSF Figure 
9.4A, p=0.34), although there was a non-significant trend for longer (GT)n repeats to associate 
with higher DLPFC parenchymal HIV-1 RNA (Figure 9.4B; p=0.06). However, this trend is driven 
largely by three patients with short total (GT)n repeats and low viral load. Moreover, within the 
HIV+ cohort, we did not observe a correlation between total HO-1 (GT)n polymorphism length  
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Figure 9.3 Longer HO-1 (GT)n polymorphism repeat length correlates with prefrontal 
cortex CD163 RNA. RNA expression of the macrophage markers CD163 and CD68 were 
quantified by qPCR in 55-HIV negative subjects within our cohort. Correlation between HO-1 
(GT)n polymorphism repeat length and DLPFC (A) CD163 and (B) CD68 mRNA. Correlations 
were assessed by Spearman’s correlation with line of best fit determined by linear regression. 
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Figure 9.4 HO-1 (GT)n polymorphism repeat length did not correlate with CNS HIV 
replication or markers of macrophage activation within the prefrontal cortex of HIV+ 
subjects. CSF viral loads were determined with the Amplicor HIV-1 Monitor test v1.1 through 
v1.5 (Roche) for 61 of the 91 HIV-positive subjects. RNA expression of HIV-1 in the DLPFC was 
quantifiable by qPCR in 80 of the 91 HIV-positive subjects. RNA expression of the macrophage 
markers CD163 and CD68 were quantified by qPCR in 90 of the 91 HIV-positive subjects. 
Correlation between HO-1 (GT)n polymorphism repeat length and (A) CSF HIV-1 RNA, (B) 
DLPFC HIV-1 RNA, (C) DLPFC CD163 RNA, and (D) DLPFC CD68 RNA. Correlations were 
assessed by Spearman’s correlation with line of best fit determined by linear regression. 
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and either CD163 or CD68 expression (Figure 9.4, C and D). This lack of association was 
expected as more acute factors such as CNS HIV-replication and clinical disease status are likely 
stronger drivers of HIV-associated inflammation and CNS macrophage activation than differences 
in HO-1 induction. 
 
Longer HO-1 promote region (GT)n polymorphism repeat length associates with increased risk of 
HIV-encephalitis (HIVE) 
 
HIVE is the post-mortem pathological diagnosis associated with profound neuroinflammation and 
fulminant HIV-infection of the CNS. To examine the association of the HO-1 (GT)n polymorphism 
on HIVE-risk within our HIV+ cohort, we stratified (GT)n allele lengths as short (S; < 30, the 
median) and long repeats (L; ≥ 30) and assessed the prevalence of HIVE diagnosis within each 
group. There was a significant difference in HIVE-prevalence between the genotype groups 
(Figure 9.5A; p=0.032), with  HIV+ subjects with longer HO-1 (GT)n polymorphism repeats having 
an increased prevalence of HIVE. This data suggests that patients with longer HO-1 (GT)n 
polymorphisms have a higher risk of developing HIVE, suggesting that decreased HO-1 
inducibility predisposes to a neuroinflammatory state in HIV-infected individuals potentially as a 
result of a loss of anti-inflammatory effects of HO-1.  
 
In this cohort we found no association with HO-1 (GT)n polymorphism genotype and HAND 
diagnosis (Figure 9.5B). While this cohort had 46 individuals that were diagnosed with HAND by 
neuropsychological testing, this analysis was extremely limited as this cohort only had 6 
neurocognitively-normal controls. Larger cohort studies are needed to determine if HO-1 (GT)n 
polymorphism modulates neurocognitive impairment in HIV-infected individuals.  
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Figure 9.5 Longer HO-1 promote region (GT)n polymorphism repeat length associates with 
increased risk of HIV-encephalitis (HIVE). HO-1 (GT)n polymorphism allele repeat lengths 
were classified as short (S; < 30, the median) and long (L; ≥ 30). SS and SL genotype groups 
were combined for analysis as only 4 HIV-positive subjects had the SS genotype. All 91 HIV-
positive subjects were pathologically diagnosed for HIVE and 43 subjects underwent 
neuropsychological testing to determine HAND status. Only 6 subjects were classified as 
neurocognitively normal (NCN). Frequency of (A) HIVE and (B) HAND stratified by subject HO-1 
(GT)n polymorphism genotype, SS+SL or LL. Statistical differences in distributions were analyzed 
by Fischer’s Exact test.  
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9.4 Discussion  
 
We have previously demonstrated a deficiency of HO-1 in the prefrontal cortex of HIV-infected 
individuals with HAND and that this deficiency associated with CNS viral load and markers of 
neuroinflammation (43). An earlier study by Seu et al. has shown that a (GT)n repeat 
polymorphism within the HO-1 promoter region is associated with altered HO-1 inducibility in 
PBMCs from HIV-positive individuals (489). Specifically, longer (GT)n repeat length associated 
with lower HO-1 induction, consistent with previous reports in cell lines (482, 485, 486, 488). 
Furthermore, longer (GT)n repeat length in HIV-infected African Americans correlated with viral 
load and increased plasma levels of the macrophage activation marker sCD14, suggesting a link 
with systemic HIV disease progression (489). In this study, we examined a role of the HO-1 
promoter region (GT)n repeat polymorphism in CNS HIV disease progression using a well 
characterized cohort of HIV-infected and HIV-negative individuals.  
 
Our analysis demonstrated a significant positive association between longer (GT)n repeats 
(associated with lower HO-1 induction) and the risk of HIVE in our HIV+ cohort. Moreover, in the 
HIV-negative cohort, where HIV-driven neuroinflammation and immune activation is absent, we 
observed a significant correlation between longer (GT)n repeats and higher RNA levels of the 
macrophage activation marker CD163, though not CD68. These results expand upon and 
strengthen our previous findings suggesting an association between HO-1 and HIV neurological 
disease progression and neuroinflammation (43) and are consistent with an anti-inflammatory 
role of HO-1. Specifically, these data link HO-1 with CNS macrophage activation and suggest that 
differences in HO-1 regulation may be capable of modulating HIV and other CNS inflammatory 
diseases, potentially through modulating inflammation within the CNS. Within this cohort, we did 
not observe significant correlations between HO-1 promoter (GT)n polymorphism and a clinical 
diagnosis of HAND. However, this analysis was limited as our HIV+ cohort only had 6 
neurocognitive-normal controls. Additional studies of the associations between HO-1 
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polymorphisms and risk for HIV disease progression, particularly neurocognitive impairment, in 
larger population cohorts are clearly needed.  
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10.1 Abstract 
 
Expression of the cytoprotective enzyme heme oxygenase-1 (HO-1) is significantly reduced in 
brain prefrontal cortex of HIV-positive individuals with HIV-associated neurocognitive disorders 
(HAND). Furthermore, this HO-1 deficiency correlates with brain viral load, markers of 
macrophage activation, and type I interferon responses. Previously, we showed that HIV infection 
of monocyte-derived macrophages (MDM) reduces HO-1 protein expression in association with 
increased neurotoxin production. We now demonstrate that HIV-infection of MDM drives a time-
dependent and progressive selective loss of HO-1 that occurs concomitantly with increased 
extracellular levels of glutamate, a HAND associated excitotoxin, and associated supernatant 
neurotoxicty. Morover, this HIV-mediated macrophage HO-1 deficiency and associated glutamate 
release and neurotoxicity is a conserved feature of infection with macrophage-tropic HIV-1 strains 
that extends to HIV-2 infection. We further demonstrate that this HO-1 deficiency does not 
depend specifically upon the HIV-1 accessory genes nef, vpr or vpu, but rather on HIV replication, 
even when markedly limited. Finally, antiretroviral therapy (ART) applied to MDM after HIV 
infection is established does not prevent HO-1 loss and associated neurotoxin production. This 
work defines a predictable relationship between HIV replication, HO-1 loss, and glutamate-
mediated neurotoxicity in MDM that likely reflects processes in place in the HIV-infected brain of 
individuals receiving ART. It further suggests that correcting this HO-1 deficiency in HIV-infected 
MDM could provide neuroprotection above that provided by current ART or proposed antiviral 
therapies directed at limiting Nef, Vpr or Vpu functions. The ability of HIV-2 to reduce HO-1 
expression suggests that this is a conserved phenotype among macrophage-tropic human 
immunodeficiency viruses that could contribute to neuropathogenesis. 
 
10.2 Introduction  
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Heme oxygenase-1 (HO-1) is a highly inducible phase II detoxifying enzyme that has emerged as 
a critical effector for limiting cellular injury associated with oxidative stress and inflammation 
within the central nervous system (CNS) and other tissues in several disease states, including 
HIV infection (42, 43, 585). It is a member of a family of antioxidant response element (ARE) 
promoter-driven genes that are induced by the transcriptional regulator Nrf2 in response to variety 
of cellular insults (404). The protective functions of HO-1 have been linked to its degradation of 
heme and the subsequent generation of carbon monoxide, biliverdin, and bilirubin, which have 
immunomodulatory and anti-oxidative properties (44). In addition, HO-1 has nonenzymatic 
cytoprotective functions through activation of transcription factors (410, 411). A constitutively 
expressed heme oxygenase isoform, HO-2, catabolizes the same enzymatic reaction, although it 
is not regulated by the ARE, and, unlike HO-1, HO-2 is not considered to be a critical mediator of 
acute cellular injury responses. Protective effects of HO-1 have been demonstrated in vitro and in 
vivo in animal models of oxidative, ischemic, and inflammatory diseases (412-415). Our in vitro 
studies have identified HO-1 as a potential protective host factor against HIV-associated 
excitotoxic injury and our analysis of autopsy brain specimens from a large cohort of HIV-infected 
decedents further demonstrated an association between brain HO-1 deficiency and cognitive 
impairment, thus suggesting a role for HO-1 deficiency in HIV neuropathogenesis (42, 585).  
 
Because brain HO-1 deficiency is associated with cognitive impairment in HIV-infected 
individuals, we have proposed targeting HO-1 as a therapeutic target for neuroprotection against 
HIV as an adjunctive therapy to antiretroviral therapy (ART) for preventing pathogenic effects of 
HIV infection of the CNS (43, 585). HIV infection is associated with a syndrome of cognitive 
dysfunction (HIV-associated neurocognitive disorders (HAND)) in up to 50% of ART-treated HIV-
infected individuals (180, 598, 599), which is thought to result in part from persistent inflammation 
and oxidative stress within both the CNS and systemic compartments (600). Within the CNS, 
such effects are driven largely by HIV infection of macrophages and microglia, long-lived HIV 
reservoirs that persist in ART-treated individuals (41).  
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The brain deficiency of HO-1 in HIV-infected individuals correlates with CNS HIV replication 
levels, immune activation markers, and the presence of HAND (43). In vitro, productive replication 
of HIV-1 in monocyte-derived macrophages (MDM) drastically reduces HO-1 protein and 
enhances supernatant neurotoxicity (42, 46). Together, these observations suggest a heretofore 
unknown neuropathological link between HIV replication in macrophages and a failure of a 
normal host cytoprotection surveillance response (HO-1 induction), which may promote 
neurodegeneration through inflammation-associated excitotoxic injury. 
 
To further define this HIV-mediated macrophage HO-1 deficiency, we now determine the effects 
of HIV macrophage replication over the course of infection on the expression of HO-1, HO-2, and 
a panel of ARE proteins. In addition, we examined the association between HO-1 loss in HIV-
MDM, supernatant neurotoxicity, and the release of the HAND relevant excitotoxin glutamate. 
Next we expanded our study to include an examination of a broader group of macrophage-tropic 
clade B HIV-1 strains (n = 13), a macrophage-tropic clinical HIV-2 isolate, and an examination of 
the potential roles for the HIV-1 accessory proteins Nef, Vpr, and Vpu in modulating HO-1 
expression and associated neurotoxicity in infected MDM. Finally, to address the association 
between HIV replication and HO-1 deficiency in the setting of ART use, we determined the ability 
of clinically-relevant ART regimens applied pre- and post-infection to prevent HO-1 loss and 
associated neurotoxicity in HIV infected MDM. We found that induction of HO-1 loss in MDM was 
relatively selective; we observed no reduction in the expression of HO-2 or other ARE proteins in 
HIV-MDM. This loss of HO-1 was a consistent feature of macrophage-tropic HIV-1 strains and we 
observed a similar effect with HIV-2 infection. HIV replication levels correlated negatively with 
HO-1 protein expression and positively with culture supernatant glutamate levels and associated 
neurotoxicity. Induction of HO-1 deficiency did not require the HIV-1 accessory genes nef, vpr, or 
vpu. Finally, ART ameliorated the neurotoxic effects of HO-1 deficiency by prevention of HIV 
replication in newly-infected MDM, but no such protection was seen in MDM with established HIV 
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infection. These observations suggest that HO-1 deficiency in the pool of infected macrophages 
within the CNS of infected individuals may associate with macrophage neurotoxin production and 
represents a unique target for adjunctive therapies for neuroprotection in ART-treated individuals.  
 
10.3 Results  
 
HO-1 protein deficiency in HIV-infected macrophages occurs concomitantly with increased 
supernatant glutamate and neurotoxicity 
  
Many published studies, including our own, have linked HIV-associated macrophage/microglial 
immune activation to neuronal injury and neurodegeneration in vitro and in vivo (33, 36, 42, 46, 
530, 601). We therefore investigated the link between macrophage HIV infection, HO-1 
expression, and associated neuronal injury in our in vitro HIV neurodegeneration model system of 
the course of infection. Analogous with the brain HO-1 deficiency that we observed in HIV+ 
individuals, HIV-infection of MDM in vitro drastically reduced HO-1 expression. This reduction in 
HIV-MDM HO-1 expression was progressive and time-dependent, typically showing a significant 
drop within 6-9 days after virus inoculation as replication approached its highest level (Figure 
10.1, A and B). Furthermore, in contrast with this progressive HO-1 reduction, the expression of 
other ARE proteins (superoxide dismutase 1, SOD1; ferritin heavy chain 1, FTH1; peroxiredoxin1, 
PRDX1; glutathione S-transferase pi 1, GSTP1; thioredoxin reductase 1, TRXR1; NQO1; GPX1) 
was not consistently altered during infection (Figure 10.1C). Several of these proteins showed a 
transient increase from basal levels immediately after infection (day 0), but only HO-1 exhibited a 
progressive and persistent change from baseline over the course of infection. This suggests that 
the decrease in HO-1 protein expression in HIV-MDM is relatively specific and not a consequence 
of global suppression of ARE-driven gene expression. Finally, we did not observe a decrease in 
expression of HO-2, which further suggests that the decrease of the HO-1 isoform is relatively 
specific.  
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Figure 10.1 HIV infection of MDM reduces HO-1 protein expression and concomitantly 
increases supernatant glutamate levels and neurotoxicity. Infected (HIV-MDM) and mock-
infected cultures (mock-MDM) were sampled and harvested every 3 days post infection (DPI) for 
analysis of supernatant glutamate content, supernatant neurotoxicity, and cellular protein 
expression. (A) Mean supernatant RT activity from representative HIV-infected cultures. (B) 
Western blot of selected ARE proteins (NQO1, HO-1, and GPX1) over the 15-day course of 
representative HIV-MDM infections. (C) Quantification of expression of canonical ARE proteins 
and HO-2 over the course of infection, as determined by Western blotting. Values represent 
mean ± SEM (n = 4 different macrophage donor cultures) of the fold change in protein expression 
in HIV-infected versus mock-infected MDM. (D) Supernatant glutamate concentration and (E) 
supernatant neurotoxicity as measured by MAP2 expression in supernatant-exposed rat primary 
neuronal cultures) normalized to untreated (UT). RT, glutamate, and neurotoxicity data are 
representative of 4 independent experiments, with each replicate performed on MDM 
preparations from different donors. (F) Quantification of MDM cell death at 12 days after HIV 
infection. Results are averaged from 3 independent donors. Camptothecin (CT, 6 hour exposure) 
and complete cell lysis (max, maximum cytotoxicity) served as positive controls. All values 
represent mean ± SEM. Statistical comparisons were made by paired Student’s t test. *P < 0.05; 
**P < 0.01; ***P < 0.001. 
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Suppression of HO-1 expression in human macrophages is a consistent phenotype of infection by 
macrophage-tropic HIV-1 strains 
 
Our previous studies demonstrated the ability of several prototypic macrophage-tropic HIV-1 
strains (89.6, Jago) to selectively reduce expression of the antioxidant response enzyme, HO-1, 
in human MDM, which is associated with a marked increase in MDM glutamate release and 
culture supernatant neurotoxicity (42, 43). This macrophage response suggests a plausible 
mechanism by which HIV-1 infection of brain macrophages could exacerbate oxidative stress and 
glutamate-induced neuronal injury, each of which is associated with neurocognitive dysfunction in 
infected individuals (174, 239). To determine whether this unique macrophage response to HIV is 
a consistent feature of macrophage-tropic HIV strains, we examined a broader panel of 13 clade 
B HIV-1 strains used to infect MDM derived from five independent human donors. All donors were 
confirmed negative for presence of the CCR5-Δ32 allele, a deletion mutation resulting in a 
nonfunctional CCR5 receptor that prevents infection by CCR5 using strains.  
 
Among these 13 HIV-1 strains we observed a ~3 log range of replication in MDM derived from the 
different human MDM donors (Figure 10.2 and 10.3). Two-way ANOVA analysis by viral strain 
and MDM donor demonstrated that the variability in HIV replication level as determined by 
supernatant reverse transcriptase (RT) activity (Figure 10.2, A and B) and cell-associated HIV-1 
p24 antigen (Figure 10.2, C-E) was accounted for primarily by viral strain (75.3% for supernatant 
RT, p<0.001; 86.9% for cell-associated p24, p <0.001) and much less by donor (9.4% 
supernatant RT, p<0.001; 1.2% cell-associated p24, p<0.05). As predicted, supernatant RT 
activity strongly positively correlated with cell-associated p24 content (Figure 10.2F), suggesting 
proportional production of intracellular viral proteins and release of viral particles and consistency 
among MDM cultures. Thus, an HO-1 response associated with infection of MDM with these 
strains can be attributed to an HIV replication-dependent phenotype.  
 
147 
  
 
Figure 10.2 Supernatant reverse transcriptase activity and cell-associated HIV-1 p24 antigen 
content are highly correlated markers of HIV-1 replication in macrophages. MDM isolated from 
five healthy donors were infected with each of fifteen HIV-1 strains (inoculum of 25ng HIV-1 p24 
content per 4x105 MDM). Replication was assessed on day 12 post infection by supernatant 
reverse transcriptase (RT) and by cell-associated HIV-1 p24 expression as quantified by Western 
blot. (A) Day 12 MDM supernatant RT activity (all 5 donors) stratified by strain normalized to 
uninfected/Mock-MDM. (B) Representative Western blot of cell-associated p24 on day 12 post 
infection from Donor A. (C) Densitometry analysis of cell-associated p24 expression (all 5 donors) 
stratified by strain and normalized to GAPDH and Mock-MDM background. (D) Correlation 
between supernatant RT activity and cell-associated p24 expression on day 12 post-infection. (E) 
Key for HIV strain and MDM donor symbols. RT and p24 values for Mock-MDM were set to 0 on 
a log scale (dotted line). Error bars indicate mean ± SEM. Statistical comparisons to Mock-MDM 
were made by two-way ANOVA with Holm-Sidak post hoc test. Correlations were assessed by 
Pearson's correlation with line of best fit determined by linear regression. * p <0.05, ** p <0.01, 
***p<0.001. 
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Figure 10.3 HIV-1 strain replication in primary human macrophages from different donors.  
Replication of fifteen HIV-1 viral strains (inoculum 25ng p24 per 400,000 cells) in monocyte-derived 
macrophages (MDM) isolated from five healthy donors was assessed every 3 days over 12 days of 
infection by supernatant reverse transcriptase (RT) activity. (A) Supernatant RT activity in Donor C 
over the course of infection normalized to Mock-MDM background. Values represent mean ± SEM. 
(B) Average supernatant RT activity in all five donors over the course of infection normalized to Mock-
MDM background. Errors bars are not shown for clarity. (C) Day 12 supernatant RT activity in all 5 
donors stratified by donor normalized to uninfected/Mock macrophages. (D) Day 12 HIV-MDM lysate 
p24 content in all five donors stratified by donor as assessed by Western blot. (E) Key for HIV strain 
symbols. Error bars indicate mean ± SEM. Statistical comparisons to between donors were made by 
two-way ANOVA with Holm-Sidak post hoc test. * p <0.05, ***p<0.001 
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Productive infection of MDM with 11 of the 13 macrophage-tropic HIV-1 strains significantly 
decreased HO-1 protein expression (Figure 10.4, A and B), while infection with the two remaining 
strains (CSF-2, BR2) did not. Non-productive infection with the non-macrophage-tropic 3B swarm 
or the related NL43 strain also did not significantly reduce HO-1 expression. No effect on 
expression of the constitutive heme oxygenase isoform, HO-2, by any HIV strain was observed 
(Figure 10.4C), consistent with our previous observations of a selective suppression of HO-1 
expression by the prototypic HIV-1 strains 89.6 and Jago. Expression of HO-1 correlated 
negatively with HIV replication level when analyzed across all five macrophage donors and all 
HIV strains (Figure 10.4, D and E), thus demonstrating consistency of this HO-1 deficiency with 
infection of macrophages by most, but not all, infecting strains. We confirmed the strong 
association between HIV replication level and HO-1 protein reduction seen among different HIV-1 
strains by examining HO-1 reduction with different levels of replication by a single strain, 89.6 
(Figure 10.5). Achieving increasing levels of replication in MDM by inoculating with increasing 
amounts of virus (Figure 10.5A), resulted in increasing HO-1 deficiency (Figure 10.5, B and C). 
This relationship was confirmed in each of three independent macrophage donors (Figure 10.5, 
D-F). This suggests that for individual macrophage-tropic strains, varying levels of replication 
would predictably decrease HO-1 expression. Notably, the decrease in HO-1 protein expression 
is associated with a highly significant and strongly correlated decrease in HO-1 RNA expression 
(Figure 10.6, A and B). Consistent with Western blot analysis of HO-2 protein expression, we did 
not observe any changes in HO-2 RNA expression in HIV-MDM with 89.6 infection (Figure 
10.6C). Thus, varying levels of MDM infection by a viral swarm within an individual or among 
different individuals infected with genetically distinct macrophage-tropic HIV strains could be 
expected to result in varying, albeit significant, reduction in levels of HO-1 expression within the 
MDM compartment.   
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Figure 10.4 HIV-1 replication consistently induces HO-1 deficiency in macrophages. MDM 
isolated from five healthy donors were infected with each of fifteen HIV-1 viral strains (inoculum of 
25ng HIV-1 p24 per 4x105 MDM). On day 12 post infection, MDM lysates were assessed for HO-1, 
HO-2, HIV-1 p24, and GAPDH protein expression by Western blot. Replication was assessed on day 
12 post infection by supernatant RT activity and by cell-associated HIV-1 p24. (A) Representative 
Western blot of HO-1, HO-2, HIV-1 p24, and GAPDH in HIV-MDM from one donor. Densitometry 
analysis of (B) HO-1 and (C) HO-2 protein expression in HIV-MDM (all 5 donors) stratified by strain 
and normalized to GAPDH and presented as fold change from Mock-MDM. HO-1 and HO-2 
expression levels in Mock-MDM were set to 0 on a log scale (dotted line). Error bars indicate mean ± 
SEM. Correlation between macrophage HO-1 protein expression and (D) supernatant RT and (E) cell-
associated HIV-1 p24. (F) Key for HIV strain and MDM donor symbols. Statistical comparisons to 
Mock-MDM were made by two-way ANOVA with Holm-Sidak post hoc test. Correlations were 
assessed by Pearson's correlation with line of best fit determined by linear regression. * p <0.05, ** p 
<0.01, ***p<0.001. 
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Figure 10.5 HIV-1 replication level predicts HO-1 loss within an HIV-MDM culture. MDM were 
infected with different inocula (0.2 to 50ng/ml HIV p24 per 4x105 cells) of HIV-1 89.6. 
Representative data from one MDM donor infection showing (A) HIV replication (n = 2 technical 
replicates) and (B) HO-1 and GAPDH protein Western blot (day 12 post infection) over the range 
of viral inocula tested. (C) Quantification of HO-1 protein expression normalized to GAPDH (n = 3 
MDM donors). (D-F) Correlation between day 12 post infection HO-1 protein expression and RT 
activity for each individual donor. Error bars indicate mean ± SEM. Statistical comparisons to Mock-
MDM were made by one-way ANOVA with Holm-Sidak post hoc test. Correlations were assessed 
by Pearson's correlation with line of best fit determined by linear regression. * p <0.05, ***p<0.001 
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Figure 10.6 HIV-MDM HO-1 protein expression correlates with HO-1 RNA expression. Protein 
and RNA expression of HO-1 and GAPDH in HIV-MDM lysates were assessed by Western blot 
and qPCR, respectively, on day 12 post HIV infection (89.6 or Jago strains). (A) Protein and RNA 
expression of HO-1 normalized to GAPDH expression in HIV-MDM from 5-6 independent donors. 
(B) Correlation between HO-1 protein and RNA expression levels in HIV-MDM from 5 
independent donors (distinguished by symbol shape) infected with HIV-1 strains 89.6 (closed 
shapes) or Jago (open shapes). Mock-MDM HO-1 protein and RNA expression was set to 1. 
Error bars indicate mean ± SEM. Statistical comparisons to Mock-MDM were made by one-way 
ANOVA with Holm-Sidak post hoc test. Correlations were assessed by Pearson's correlation with 
line of best fit determined by linear regression. ** p <0.01, *** p <0.001. 
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HO-1 deficiency in HIV-MDM correlates with supernatant glutamate level and associated 
neurotoxicity 
 
Previously, we demonstrated that modulating HO-1 in HIV-MDM modulates supernatant 
neurotoxicity (42, 43). Thus, we assessed the association between HIV-driven HO-1 reduction 
and neurotoxin production in our panel of HIV-1 strains. Replication in MDM by five of the six 
highest replicating viral strains (Bal-1, Jago, SF162, YU2, and 89.6) produced significant 
supernatant neurotoxicity in our neuronal/glial cell-based ELISA (Figure 10.7A). Notably, MDM 
derived from one of the five donors produced significantly higher levels of HIV-MDM supernatant 
neurotoxicity in comparison with the other donors (Figure 10.7B). A two-way ANOVA analysis 
demonstrated that while most supernatant neurotoxicity was accounted for by the viral strain 
(69.6%, p < 0.001), neurotoxicity variability could also be attributed to donor variability (16.0%, p 
< 0.001). These data suggest that host macrophage determinants that affect neurotoxic potential, 
potentially such as differential donor HO-1 inducibility or basal HO-1 expression, can play a 
significant role in determining neurotoxin output in response to HIV infection.  
 
We and others previously identified glutamate as a major neurotoxin released from HIV-infected 
MDM and microglia (43, 46, 229, 602). The six most robustly replicating HIV strains (Bal-1, Jago, 
SF162, YU2, ADA, and 89.6) significantly increased MDM supernatant glutamate content (Figure 
10.7C). Although there was significant variability in supernatant glutamate levels among different 
donors (Figure 10.7D), these differences were minimized when supernatant glutamate content 
was expressed as a fold-increase over matched Mock-MDM glutamate content (Figure 10.7E). 
Supernatant neurotoxicity positively correlated (p < 0.001) with supernatant glutamate content 
across all donors and strains (Figure 10.7F), which is consistent with glutamate toxicity being a 
primary component of HIV-MDM supernatant neurotoxicity (46, 229). These data suggest that 
while basal levels of glutamate production differ among donors the proportional HIV induction of 
MDM glutamate and associated neurotoxicity is similar among donors. 
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Figure 10.7 HIV-1 infection of MDM induces glutamate-associated supernatant neurotoxicity. 
Neurotoxicity of HIV-MDM supernatants was assessed by applying supernatants (day 12; 1:20 
dilution) to primary rat neuroglial cultures for 24 hours, followed by quantification of culture MAP-2 
content by ELISA. Supernatant glutamate content was quantified by Amplex Red Glutamate 
Assay. Supernatant neurotoxicity (loss of MAP2; Mock-MDM set to 100% expression of MAP2) 
stratified by (A) strain and (B) by MDM donor (n = 5). Supernatant glutamate concentrations 
stratified by (C) strain and by (D) MDM donor (n = 5). (E) Fold supernatant glutamate levels in all 5 
donors stratified (E) by donor normalized to Mock-MDM supernatant glutamate. (F) Correlation 
between supernatant neurotoxicity and glutamate level across all five donors and all 15 HIV-1 
strains. (G) Key for HIV strain and MDM donor symbols. Error bars indicate mean ± SEM. 
Statistical comparisons to Mock-MDM or between donors were made by two-way ANOVA with 
Holm-Sidak post hoc test. Correlations were assessed by Pearson's correlation with line of best 
fit determined by linear regression. ** p <0.01, ***p<0.001. 
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Within our HIV-1 panel, HIV-MDM supernatant neurotoxicity and glutamate level correlated with 
HO-1 deficiency (Figure 10.8, A and B) and HIV strain replication (Figure 10.8, C-F)in the 
supplemental material), consistent with our previous studies (42, 43). Despite these correlations 
between HO-1 loss, neurotoxicity, and replication, however, several poorly replicating HIV-1 
strains significantly reduced HO-1 protein expression without significantly increasing supernatant 
neurotoxicity or glutamate content. This suggests that a ‘threshold’ level of replication is 
necessary for increasing glutamate release from HIV-MDM in the context of HO-1 deficiency. 
Consistent with this, HO-1 reduction in MDM by siRNA knockdown in the absence of HIV 
infection did not increase supernatant glutamate content or supernatant neurotoxicity (Figure 
10.9, A-C). Thus, HIV replication concomitant with HO-1 reduction appears necessary to increase 
glutamate release, suggesting critical virus-specific effects that create a permissive environment 
in MDM for enhanced glutamate release in a state of HO-1 deficiency. 
 
Antiretroviral treatment of established HIV-MDM infection fails to limit HO-1 deficiency and 
associated neurotoxicity  
 
Given the strong correlation between HIV replication and HO-1 loss, we determined the ability of 
ART treatment to prevent HO-1 loss and neurotoxicity associated with HIV-MDM. We utilized 
three ART regimens recommended for initial treatment in ART naïve patients (603). Each 
regimen included the two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir disoproixil 
fumarate (TDF, 20nM) and emtricitabine (FTC, 500nM), in addition to either i) efavirenz (EFZ, 
40nM), a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (regimen 1); ii) 
atazanavir boosted with ritonavir (ATV/r, 15nM/10nM), a protease-inhibitor (PI)-based regimen 
(regimen 2); or iii) raltegravir (RAL, 50nM), a integrase strand transfer inhibitor (INSTI)-based 
regimen (regimen 3). The chosen drug concentrations were based upon reported cerebrospinal 
fluid drug concentrations in ART-treated patients (189). To more effectively suppress HIV  
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Figure 10.8 Supernatant neurotoxicity and glutamate levels correlate with HO-1 loss and 
replication in HIV-MDM. MDM isolated from five healthy donors were infected with each of fifteen 
HIV-1 viral strains (inoculum of 25ng HIV-1 p24 per 4x105 MDM). On day 12 post infection, MDM 
lysates were assessed for HO-1, HIV-1 p24, and GAPDH protein expression by Western blot. 
Replication was assessed on day 12 post infection by supernatant RT activity and by cell-associated 
HIV-1 p24. Correlation between macrophage HO-1 protein expression and supernatant (A) 
neurotoxicity and (B) glutamate concentration. Correlation between supernatant RT activity and 
supernatant (C) neurotoxicity and (D) glutamate concentration. Correlation between cell-associated 
HIV p24 protein expression and supernatant (E) neurotoxicity as measured by MAP2 ELISA and (F) 
glutamate concentration. (G) Key for HIV strain and MDM donor symbols. Correlations were assessed 
by Pearson's correlation with line of best fit determined by linear regression.  
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Figure 10.9 Targeted siRNA knockdown of HO-1 or the HO-1 repressor BACH1 in uninfected 
MDM does not alter supernatant neurotoxicity or glutamate content. MDM from 4 independent 
donors were transfected using Lipofectamine RNAiMax with 50nM of siRNA targeting either HO-1 
or BACH1. Two distinct Silencer Select (Ambion) siRNAs targeting HO-1, s6673 (73) and s6674 
(74), or BACH1, s1859 (59) and s1860 (60), were used independently to efficiently knockdown or 
derepress HO-1, respectively. Additional MDM were either left untreated (UT), exposed to 
lipofectamine (Lip), or transfected with scramble siRNA (Scr; #4390856 Ambion). (A) 
Representative Western blot for HO-1, BACH1, NQO1, and GAPDH at 24 hours and 72 hours 
post transfection with select siRNAs. MDM supernatant (B) neurotoxicity as measured by MAP2 
ELISA and (C) glutamate content 72 hours post transfection. Errors bars indicate mean ± SEM (n 
= 4). Statistical comparisons to Mock-MDM were made by one-way ANOVA with Holm-Sidak post 
hoc test. n.s. = not significant. 
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replication, we also used a high-dose PI-based regimen with five-fold higher ATV/r concentrations 
(75nM/50nM) and unchanged TDF and FTC concentrations (regimen 4).  
 
To attempt to fully determine the effectiveness of ART in preventing HO-1 loss in HIV-MDM, we 
applied the treatment prior to and after establishing HIV infection in MDM. We pre-treated MDM 
with each ART regimen one hour prior to HIV infection and replenished all ART drugs with each 
media change. To model the ability of ART to impact already-infected macrophages, we also 
treated HIV-MDM with each ART regimen after HIV inoculation (beginning days 3 and 6 post-
infection), and replenished all ART drugs with each media change. We analyzed HIV replication 
over the course of infection and we analyzed HO-1 expression and supernatant neurotoxicity 
from the last day of infection. Pre-treatment with each ART regimen resulted in no detectable viral 
replication or HO-1 loss, and dramatically reduced supernatant neurotoxicity (Figure 10.10, A-D). 
Notably, supernatants from ART pre-treated HIV-MDM showed a non-significant trend for 
enhanced neurotoxicity compared to Mock-MDM supernatants, although only those derived from 
MDM treated the NNRTI-based regimen (#1) reached statistically significance (Figure 10.10B).  
 
Treatment of HIV-MDM on day 3 post-infection significantly reduced HIV replication, but only 
regimen 4 (high-dose PI) treatment significantly reduced HO-1 loss and supernatant neurotoxicity 
(Figure 10.10, A-D). No treatment regimen applied on day 6 post-infection reduced replication 
(Figure 10.10A), supernatant neurotoxicity (Figure 10.10B), or HO-1 loss (Figure 10.10, C and D). 
These data confirm the correlations between viral replication, HO-1 loss, and supernatant 
neurotoxicity in HIV-MDM. Furthermore, these findings strongly suggest that, although 
physiologically-relevant CNS concentrations of ART can protect against HO-1 loss by preventing 
HIV infection, they cannot prevent HO-1 loss and associated neurotoxicity from HIV-infected 
MDM. This ART failure to protect HIV-MDM from HO-1 loss and increased neurotoxicity 
underscores the potential importance of a persistently infected CNS macrophage reservoir in 
mediating neuronal injury even in ART-treated individuals.  
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Figure 10.10 Antiretroviral drug treatment prior to, but not after, HIV-infection of MDM 
prevents HO-1 loss and associated neurotoxicity. MDM were treated with ART regimens either 
1 hour prior to, 3 days after, or 6 days after HIV-1 (89.6) infection. ART drugs were replenished 
every 3 days with media changes. ART regimens were as follows: Regimen 1: 20nM TDF, 500nM 
FTC, and 40nM EFZ. Regimen 2: 20nM TDF, 500nM FTC, 15nM/10nM ATV/r. Regimen 3: 20nM 
TDF, 500nM FTC, and 50nM RAL. Regimen 4: 20nM TDF, 500nM FTC, and 75nM/50nM ATV/r. 
(A) HIV replication and (B) supernatant neurotoxicity in HIV-MDM (n=4). (C) Representative 
Western blot, and (D) densitometry quantification of HO-1 protein expression from last day of 
infection in all 4 donors. Error bars indicate mean ± SEM. Statistical comparisons to Mock-MDM 
(*) and Vehicle (#) were made by one-way ANOVA with Holm-Sidak post hoc test. *,# p <0.05, 
***,###p<0.001. 
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Accessory genes nef, vpr, and vpu are not required for HIV-1 mediated HO-1 reduction in 
infected macrophages  
 
In addition to viral proteins required for genome replication and viral particle assembly, HIV-1 
expresses several accessory proteins, Nef, Vpr, and Vpu, which can downregulate, degrade, or 
functionally inactivate certain host cell proteins, particularly viral restriction factors (604). To 
determine whether nef, vpr, or vpu might directly modulate HO-1 protein loss in HIV-MDM, we 
analyzed effects of infectious HIV mutant strains deficient in each (or all) of these accessory 
genes. We infected MDM with the wild-type (WT) molecular clone 89.6 or 89.6 clones deleted (Δ) 
individually for nef, vpr, or vpu, or the combination of all three (528).  
 
The Δnef, Δvpr, and Δvpu 89.6 mutants each replicated productively in MDM, albeit to different 
levels (Figure 10.11A). We found that 89.6 Δnef and 89.6 Δvpu replicated less robustly than WT 
89.6, while 89.6 Δvpr replicated to levels comparable to those of WT 89.6. As previously reported 
(528), 89.6 Δnef/vpr/vpu did not replicate to detectable levels in MDM. Each replicating strain 
significantly reduced the MDM HO-1 expression (Figure 10.11, C and D) and increased 
associated supernatant neurotoxicity (Figure 10.11B), while the non-replicating 89.6 Δnef/vpr/vpu 
did not. Furthermore, as predicted by our observations across all HIV-1 strains examined (Figure 
10.4), the profile of HO-1 loss in infected MDM (Figure 10.11D) closely resembled the profile of 
neurotoxicity of the corresponding culture supernatants (Figure 10.11B). These data thus 
demonstrate that nef, vpr, and vpu accessory genes are not themselves directly required for HIV-
1 mediated HO-1 loss in infected MDM, although their effects on HIV-1 replication do indeed 
modulate the level of HO-1 expression and associated supernatant neurotoxicity.  
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Figure 10.11 HIV-1 accessory genes nef, vpr, and vpu are not required for induction of HO-1 
deficiency or associated neurotoxicity in HIV-MDM. MDM from 5 different donors were infected 
with wild-type (WT) 89.6 or mutant 89.6 lacking (Δ) nef, vpr, or vpu genes singularly or in 
combination (n/v/v). Supernatants (day 12 post infection) were analyzed for (A) HIV-replication 
and (B) supernatant neurotoxicity. (C) Representative Western blot and (D) summary 
densitometry analysis of HO-1 expression in HIV-MDM (day 12). Errors bars indicate mean ± 
SEM (n = 5). Statistical comparisons to Mock-MDM (*) or WT 89.6 (#) were made by one-way 
ANOVA with Holm-Sidak post hoc test. *,# p <0.05, **,## p <0.01, ***,### p<0.001. 
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Macrophage tropic HIV-2 strain CBL-20 reduces HO-1 protein expression in infected MDM 
comparably to HIV-1 strain 89.6  
 
The observation that 11 of 13 macrophage tropic HIV-1 strains tested significantly reduce HO-1 
protein expression in MDM suggests that HO-1 loss is a highly conserved response to HIV-1 
infection. This finding along with the lack of HIV-1 accessory gene requirement for HO-1 loss 
suggests that the other major human immunodeficiency virus group, HIV-2, which also causes 
immune deficiency, albeit less severely (605), might also induce HO-1 loss in MDM. We infected 
MDM derived from eight different human donors with HIV-2 CBL-20 (606) and HIV-1 89.6. While 
89.6 replicated robustly and reduced MDM HO-1 protein expression in all donor cultures, HIV-2 
CBL-20 replicated as robustly as 89.6 in MDM derived from only two of the eight donors (Figure 
10.12A; Figure 10.13A). In these HIV-2-MDM cultures HO-1 protein expression was reduced 
similarly to that of 89.6-MDM, with comparable levels of supernatant neurotoxicity and glutamate 
content (Figure 10.12, B and C; Figure 10.13, B and C). Moreover, among all MDM donors, HO-1 
protein loss in MDM correlated significantly with HIV-2 replication level (Figure 10.12D). Similar to 
HO-2-sparing effects of HIV-1 replication, we did not observe changes in HO-2 protein expression 
with HIV-2 replication (Figure 10.12B). These data suggest that HIV-driven HO-1 deficiency, 
glutamate release, and associated neurotoxicity are consistent features of HIV-1 and HIV-2 MDM 
infection.  
 
10.4 Discussion 
 
The continued prevalence of HAND and associated inflammation and oxidative stress in ART-
treated HIV-infected individuals highlights the need for adjunctive therapies that target these 
neuropathological processes, which persist in both the CNS and systemic compartments. To this 
end, we have identified the anti-inflammatory and anti-oxidative enzyme HO-1 as a targetable 
host factor for adjunctive neuroprotective therapy for HAND. We previously demonstrated a 
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Figure 10.12 HIV-2 replication in MDM induces HO-1 deficiency and associated supernatant 
neurotoxicity. MDM (8 independent donors) were infected with HIV-2 CBL-20 and HIV-1 89.6. 
HIV-2 infection of MDM from 2 of 8 donors showed (A) replication levels comparable to those of 
HIV-1 89.6. (B) Western blot analysis of HO-1, HO-2, and HIV-1 p24, and (C) supernatant 
neurotoxicity in these representative infections. (D) Correlation between HO-1 protein expression 
and supernatant RT activity for HIV-2 MDM infections (all 8 donors). Errors bars indicate mean ± 
SEM. Statistical comparisons to Mock-MDM were made by one-way ANOVA with Holm-Sidak 
post hoc test. Correlations were assessed by Pearson's correlation with line of best fit determined 
by linear regression. *** p<0.001. 
 
 
0 3 6 9 12
1
10
100
Day Post Infection
RT
 A
cti
vit
y
 (L
og
10
 Fo
ld 
Ov
er
 M
oc
k)
CBL-20 HIV-2 
89.6 HIV-1
89.6 HIV-1
CBL-20 HIV-2 
Donor A
Donor B
Mo
ck
HIV
-1
HIV
-2
0
25
50
75
100
125
M
AP
2 E
xp
re
ss
ion
(%
 M
oc
k-M
DM
)
*** ***
HO-1
HO-2
HIV-1 p24
GAPDH
Mo
ck
HIV
-1
HIV
-2
29kD
37kD
24kD
36kD
Mo
ck
HIV
-1
HIV
-2
Donor A Donor B
A B
C D
1 10 100
0
20
40
60
80
100
120
RT Activity
 (Fold Over Mock)
HO
-1
 P
ro
tei
n E
xp
re
ss
ion
(%
 of
 M
oc
k-M
DM
) r = - 0.852p = 0.007
164 
  
 
 
 
 
 
Figure 10.13 HIV-2 replication in MDM induces HO-1 deficiency and associated extracellular 
glutamate and supernatant neurotoxicity. MDM from 8 independent donors were infected with 
either HIV-2 CBL-20 or HIV-1 89.6. Supernatants and MDM lysates were analyzed from day 12 
post infection. The 5 of the 8 donor MDM infections that demonstrated significant HIV-2 
replication were analyzed. (A) HO-1 protein expression normalized to GAPDH as determined by 
Western blot densitometry analysis. (B) Supernatant glutamate content as determined by Amplex 
Red Assay. (C) Correlation between supernatant glutamate content and MAP2 ELISA 
neurotoxicity from day 12 post infection supernatants from HIV-2 infected MDM. Errors bars 
indicate mean ± SEM (n = 5). Statistical comparisons to Mock-MDM were made by one-way 
ANOVA with Holm-Sidak post hoc test. Correlations were assessed by Pearson's correlation with 
line of best fit determined by linear regression. * p<0.05, *** p<0.001 
 
 
Mo
ck
HIV
-1
HIV
-2
0
25
50
75
100
125
HO
-1
 P
ro
tei
n E
xp
re
ss
ion
(%
 of
 M
oc
k-M
DM
)
***
***
***
n.s
Mo
ck
HIV
-1
HIV
-2
10
100
1000
Gl
uta
m
ate
 (u
M
)
***
*
10 100 1000
0
20
40
60
80
100
120
Glutamate  (uM)
M
AP
2 E
xp
re
ss
ion
(%
 M
oc
k-M
DM
)
r = - 0.921
p = 0.026
A B
C
165 
  
 
 
significant deficiency of HO-1 protein within the brains of HIV-infected individuals with HAND and 
we further showed that this deficiency correlated with brain and CSF viral loads and markers of 
immune activation (43). Furthermore using two HIV-1 strains (Jago and 89.6), we demonstrated 
that HIV infection of macrophages reduces HO-1 protein expression in conjunction with 
neurotoxin production (42). 
 
To expand on these initial observations, we examined the expression of HO-1, HO-2, and an 
expanded panel of ARE effector proteins over the course of HIV-MDM infection. These data 
demonstrated that HO-1 loss in HIV-MDM was progressive and time-dependent, typically 
showing a significant drop within 6-9 days after virus inoculation. This loss of HO-1 temporally 
associated with HIV-MDM glutamate release and supernatant neurotoxicity. The progressive 
deficiency of HO-1 was relatively specific, as other members of the ARE-driven gene family and 
the heme oxygenase isoform HO-2 were unaffected. To further define this neuropathological 
phenotype, we expanded these studies to examine a broader group of macrophage-tropic HIV-1 
strains (n = 13). We demonstrated that most (11 of 13) clade B HIV-1 macrophage tropic strains 
induce a loss of HO-1 protein, in contrast to unaltered expression of HO-2 protein, and that loss 
of HO-1 protein in HIV-MDM correlates with decreased HO-1 RNA expression.  We show that this 
loss of HO-1 expression in HIV-MDM associates significantly with viral replication and excitotoxic 
levels of supernatant glutamate. The HIV-1 accessory genes nef, vpr, or vpu, which are 
implicated in downregulating multiple host factors, are not required for this HO-1 deficiency 
phenotype, as mutant HIV-1 molecular clones lacking expression these accessory genes 
maintained the ability to reduce HO-1 protein expression and induce supernatant neurotoxicity in 
infected macrophages to an extent commensurate with their overall replication levels.  
 
We further demonstrated that the other major human immunodeficiency virus, HIV-2, also 
reduces HO-1 protein expression and increases neurotoxin release in infected macrophages. 
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Although, HIV-1 and HIV-2 share many similarities including basic gene organization, replication 
pathways, and modes of transmission, HIV-2 shares only 50-60% nucleic acid homology with 
HIV-1 and it is more closely related to the simian-immunodeficiency virus (SIV). Compared to 
HIV-1, HIV-2 causes less severe disease as determined by lower plasma viral loads, less CD4+ T 
lymphocyte loss, reduced risk of progression to AIDS, and decreased mortality (605). Despite 
reduced pathogenic potential, HIV-2 infiltrates into the CNS and can cause neurological 
impairment and neuropathologic changes similar to those of HIV-1 (607). Our data suggest that 
this HO-1-deficient neurotoxic phenotype in macrophages is conserved across HIV-1 and HIV-2 
strains and thus HO-1 loss may have a conserved role in neurological disease and 
neurocognitive impairment in both HIV-1 and HIV-2 infected individuals. In each of our HIV-1 and 
HIV-2 macrophage infection experiments, HO-1 deficiency correlated with viral replication. 
Despite this correlation, our data clearly demonstrate that even low-level HIV replication in 
macrophages can promote HO-1 loss. The conservation of this HO-1 deficiency phenotype 
across human immunodeficiency viruses suggests that reduction in HO-1 protein expression 
might provide a selective advantage for HIV survival in macrophages and ultimately therefore 
contribute to HIV pathogenesis.  
 
A role for HO-1 in the pathogenesis of virus infections has been suggested not only for HIV-1, but 
also for other viruses. Induction of HO-1 expression in uninfected macrophages has been shown 
to reduce subsequent HIV-1 infection and replication (608, 609). An anti-viral effect of HO-1 
induction has been observed in infection studies of hepatitis C (HCV) (610), hepatitis B (HBV) 
(611), ebola (612), enterovirus 71 (EV71) (613), vaccinia (614), and porcine reproductive and 
respiratory syndrome virus (615). Interestingly, HCV has been reported to downregulate HO-1 
protein expression (616, 617), although contrasting studies report HO-1 induction by HCV (618, 
619).  
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How HO-1 expresses antiviral effects is unknown. Recent work suggests that HO-1 expression in 
myeloid cells is required for induction of type I interferon expression and associated innate 
immune responses (471, 620). These effects might occur through signaling by biliverdin, an HO-1 
enzymatic product (621). Thus, HO-1 might promote an interferon-mediated anti-viral state. Other 
proposed HO-1 antiviral effects include post-transcriptional destabilization of viral core proteins, 
as for HBV (611), and inhibition of viral enzymes, as for the HIV protease by biliverdin and 
bilirubin (622). The consistent ability of HIV to decrease HO-1 expression in macrophages 
suggests an adaptive benefit for the virus; however, the HIV-mediated loss of HO-1 in MDM 
seems unlikely to have a significant effect on HIV replication as HO-1 deficiency is not observed 
until 6-9 days post-infection, after robust infection is established (43). Although induction of HO-1 
in macrophages prior to HIV infection has been reported to reduce subsequent HIV replication, 
enzymatic inhibition of target cell HO-1 prior to infection does not augment subsequent HIV 
replication (609). Moreover, we demonstrated that potent HO-1 knockdown, HO-1 enzymatic 
inhibition, or induction of HO-1 expression in macrophages in which productive HIV replication is 
established does not alter replication (43). Thus, a role for HO-1 in modulating HIV replication in 
macrophages has not been clearly established, in contrast to a clear role for HIV replication in 
macrophages in reducing HO-1 expression. The consequences and full effects of HIV-mediated 
HO-1 deficiency in macrophages clearly require further study.  
 
To address the association between HIV replication and HO-1 deficiency in the context of ART 
use, we determined the ability of clinically-relevant ART regimens applied pre- and post-infection 
to prevent HO-1 loss and associated neurotoxicity in HIV-MDM. We demonstrated that ART 
exposure at CNS-relevant concentrations fails to prevent HO-1 loss and neurotoxicity in HIV-
MDM once infection is already established. This suggests that long-lived CNS macrophage 
reservoirs in HIV-infected individuals, even those on suppressive ART, can maintain an HO-1 
deficient, neurotoxic phenotype.  
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This inability for ART to attenuate this phenotype once established may be especially relevant 
given the recent evidence for plasma and CSF viral blipping (intermittent HIV replication) in ART-
treated individuals and its association with immune activation. Recent studies suggest that 
despite apparently prolonged plasma HIV suppression by ART (< 50 HIV RNA copies/ml), 
intermittent viral replication is detectable in the plasma and/or cerebrospinal fluid (133). Moreover, 
CSF viral blipping, which can occur independently from plasma blipping, associates with 
monocyte activation (neopterin) and emergence of CNS-compartmentalized ART resistance 
mutations (134, 281). Intermittent viral replication within the CNS macrophage compartment could 
promote the persistence of an HO-1 deficient neurotoxic phenotype that is resistant to 
suppressive ART therapy. This suggests a plausible mechanism by which HIV infection of brain 
macrophages in ART-treated individuals could exacerbate oxidative stress and glutamate-
induced neuronal injury, each of which is associated with neurocognitive dysfunction in infected 
individuals (174, 239).  
 
The conservation of the ability to induce HO-1 deficiency and associated neurotoxin production 
across macrophage-tropic HIV strains and the association of brain HO-1 deficiency with 
neurocognitive impairment makes it an attractive therapeutic target in HIV-infected individuals 
with HAND (43). The failure of ART to prevent this HO-1 loss in established infection highlights 
the potential value of HO-1-inducing drugs as adjunctive therapy to ART. Our current findings 
suggest that induction of HO-1 deficiency associated with excess glutamate production and 
neurotoxicity is a highly conserved phenotype of macrophage-tropic HIV strains, which can 
persist in the macrophage compartment in the presence of ART. Our studies further suggest a 
role for HO-1 deficiency in ongoing neuronal injury in HAND, which is only partially prevented by 
ART. Therapies that target HO-1 deficiency in chronic HIV infection could provide additional 
neuroprotection to ART.  
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11.1 Abstract  
 
Heme oxygenase-1 (HO-1) is an inducible, detoxifying enzyme critical for limiting oxidative stress, 
inflammation, and cellular injury within the CNS and other tissues. Our analysis of HO-1 
expression in the brains of HIV-infected individuals demonstrated a significant HO-1 protein 
deficiency that correlated with cognitive dysfunction, CNS HIV replication, and neuroimmune 
activation. Furthermore, our in vitro analysis of HO-1 expression in HIV-infected macrophages, a 
primary CNS HIV reservoir along with microglia, demonstrated consistent and highly conserved 
HO-1 deficiency associated with increased culture supernatant glutamate and neurotoxicity, 
suggesting a link between HIV infection, macrophage HO-1 deficiency, and neurodegeneration. 
To determine a causative role for HO-1 in modulating macrophage neurotoxin production, we 
used pharmacologic and genetic approaches to manipulate HO-1 in HIV-infected macrophages.  
HO-1 siRNA knockdown and HO enzymatic inhibition in HIV-infected macrophages increased 
supernatant glutamate and neurotoxicity. In contrast, increasing HO-1 expression through siRNA 
derepression or with non-selective pharmacologic inducers, including the CNS-penetrating drug 
dimethyl fumarate (DMF), decreased supernatant glutamate and neurotoxicity. These findings 
identify HO-1 as a protective host factor against HIV-mediated neurodegeneration and further 
suggest that HO-1 deficiency contributes to such degeneration. Inducing HO-1 in the CNS of HIV-
infected antiretroviral therapy-treated patients could provide a novel approach for protection 
against neurodegeneration and associated cognitive dysfunction. 
 
11.2 Introduction  
 
Through analysis of post-mortem brain tissue specimens, we have demonstrated that HO-1 
protein expression is deficient in the dorsolateral prefrontal cortex (DLPFC) of HIV-infected 
subjects and that this HO-1 deficiency is correlated with CNS viral load and markers of immune 
activation (see Chapter 8). Using our in vitro model of HIV-mediated neurotoxicity, in which HIV 
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infection of monocyte-derived macrophages (HIV-MDM) induces release of soluble neurotoxins 
(46, 623), we have identified an association between HIV-driven HO-1 deficiency and a glutamate 
production and associated neurotoxicity (see Chapter 10). Overexpression of HO-1 has been 
shown to be protective in animal models of inflammatory diseases, including cardiac ischemia 
(412), pulmonary hypoxia and inflammation (413, 624), and stroke (414); such studies have 
promoted the study of pharmacological HO-1 inducers in human diseases (521). Among these 
HO-1 inducers are the fumaric acid esters, notably dimethyl fumarate (DMF) and its primary CNS-
penetrating in vivo metabolite monomethyl fumarate (MMF). Both DMF and MMF induce 
expression of ARE-driven genes, including HO-1, and modulate immune responses in various cell 
lineages through inhibition of NF-κB signaling, thereby promoting an anti-inflammatory and anti-
oxidative cellular state (reviewed in (625)). Recently, an oral DMF preparation, Tecfidera™, 
received FDA approval for the treatment of multiple sclerosis, a disease characterized by 
recurrent neuroinflammation and oxidative stress.  
 
To determine the role of HO-1 deficiency in modulating glutamate production and associated 
neurotoxicity in HIV-MDM, we utilized siRNA knockdown of HO-1 and pharmacologic HO 
enzymatic inhibition to further reduce HO-1 expression and enzymatic activity. Decreasing HO-1 
expression or inhibiting enzymatic activity in HIV-MDM significantly augmented neurotoxin 
production. To determine the ability of HO-1 induction to ameliorate glutamate production and 
associated neurotoxicity in HIV-infected macrophages, we utilized siRNA depression and 
pharmacologic inducers of HO-1 to increase HO-1 expression. We demonstrated that induction of 
HO-1, including by DMF and MMF, can ameliorate HIV-MDM glutamate release and 
neurotoxicity. These findings suggest that HO-1 deficiency contributes significantly to HAND 
neuropathogenesis through modulation of neurotoxin production and that restoring CNS HO-1 
expression could attenuate neurodegenerative processes and thereby reduce the persistent risk 
of HAND in ART-treated individuals.  
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11.4 Results  
 
Pharmacologic inducer of HO-1 expression decreases HIV-MDM supernatant glutamate and 
neurotoxicity 
 
Given the association between decreased HO-1 protein expression and glutamate production in 
HIV-MDM, we hypothesized that HO-1 modulates the release of glutamate from MDM and the 
associated neurotoxicity. To test this, we induced HO-1 expression in HIV-MDM with cobalt (III) 
protoporphyrin IX chloride (CoPP) and determined effects on supernatant glutamate and 
neurotoxicity (Figure 11.1). CoPP robustly induces HO-1 protein expression in MDM (~ 20-fold) 
with limited induction of other ARE proteins (NQO1 and TRXR1, ~1.5-2 fold) with no effect on 
HO-2, GPX1, or GSTP1 expression (Figure 11.2, A and B). We applied CoPP to HIV-MDM during 
days 6-15 of HIV infection, when glutamate production and supernatant neurotoxicity are 
generally robust (see Figure 10.1). The addition of CoPP profoundly increased HO-1 expression 
in HIV-MDM while modestly increasing expression of NQO1 (Figure 11.1B). No effect on HIV 
replication was observed (Figure 11.1A). However, CoPP treatment significantly reduced 
supernatant glutamate (Figure 11.1, C and E) and associated neurotoxicity (Figure 11.1, D and 
F). A similar reduction in supernatant glutamate and neurotoxicity was observed as expected 
when viral replication was inhibited via treatment of HIV-MDM with the reverse transcriptase 
inhibitor efavirenz. These data suggest that HO-1 induction may suppress HIV-mediated 
macrophage glutamate production and neurotoxicity independently of viral replication.  
 
A pharmacologic inhibitor of HO enzymatic activity increases HIV-MDM supernatant glutamate 
and neurotoxicity 
 
To further confirm the role for HO-1 in modulating macrophage glutamate production and 
neurotoxicity, we used tin (IV) mesoporphyrin IX dichloride (SnMP), a potent inhibitor of HO-1 and 
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Figure 11.1 Inducers of HO-1 expression reduce HIV-MDM supernatant glutamate 
accumulation and neurotoxicity independently of HIV replication. CoPP, a potent inducer of 
HO-1, was added to HIV-MDM cultures on days 6, 9, and 12 post infection. Efavirenz (EFV) (20 
nM) was added1 hour prior to HIV inoculation and replenished with each medium exchange to 
suppress HIV replication. (A) HIV replication (supernatant RT activity). (B) Western blot of cell 
lysates (day 12) for detection of ARE proteins HO-1, NQO1, and GPX1. (C) Supernatant (day 12) 
glutamate concentration and (D) supernatant neurotoxicity. (E) Supernatant (day 15) glutamate 
concentration and (F) supernatant neurotoxicity. Values represent mean ± SEM of technical 
replicates from a representative experiment of 3 independent experiments, with each biological 
replicate performed on MDM preparations from a different donor. Statistical comparisons were 
made by 1-way ANOVA plus Hold-Sidak post hoc test. **P < 0.01; ***P < 0.001. 
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Figure 11.2 CoPP and SnMP induce HO-1, but not HO-2, protein expression in MDM. 
Uninfected MDM were exposed to 10µM CoPP or SnMP for 24 hours and assessed for protein 
expression by Western blot. (A) Representative Western blot of HO-1, HO-2, TRXR1, NQO1, 
GSTP1, and GPX1 expression. (B) Quantification of Western blot expression by densitometry 
analysis. Data points represent mean ± SEM from 6 different MDM donors. Statistical 
comparisons were made by one-way ANOVA plus Hold-Sidak post hoc test. *p < 0.05, ***p < 
0.001. 
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HO-2 enzymatic activity (626), which also induces HO-1 expression, through derepression of the 
HO-1 promoter (627). As expected, the addition of SnMP to HIV-MDM cultures under conditions 
identical to those of the CoPP treatments did not alter HIV replication and did induce HO-1 
protein expression (Figure 11.3, A and B). Strikingly, SnMP treatment dose-dependently 
increased supernatant glutamate (Figure 11.3, C and E) and neurotoxicity (Figure 11.3, D and F), 
suggesting that inhibition of heme oxygenase (HO-1 and/or HO-2) enzymatic activity enhances 
HIV-MDM glutamate production. Notably, SnMP also modestly increased NQO1 expression in 
MDM without altering HO-2, TRXR1, GSTP1, or GPX1 expression, similar to the effects of CoPP 
(Figure 11.2, A and B)). As both CoPP and SnMP have similar effects on ARE protein 
expression, but only SnMP inhibits HO-1 and HO-2 enzymatic activity, these data strongly 
suggest that heme oxygenase enzymatic activity mediates the effects on HIV-MDM glutamate 
production and neurotoxicity. Additionally, similar effects of SnMP were observed in uninfected 
MDM, with SnMP treatment dose-dependently increasing supernatant glutamate and 
neurotoxicity (Figure 11.4, A and B). Importantly, we did not observe SnMP cytotoxicity in MDM at 
the doses used (Figure 11.4, C and D). This further supports the hypothesis that deficiency of 
heme oxygenase enzymatic activity in MDM may induce glutamate release and neurotoxicity.  
 
Finally, inhibitors of NQO1 (dicoumarol, DCM) and GPX1 (mercaptosuccinic acid, MSA) 
enzymatic activity did not increase MDM supernatant glutamate or neurotoxicity (Figure 11.4, A 
and B), further supporting the specificity of heme oxygenase effects. These results suggest that 
HO-1 modulates MDM glutamate production and neurotoxicity, and they further suggest that the 
brain HO-1 deficiency observed in HIV-infected individuals may directly contribute to HIV-
mediated neurodegeneration.  
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Figure 11.3 Exposure of HIV-MDM to an inhibitor of heme oxygenase enzymatic activity 
(SnMP) enhances glutamate release and supernatant neurotoxicity independently of HIV 
replication. SnMP, an inhibitor of heme oxygenase activity, was added to HIV-MDM cultures on 
days 6, 9, and 12 post infection. (A) HIV replication (supernatant RT activity). (B) Western blot of 
cell lysates (day 15) for detection of ARE proteins HO-1, NQO1, and GPX1. (C) Supernatant (day 
12) glutamate concentration and (D) supernatant neurotoxicity. (E) Supernatant (day 15) 
glutamate concentration and (F) supernatant neurotoxicity. Values represent mean ± SEM of 
technical replicates from a representative experiment of 3 independent experiments, with each 
biological replicate performed on MDM preparations from a different donor. Statistical 
comparisons were made by 1-way ANOVA plus Hold-Sidak post hoc test. ***P < 0.001 
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Figure 11.4 Exposure of non-infected MDM to an inhibitor of HO-1 and HO-2 enzymatic 
activity (SnMP) enhances supernatant glutamate and neurotoxicity. Uninfected MDM from 4 
different donors were exposed (6 days) to Vehicle (Veh), the HO-1 inhibitor SnMP (1, 5, 10, 
20µM), the HO-1 expression inducer CoPP (10µM), the GPX1 inhibitor MSA (100 and 1000µM), 
the NQO1 inhibitor DCM (1 and 10µM), or left untreated (UT) and culture supernatants were 
assayed for (A) glutamate concentration and (B) neurotoxicity normalized to Vehicle. SnMP 
induced toxicity was quantified by (C) total dead cell luminescence and (D) the live/dead cell ratio 
in MDM cultures from 3 different donors. Camptothecin (CT; 6 hour exposure) and complete cell 
lysis (maximum cytotoxicity, Max) served as a positive controls. Values represent mean ± SEM. 
Statistical comparisons were made by one-way ANOVA plus Hold-Sidak post hoc test. **p < 0.01, 
***p < 0.001. 
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siRNA-mediated induction and inhibition of HO-1 expression modulate HIV-MDM supernatant 
glutamate and neurotoxicity 
 
Given our evidence that pharmacologic modulations of HO-1 alter supernatant glutamate and 
neurotoxicity, we attempted to confirm the role of HO-1 in HIV-MDM neurotoxin production using 
an siRNA knockdown approach. We tested two siRNAs targeted against HO-1 and two siRNAs 
against BTB and CNC Homology 1 (BACH1) transcription factor, a robust negative transcriptional 
regulator of HO-1 (628). Transfection efficiency in four independent MDM donor cultures ranged 
from 84-96%, as determined by transfection of a fluorescent control RNA oligomer (Figure 
11.5A). We confirmed that both siRNAs targeted against HO-1 reduced HO-1 protein expression 
by ~10 fold in MDM and HIV-MDM, while siRNAs targeting BACH1 were able to reduce BACH1 
protein expression by ~ 3 fold (Figure 11.5, B-D). Associated with this BACH1 knockdown was a 
~10 fold increase in HO-1 expression. Furthermore, neither the HO-1 nor BACH1 siRNAs altered 
HO-2 expression, in contrast to two siRNAs targeted to HO-2. Thus we were able to selectively 
modulate HO-1 expression by siRNA without altering HO-2 expression.  
 
Therefore, to further confirm the role for HO-1 in regulating glutamate and neurotoxicity in HIV-
MDM, we used siRNA targeting both HO-1 and BACH1 alone and in combination on day 6 post 
HIV infection of MDM. We transfected HIV-MDM with either scramble siRNA, HO-1 siRNA, 
BACH1 siRNA, BACH1 + scramble siRNA, or BACH1 + HO-1 siRNA and analyzed protein 
lysates and supernatants on day 12 post infection. Successful siRNA knockdown of HO-1 and 
BACH1 was confirmed by Western blot and neither knockdown altered HIV replication (Figure 
11.6, A and B). Knockdown with BACH1 siRNA (or BACH1 siRNA + scramble siRNA) reduced 
extracellular glutamate and supernatant neurotoxicity, while knockdown of HO-1 increased 
extracellular glutamate and supernatant neurotoxicity (Figure 11.6, C and D). Furthermore, 
BACH1 + HO-1 knockdown partially reversed the reduced glutamate and neurotoxicity effects, 
suggesting that BACH1 siRNA modulation of glutamate and neurotoxicity is in part an effect of 
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Figure 11.5 HO-1 and BACH1 siRNAs effectively knockdown and induce HO-1 expression, 
respectively, in uninfected and infected MDM. 50nM of each siRNA was transfected into MDM 
using Lipofectamine RNAiMax. (A) Representative fluorescent microscopy images of MDM 24 
hours post-transfection with fluorescent oligos (BLOCK-IT™ Alexa Fluor® Red Fluorescent 
Oligo). (B) Representative Western blot for HO-1, HO-2, BACH1, NQO1, and GAPDH at 24 
hours, 72 hours, and 144 hours post-transfection with siRNA targeting either HO-1, HO-2, or 
BACH1. (C) Densitometry analysis of HO-1 Western blot protein expression 72 hours post siRNA 
transfection. Values represent log mean ± SEM of HO-1 expression normalized to GAPDH 
(Vehicle set to 0) from 4 different MDM donors. (D) Representative Western blot of HIV-infected 
MDM 3 days and 6 days post siRNA transfection. HIV-MDM were transfected with selected 
siRNA targeting HO-1 or BACH1 on day 6 post HIV infection. Protein lysates were either 
collected on day 9 post-infection (day 3 post transfection) or media was fully exchanged and 
protein lysates were collected on day 12 post-infection. Statistical comparisons were made by 
one-way ANOVA plus Hold-Sidak post hoc test. **p < 0.01. 
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Figure 11.6 Knockdown of HO-1 and BACH1 by siRNA modulates extracellular glutamate 
and supernatant neurotoxicity in HIV-MDM independently of HIV replication. On day 6 post 
infection, siRNA targeting HO-1 or BACH1 or a scramble negative control siRNA were transfected 
into HIV-MDM alone or in combination using Lipofectamine RNAimax. On day 9, medium was 
fully exchanged without retransfection. Representative data from a single donor infection showing 
(A) HIV replication (supernatant RT activity), (B) Western blot of cell lysates (day 12) for detection 
of HO-1, BACH1, HO-2, and GAPDH, (C) supernatant (day 12) glutamate concentration, and (D) 
supernatant neurotoxicity. Values represent mean ± SEM. Statistical comparisons were made by 
1-way ANOVA plus Hold-Sidak post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 versus HIV-
MDM scramble siRNA; #P < 0.05, ###P < 0.001 for indicated comparison. 
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HO-1 protein induction (Figure 11.6, C and D). These siRNA mediated effects on glutamate levels 
were seen in 2 additional independent experiments from 2 additional MDM donors. Among these 
two replicate experiments, one donor failed to achieve a significant increase in neurotoxicity with 
HO-1 and BACH1 double knockdown compared to BACH1 + scramble, although HO-1 and 
BACH1 knockdown alone did increase and decrease neurotoxicity, respectively (data not shown). 
Overall, these siRNA knockdown data support the conclusion that HO-1 modulates supernatant 
neurotoxicity and glutamate in HIV-MDM independently of HO-2.    
 
The therapeutic ARE- and HO-1-inducer, dimethyl fumarate, attenuates HIV-MDM supernatant 
glutamate and neurotoxicity 
  
The potential benefit of therapeutic induction of HO-1 expression in the brains of HIV-infected 
individuals prompted us to examine the CNS-penetrating HO-1 inducer DMF for effects on MDM 
glutamate production and neurotoxicity. We previously showed that DMF and its primary in vivo 
metabolite, MMF, reduce neurotoxicity of HIV-MDM supernatants when applied to MDM cultures 
prior to inoculation with HIV (42). This effect was associated with both increased HO-1 expression 
and reduced HIV replication, both of which likely contributed to the reduction in neurotoxicity. We 
have now extended these studies to examine effects of DMF and MMF on glutamate production, 
HIV replication, and neurotoxicity when applied to MDM after HIV infection is established, as 
would reflect the state of the brain in HIV-infected individuals. Although less specific for HO-1 
than CoPP, the ARE-inducers DMF, MMF, and tert-butylhydroquinone (tBHQ), nonetheless 
significantly induce the expression of HO-1, as well as other ARE proteins (Figure 11.7A). After 
exposure of MDM to each ARE-inducer, we observed a peak of HO-1 induction at 6-12 hours, 
with HO-1 levels returning to baseline by 48 hours (Figure 11.7, B-D).  
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Figure 11.7 Time course of HO-1 induction in MDM by tBHQ, MMF, and DMF. Uninfected 
MDM were exposed to tBHQ (T, 10µM), MMF (M, 30µM), or DMF (D, 30µM) for 0, 6, 12, 24, and 
48 hours and assessed for HO-1 expression by Western blot (V = vehicle for tBHQ, MMF, and 
DMF). For comparison, MDM were also treated with CoPP (CP, 10µM) and SnMP (SP, 10µM) for 
24 hours (V2 = vehicle for SnMP and CoPP). (A) Representative Western blot of HO-1, NQO1, 
and GPX expression. Quantification of HO-1 Western blot expression by densitometry analysis 
normalized to GAPDH for (B) tBHQ, (C) MMF, and (D) DMF treatment. Data points represent 
mean ± SEM from 6 different MDM donors. Statistical comparisons were made by Student's 
paired t-test. *p < 0.05, **p < 0.01. 
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Because of this transient effect on HO-1 expression after single doses of DMF and MMF, we 
treated HIV-MDM cultures with multiple doses beginning on day 6 and again on day 9, and then 
quantified supernatant glutamate and neurotoxicity on day 12. Similar to previous HO-1 
modulating treatments, we saw no effect of either DMF or MMF on HIV replication (Figure 11.8, A 
and D), yet we observed a significant reduction in supernatant glutamate (Figure 11.8, B and E) 
and supernatant neurotoxicity (Figure 11.8, C and F). We saw similar effects after treatment with 
tBHQ (Figure 11.8, G-I).  
 
Notably, treatment of primary rat cortical neurons with DMF or MMF concurrently with HIV-
infected macrophage supernatant did not prevent neuronal injury and death as measured by 
MAP2 ELISA (Figure 11.9, A and B), suggesting that DMF/MMF neuroprotection in this study is 
likely due to effects on macrophages, rather than effects of any un-metabolized DMF/MMF 
remaining in the macrophage supernatant used to treat neurons. These data demonstrate that 
ARE-inducers, including DMF and MMF, at concentrations consistent with CSF MMF 
concentrations in vivo (629), can ameliorate neurotoxin production in HIV-MDM independently of 
suppression of viral replication.  
 
11.5 Discussion 
 
HIV infection of macrophages markedly reduces HO-1 expression, and this HO-1 deficiency is 
linked to increased toxic levels of glutamate, a HAND-associated neurotoxin (229, 239, 602). 
Here we confirm a direct role for HIV-driven HO-1 loss in modulating neurotoxin production from 
HIV-MDM. The inhibition of heme oxygenase (HO-1 & HO-2) enzymatic activity and selective HO-
1 knockdown increased glutamate and associated neurotoxicity in HIV-infected macrophages, 
which further implicates HO-1 in modulating macrophage-mediated neurotoxin production in HIV 
infection. This association between HO-1 deficiency and glutamate production suggests a 
potential therapeutic benefit of restoring HO-1 expression in HIV-infected brain macrophages.  
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Figure 11.8 DMF and MMF reduce glutamate release and associated supernatant 
neurotoxicity in HIV-MDM independently of HIV replication. DMF and MMF were added to 
HIV-MDM on day 6 post infection and replenished on day 9 post infection. tBHQ was added on 
day 9 post infection and not replenished. Culture supernatants (day 12 post infection) were 
assayed for glutamate concentration and neurotoxicity normalized to untreated primary rat 
neuronal cultures (UT). (A) HIV replication (supernatant RT activity), (B) supernatant glutamate 
concentration, and (C) supernatant neurotoxicity in DMF-treated HIV-MDM. Similar effects of 
DMF treatment in HIV-MDM were observed in 4 of 5 independent experiments, with each 
replicate performed on MDM preparations from a different donor. (D) HIV replication (supernatant 
RT activity), (E) supernatant glutamate concentration, and (F) supernatant neurotoxicity in MMF-
treated HIV-MDM. Similar effects of MMF treatment in HIV-MDM were observed in 3 of 4 
independent experiments, with each replicate performed on MDM preparations from a different 
donor. (G) HIV replication (supernatant RT activity), (H) supernatant glutamate concentration, and 
(I) supernatant neurotoxicity in tBHQ-treated HIV-MDM. Similar effects of tBHQ treatment in HIV-
MDM were observed in 3 of 3 independent experiments, with each replicate performed on MDM 
preparations from a different donor. Values represent mean ± SEM. Statistical comparisons were 
made by 1-way ANOVA plus Hold-Sidak post hoc test. Veh, vehicle. *P < 0.05; **P < 0.01; ***P < 
0.001 versus vehicle. 
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Figure 11.9 Concurrent treatment with DMF and MMF does not protect neurons in 
neuroglial cultures from HIV-MDM mediated neurotoxicity. Day 14 in vitro primary rat 
cerebrocortical neuroglial cultures were exposed to Mock-MDM or HIV-MDM supernatant from 
day 12 post infection at a 1:20 dilution. HIV-MDM exposed neuroglial cultures were co-treated 
with increasing doses of (A) DMF and (B) MMF. Positive control neuroglial cultures were pre-
treated (5 minutes) with either MK801 (a nonselective noncompetitive antagonist of the NMDA 
receptor) or Ifenprodil (a selective noncompetive antagonist of NR2B subunit-containing NMDA 
receptors). 24 hours after exposure neuroglial cultures were assessed for MAP2 expression by 
MAP2 ELISA. MAP2 expression was normalized to untreated neuroglial cultures. Values 
represent the mean ± SEM from 3 experiments using supernatant from HIV-MDM infections from 
3 independent donors. Statistical analysis comparing vehicle treated neuroglial cultures to all 
other groups were made by one-way ANOVA plus Hold-Sidak post hoc test. ***p < 0.001. 
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To this end, we have shown using both pharmacological and genetic approaches, that HO-1 
induction decreased HIV-MDM glutamate production and associated neurotoxicity. However, the 
contribution of other ARE-induced genes (e.g. NQO1), which were induced to varying extents by 
these approaches, cannot be ruled out. Given that microglia can support robust HIV replication 
and that HIV-infection of microglia similarly enhances extracellular glutamate and associated 
neurotoxicity (602), we hypothesize that HIV reduces HO-1 expression and that HO-1 modulates 
neurotoxin production in HIV-infected microglia.   
 
Our studies support a role for induction of HO-1 expression as a protective strategy against HIV 
disease progression, and they further suggest that drugs such as DMF could serve this 
therapeutic role. DMF and its primary metabolite monomethyl fumarate  (MMF) are potent 
inducers of HO-1 expression and MMF is detectable within the CSF after oral delivery of DMF at 
concentrations (4.4µM) that effectively induce macrophage HO-1 expression and suppress 
production of neurotoxic levels of glutamate (629). Other effects of DMF and MMF (inhibition of 
HIV infection of macrophages, inhibition of macrophage NF-κB nuclear translocation and TNFα 
release, and reduction of CCL2-mediated monocyte chemotaxis) could also have beneficial 
effects in ART-treated individuals (42), although whether these effects are related to HO-1 
induction is not clear. Notably, HO-1 has been reported to inhibit NF-κB through inhibition of 
phosphorylation of the p65 (NF-κB subunit) at serine 276 (630), a mechanism of inhibition also 
reported in response to DMF treatment in dendritic cells (631). Thus, inhibition of NF-κB signaling 
may play a role in the DMF/HO-1 mediated decrease in HIV-infected macrophage neurotoxin 
production. Considerable evidence therefore supports the testing of HO-1 inducers such as DMF 
as adjunctive therapy for prevention of both systemic and CNS complications of HIV infection in 
ART-treated subjects (reviewed in (625)) and additional studies of the role of HO-1 in HIV disease 
progression are needed. 
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12.1 Abstract  
 
The persistence of chronic immune activation and oxidative stress in human immunodeficiency 
virus (HIV)-infected, antiretroviral drug-treated individuals are major obstacles to fully preventing 
HIV disease progression. The immune modulator and antioxidant dimethyl fumarate (DMF) is 
effective in treating immune-mediated diseases and it also has potential applications to limiting 
HIV disease progression. Among the relevant effects of DMF and its active metabolite 
monomethyl fumarate (MMF) are induction of a Th1 à Th2 lymphocyte shift, inhibition of pro-
inflammatory cytokine signaling, inhibition of NF-κB nuclear translocation, inhibition of dendritic 
cell maturation, suppression of lymphocyte and endothelial cell adhesion molecule expression, 
and induction of the Nrf2-dependent antioxidant response element (ARE) and effector genes. 
Associated with these effects are reduced lymphocyte and monocyte infiltration into psoriatic skin 
lesions in humans and immune-mediated demyelinating brain lesions in rodents, which confirms 
potent systemic and central nervous system (CNS) effects. In addition, DMF and MMF limit HIV 
infection in macrophages in vitro, albeit by unknown mechanisms. Finally, DMF and MMF also 
suppress neurotoxin production from HIV-infected macrophages, which drives CNS 
neurodegeneration. Thus, DMF might protect against systemic and CNS complications in HIV 
infection through its effective suppression of immune activation, oxidative stress, HIV replication, 
and macrophage-associated neuronal injury. 
 
12.2 Introduction  
 
Fumaric acid was initially proposed for treatment of psoriasis by the German chemist Walter 
Schweckendiek in 1959 (632). However, because fumaric acid is poorly absorbed after oral 
intake, developing a mixture of fumaric acid esters (FAEs) to achieve higher effective 
bioavailability after oral dosing was necessary. In 1994, an enteric-coated preparation of FAEs 
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containing 120 mg of dimethyl fumarate (DMF) and three salts of monoethyl fumarate (MEF) was 
licensed in Germany under the trade name Fumaderm® for the treatment of psoriasis. After 
positive results in psoriasis treatment trials, research into the therapeutic potential of FAEs has 
greatly accelerated. Most recently, a DMF-containing formulation, BG-12, showed marked 
efficacy in Phase III multiple sclerosis clinical trials (633, 634). Furthermore, additional in vitro and 
in vivo studies over the past decade have explored the therapeutic potential of FAEs for the 
treatment of other inflammatory diseases. With the recent FDA approval of BG-12 (brand name 
Tecfidera™) on March 27th, 2013 for the treatment of multiple sclerosis, the clinical application of 
FAEs for treating inflammatory diseases is likely to further rapidly expand. This review will assess 
the understanding of the mechanisms of FAEs in modulating immune responses and antioxidant 
responses and their potential application for treating disorders of inflammation and associated 
oxidative stress. Among the potential uses of FAEs is the treatment of HIV infection and its 
associated complications, as inflammation and oxidative stress are central to HIV pathogenesis. 
Notably, as DMF and MMF have been shown to effectively suppress inflammatory responses in 
vivo in both systemic and CNS compartments, DMF formulation therapy could offer adjunctive 
protection against both systemic and CNS complications of HIV infection.  
 
12.3 Pharmacokinetics  
 
Within minutes after oral intake, DMF is rapidly hydrolyzed by esterases within the small intestine 
to form its biologically active metabolite, monomethyl fumarate (MMF) (635). MMF, but not DMF, 
can be detected in serum after oral DMF ingestion. DMF is undetectable likely due its rapid 
hydrolysis. MMF is further metabolized through the tricarboxylic acid cycle to form H2O and 
carbon dioxide, which is excreted through respiration. There is no evidence for cytochrome P450-
dependent metabolism. Small amounts of non-metabolized MMF are detectable in the urine and 
feces.(636) In fasting healthy individuals, the half-life of MMF was estimated to be ~56 minutes 
and peak serum levels (mean 6 µM, range 3-10 µM) were observed at ~178 minutes (standard 
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deviation 39 minutes) after 120 mg of oral DMF (and 95 mg of MEF) (636). When these healthy 
individuals ingested DMF with meals, the peak MMF serum levels increased by more than 25% in 
57% of the patients, but they decreased by an average of 69% in the remaining subjects; this 
demonstrates that food intake increases variability in serum MMF concentrations. In a smaller 
study of psoriasis patients, the average half-life of MMF was estimated to be ~47 minutes with 
peak serum levels of 12.5 µM observed at ~219 minutes post-intake (two tablets of Fumaderm®, 
240 mg DMF and 190 mg MEF) (637). In both of these pharmacokinetic studies, DMF was not 
detected in serum (<0.07 µM in healthy individuals). This suggests that MMF, but not DMF, is 
absorbed into the systemic circulation, and that MMF is the functional molecule in vivo that should 
be targeted for mechanistic studies in vitro. Nonetheless, Rostami-Yazdi et al. detected the 
mercapturic acid derivative of DMF in urine from individuals taking Fumaderm®, suggesting that 
DMF might indeed enter the circulation prior to being rapidly metabolized (638). Thus, DMF might 
express some biological activity in vivo, however transiently, and therefore defining the 
mechanisms of action of FAEs requires the study of both MMF and DMF to fully define the 
biological effects of oral DMF formulation therapy.  
 
12.4 Mode of Action in Different Cell Lineages: Immunomodulation & Antioxidant 
Response  
 
NF-κB and the ARE 
 
The effects of DMF and MMF on immune responses have thus far been only partially 
characterized. Several in vitro studies have demonstrated perturbation of nuclear factor κB (NF-
κB) function through inhibition of NF-κB nuclear translocation and DNA binding (Figure 12.1). The 
NF-κB pathway plays a central role in regulating cytokine production, cellular activation, 
development, survival, and the innate and adaptive immune system among other roles (reviewed 
in (639)). NF-κB has been shown to induce TNFα, iNOS, IL-1, IL-2, IL-6, ICAM-1, and COX-2, 
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among others (640). DMF and MMF also induce the nuclear factor erythroid-2 related factor-2 
(Nrf2)-dependent antioxidant response element (ARE) pathway (Figure 12.1). The ARE response 
is a ubiquitous cytoprotective cellular stress response involving induction of multiple genes that 
protect cells from many forms of intracellular oxidative stress and injury (reviewed in (641)). 
Generally, oxidative stress occurs when cells are unable to detoxify injurious agents or repair 
damage resulting from reactive oxygen species, hydrogen peroxide, hydroxyl radicals, and other 
mediators of oxidative stress. Oxidative stress induces the translocation of Nrf2 to the nucleus 
where it binds to the ARE promoter element and activates gene transcription (642-644) of 
hundreds of genes (643, 645, 646), including many antioxidant defense enzymes such as the 
sentinel cytoprotectant heme oxygenase-1 (HO-1) (647), NAD(P)H quinone oxidoreductase-1 
(NQO1) (648), γ-glutamate cysteine ligase catalytic subunit (GCLC) (649), glutathione S-
transferase (GST) (650), and the cysteine/glutamate transporter (xCT) (651).  
 
Many studies have demonstrated complex regulatory interactions between the FAE-responsive 
Nrf2-dependent ARE and NF-κB pathways. ARE induction can inhibit the NF-κB pathway and 
thus indirectly modulate inflammatory cytokine and chemokine signaling (652). This inhibition of 
NF-κB likely occurs through ARE-driven reduction in oxidative stress, which has been shown to 
activate the NF-κB signaling pathway (653-656). Further supporting a role for Nrf2, several 
studies have demonstrated increased NF-κB activation and dysregulation of cytokines and 
chemokines in Nrf2-/- mice after inflammatory insults such as exposure to lipopolysaccharide 
(LPS) (657) or TNFα (657), after infection with respiratory syncytial virus (658), and after 
traumatic brain injury (659). Direct pharmacologic activators of Nrf2 such as tert-
butylhydroquinone, sulforaphane, and phenethyl isothiocyanate also attenuate NF-κB activation 
in vitro (660-663). Complicating the Nrf2 - NF-κB regulation, a reciprocal effect of NF-κB on Nrf2 
function has been demonstrated (664). The NF-κB p65 subunit has been shown to repress Nrf2 
signaling at the transcriptional level, through competition with Nrf2 for transcription co-activator 
CREB binding protein (CBP) and through recruitment of histone deacetylase 3, resulting in local 
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hypoacetylation of the ARE promoter element and the consequent suppression of Nrf2 signaling 
(664). Thus, the Nrf2 and NF-κB pathways regulate each other through reciprocal inhibition 
(Figure 12.1). Additional studies are needed to further define the complex interactions between 
the NF-κB and Nrf2 pathways believed to be responsible for the effects of DMF and MMF. 
Through a combination of ARE induction and NF-κB signaling inhibition, and as yet undefined 
effects of other pathways, FAEs can promote an anti-inflammatory, anti-infiltrative, and anti-
oxidative cellular state in multiple cell lineages, particularly immune cells. Notably, T-lymphocytes 
and cells of the monocyte lineage appear to be particularly sensitive to FAE exposure. The 
effects of DMF and MMF exposure on individual cell lineages is described in detail below.  
 
Effect of FAE in T-lymphocytes 
 
Early studies of Fumaderm® for psoriasis treatment demonstrated a significant decline (~30%) in 
lymphocytes, particularly T-lymphocytes, in 94% of treated patients (665). Similar results were 
observed in recent Phase III Multiple Sclerosis trials with the DMF formulation BG-12 (240 mg of 
DMF 2-3 times daily) (633, 634). However, the mechanism of DMF-induced lymphocytopenia is 
unknown. In vitro studies have demonstrated that DMF, but not MMF, induces apoptosis in 
human T-lymphocytes after 48 hours of exposure to a concentration of ~70 µM, which is 10-fold 
higher than the MMF serum levels achieved with oral DMF dosing (666). This in vitro apoptotic 
effect of DMF was not seen at ~7uM, the physiologic concentration achieved by its primary in vivo 
metabolite MMF. Because DMF is not detectable in vivo after oral dosing, the contribution of 
direct DMF cytotoxicity to this lymphocytopenia is questionable. Thus further studies of the effects 
of long term exposure of MMF on T-lymphocyte viability and proliferation are needed.  
 
Analyses of the immunomodulatory effects of FAEs on human T-lymphocytes demonstrated that 
FAEs alter cytokine production, cytokine and chemokine receptor expression, and adhesion 
molecule expression. Both DMF and MMF increased the production of multiple Th2 cytokines  
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Figure 12.1 Effects of the fumaric acid esters (FAEs) DMF and MMF on the Nrf2-dependent 
antioxidant response and NF-κB pathways. Flat head on a line instead of an arrow head 
indicates a negative or inhibitory relationship. Abbreviations used: antioxidant response element 
(ARE), CC chemokine ligand (CCL), CXC chemokine ligand (CXCL), cysteine/glutamate 
transporter (xCT), dimethyl fumarate (DMF), ferritin heavy chain 1 (FTH1), γ-glutamate cysteine 
ligase catalytic subunit (GCLC), glutathione (GSH), glutathione peroxidase-1 (GPX1), glutathione 
S-transferase (GST), heme oxygenase-1 (HO-1), intercellular adhesion molecule (ICAM), 
interferon (IFN), interleukin (IL), monomethyl fumarate (MMF), NAD(P)H quinone oxidoreductase-
1 (NQO1), nuclear factor E2-related factor 2 (Nrf2), nuclear factor κB (NF-κB), reactive oxygen 
species (ROS), thioredoxin reductase 1 (TrxR1), tumor necrosis factor (TNF). 
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(IL-4, IL-10) (667-669) in T-lymphocytes. Furthermore, DMF, but not MMF, suppressed Th1 
cytokine (IFN-γ) release and chemokine receptor (CXCR3) expression, as well as the skin-
homing chemokine receptor CCR10 (670). In contrast, DMF exposure decreased release of IL-6 
(670), a cytokine that inhibits Th1 polarization and promotes Th2 differentiation. The suppression 
of Th1 cytokine release and chemokine receptor expression is likely linked to DMF’s ability to 
inhibit NF-κB DNA binding in T-lymphocytes (671), an effect that is not induced by MMF in vitro. 
In line with these findings, DMF inhibited IFN-γ- and LPS-induced Th1 chemokine (CXCL9 and 
CXCL10) production in a dose dependent manner in human peripheral blood mononuclear cells 
(PBMC) (672). Furthermore, DMF was able to increase the expression of Th2 cytokines in 
lymphocytes in multiple sclerosis patients and mice with herpes stromal keratitis (see section V. 
FAEs In Inflammatory Diseases for further discussion), suggesting that DMF treatment maintains 
the Th1 to Th2 shift in the setting of superimposed infections and other inflammatory states. The 
persistence of this Th1 to Th2 shift after DMF therapy is stopped has not been reported.  
 
DMF has also been shown to reduce adhesion molecule expression (CD25, HLA-DR, and 
cutaneous lymphocyte-associated antigen) in treated T-lymphocytes, which can explain the 
decreased binding of treated lymphocytes to E-selectin, P-selectin, and VCAM-1 (673). Such 
effects might also explain reduced leukocyte rolling and adhesion in DMF-treated mice (673). As 
many of these in vitro effects were either not studied or were not observed with MMF treatment, it 
is unknown if they occur in vivo in DMF-treated subjects. Furthermore, the roles for DMF and 
MMF in Nrf2-driven ARE activation in T-lymphocytes, beyond its associated NF- κB modulation, 
have not been studied. Thus, although limited in scope, these in vitro studies suggest that DMF, 
and MMF in part, promote a shift from a pro-inflammatory, IFN-γ-driven Th1 T-lymphocyte profile 
to an anti-inflammatory, IL-10-driven Th2 T-lymphocyte profile. Such a shift from a Th1 response 
(autoimmune responses and the killing intracellular parasites) to a Th2 response associated with 
eosinophilic responses and counteraction against Th1 responses could result in decreased T-
lymphocyte activation and tissue infiltration in vivo. 
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Effect of FAE in B-lymphocytes  
 
Studies of the direct effects of FAE on B-Lymphocyte function have not been reported. However, 
there is evidence that disruption of NF-κB signaling can interfere with B-lymphocyte development 
and survival (639), suggesting FAE-mediated NF-κB modulation may alter B-lymphocyte function.  
 
Effect of FAE in monocytes/macrophages/microglia 
 
DMF and MMF express potent anti-inflammatory and antioxidant effects in monocytes, monocyte-
derived macrophages, and microglia. In human macrophages, DMF and MMF decreased NF-κB 
nuclear translocation and DNA binding in response to TNFα exposure and reduced TNFα 
secretion in response to phytohaemagglutinin, suggesting a decreased state of activation (42). 
Furthermore, DMF and MMF suppressed CCL2-induced chemotaxis of human monocytes (42), 
which would likely result in decreased infiltration across endothelial surfaces into tissue. In LPS-
activated microglia, DMF has been shown to decrease release of the pro-inflammatory cytokines 
IL-1β, IL-6, and TNFα (674), likely through decreased NF-κB signaling. DMF- and MMF-induced 
expression of Nrf2-dependent ARE proteins, including the ubiquitous cytoprotectant enzyme HO-
1, was also reported in macrophages and microglia (42, 675), suggesting that FAEs can 
modulate the oxidative state within these cells. However, DMF- and MMF-treated monocytes 
expressed higher levels of reactive oxygen intermediates in the respiratory burst (676), a rapid 
release of free radicals that is essential step in immunological defense, particularly against 
bacteria and fungi. In contrast, induction of HO-1 can also decrease expression of reactive 
nitrogen species, another principal component of the respiratory burst, through suppression of the 
inducible nitric oxide synthase (iNOS) expression and associated nitric oxide induction (677). 
Overall, these data suggest that DMF and MMF have potent anti-inflammatory and anti-oxidative 
effects in macrophages and microglia and this further suggests that DMF formulations could be 
effective in treating both systemic and CNS inflammatory diseases that involve 
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macrophage/microglial activation.  
 
Effect of FAE in dendritic cells 
 
Both DMF and MMF suppress monocyte-derived dendritic cell differentiation and cytokine 
production in vitro through suppression of both NF-κB and extracellular signal-regulated kinase 1 
and 2 (ERK1/2) signaling (631, 678). In addition, MMF decreased IL-12, IL-10, TNFα, and IFN-γ 
secretion from dendritic cells, which resulted in decreased dendritic cell effectiveness in 
stimulating Th1 cytokine production in T-lymphocytes (679, 680). DMF exposure to dendritic cells 
also decreased inflammatory cytokine production (IL-12, IL-23, and IL-6), dendritic cell 
maturation, and effectiveness in generating activated T-lymphocytes (631). These findings, 
coupled with reports demonstrating that DMF exposure increases the production of IL-10 by 
dendritic cells, suggest that DMF promotes the type II dendritic cell phenotype (681). In summary, 
FAE interference with dendritic cell differentiation and cytokine secretion further suppresses Th1 
responses in addition to the direct effects of FAEs on T-lymphocytes and also promotes a type II 
dendritic cell response.  
 
Effects of FAE in endothelial cells 
 
Similar to DMF effects in T-lymphocytes, macrophages, and dendritic cells, DMF has been shown 
to decrease TNFα-induced NF-κB activation and associated activation of vascular endothelial 
cells (682, 683). DMF also decreased the expression of the adhesion molecules E-selectin, 
VCAM-1, and ICAM-1 on endothelial cells, resulting in decreased leukocyte rolling, firm adhesion, 
and diapedesis in vitro (684, 685), perhaps through inhibition of NF-κB activation. Notably, these 
effects were not seen with MMF, which might indicate that DMF formulations might not induce 
these effects after oral administration. Nonetheless, these results suggest a second mechanism 
(decreased adhesion and transendothelial migration) by which FAEs decrease immune cell 
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migration into tissues, in addition to direct effects on chemotaxis by exposed lymphocytes and 
mononuclear phagocytes, which could further limit tissue inflammation.  
 
Effects of FAE in CNS cells 
 
The effects of FAEs in the CNS could be expressed through modulation of macrophages, 
microglia, endothelial cells, astrocytes, neurons, oligodendrocytes, and choroid plexus cells. 
Among those cell types in which FAE effects have been examined are monocyte-derived 
macrophages, microglia, endothelial cells (previously discussed), astrocytes, neurons, and 
oligodendrocytes. No studies of DMF or MMF effects in choroid plexus-derived cells have been 
published. DMF has been shown to decrease IL-1β, IL-6, and TNFα release from astrocytes and 
microglia (674, 686), which could contribute to an anti-inflammatory effect in the CNS 
compartment. Furthermore, DMF and MMF, through Nrf2 activation, induced the expression of 
ARE effector proteins, including NAD(P)H quinone oxidoreductase-1 and HO-1, in microglia, 
astrocytes, and neurons (674, 687, 688). Such induction of antioxidant enzymes in astrocytes and 
neurons was shown to protect against oxidative injury and glutamate toxicity (687-689). Despite 
this protection in astrocytes and neurons, DMF and MMF did not protect against oxidative injury 
in the oligodendrocyte CG4 cell line (690). These studies and those mentioned above suggest a 
role for FAEs as both indirect neuroprotectants through anti-inflammatory and anti-oxidative 
effects in macrophages, microglia, astrocytes, and endothelial cells, and as direct 
neuroprotectants through induction of the ARE in neurons. 
 
12.5 FAEs in Inflammatory Disease  
 
Psoriasis 
 
Psoriasis is a common (1-3% of the worldwide population), systemic T-lymphocyte-mediated 
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chronic inflammatory skin disease characterized by cutaneous inflammation, increased epidermal 
proliferation, abnormal keratinization, and appearance of erythematous plaques (reviewed in 
(691)). Psoriasis is the disease for which FAEs have been most widely applied for therapeutic 
benefit. The efficacy of FAEs likely results from their potent anti-inflammatory and antioxidant 
effects.  
 
Inflammation in psoriasis: Early reports demonstrated persistent Th1 T-lymphocyte activation 
within psoriatic plaques (692-694), although natural killer T-lymphocytes were also implicated 
(695-697). Recent work has shown a significantly complicated picture of the inflammatory milieu 
in psoriasis plaques. Current models now incorporate an inflammatory axis that balances the Th1, 
Th2, Th17, and T-regulatory type responses as well as contributions by dendritic cells, natural 
killer T-lymphocytes, and macrophages (reviewed in (698)). Underscoring this central role of 
inflammation in the pathogenesis of psoriasis, numerous immunomodulatory therapies have 
shown efficacy in treating psoriasis, including corticosteroids (699), tacrolimus (700), 
pimecrolimus (701), methotrexate (702), and the TNFα inhibiting therapies etanercept (703), 
infliximab (704), and adalimumab (705). 
 
Oxidative stress in psoriasis: In addition to markers of immune activation, markers of oxidative 
stress are consistently elevated in psoriasis patients and coupled with antioxidant dysfunction. 
These patients have increased carbonylation (oxidative stress marker) of macromolecules in skin 
biopsies and cultured fibroblasts (706), increased plasma malondialdehyde (lipid peroxidation 
product) (707), increased urine 8-hydroxydeoxyguanosine (a marker of DNA oxidation) and 
nitrate (a product of nitric oxide) (708) ,increased lipid hydroperoxides (709), and lower serum 
antioxidants, including paraoxonase-1 and thiols (707, 709, 710). Furthermore, the 55 L/M allele 
of paraoxonase-1 (an antioxidant enzyme implicated in psoriasis that hydrolyses lipid 
peroxidases) is a risk factor for psoriasis and allele carriers have higher levels of oxidative stress 
and lower ARE activity (711). In summary, psoriasis is a chronic inflammatory skin diseases 
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involving numerous immune axes, particularly various arms of the T-lymphocyte axis, and 
elevated oxidative stress and impaired antioxidant responses.  
 
Clinical trials of FAEs in psoriasis: Before the roles for immune activation and oxidative stress in 
psoriasis were identified, the German chemist Walter Schweckendiek empirically developed an 
FAE therapy for psoriasis (632). Although unknown at that time, the anti-inflammatory effects 
through suppression of NF-κB activity and oxidative stress reducing effects through induction of 
the ARE suggest a role for FAEs in treating psoriasis. The first randomized, double-blind trial of 
FAE therapy for psoriasis was published by Nugteren-Huying et al. in 1990 (712). This trial 
demonstrated an average reduction in the psoriatic skin lesion area by 68% in 39 psoriasis 
patients treated with a combination of DMF and MEF for 4 months, an effect significantly different 
from the groups treated with an MEF/octylhydrogen-fumarate combination or with a placebo. 
Since that initial trial, other larger and longer-term clinical trials (up to 3 years) have affirmed the 
effectiveness and safety of FAE therapy for patients with severe psoriasis (713-719). Combining 
DMF with other FAEs including MEF (Fumaderm®) showed greater efficacy and patient 
adherence to FAE therapy than DMF monotherapy (713, 715). The mechanism for this 
synergistic effect is unknown, but likely could be due to competitive metabolism.  
 
FAE effects on keratinocytes: role in psoriasis: The mechanisms of action of FAE therapy in 
effectively treating psoriasis likely represent both direct effects on keratinocytes and the 
aforementioned immunomodulatory and anti-oxidative properties of DMF and MMF on other cell 
types. Keratinocytes play a major role in the inflammatory response in psoriasis through 
expression of chemokines and cytokines (reviewed in (720)). DMF treatment in co-cultured 
keratinocytes and T-lymphocytes increased the Th2 cytokine IL-10, while decreasing IFN-γ, IL-6, 
and TGFα (668). Furthermore, DMF inhibited the expression of the chemokines CXCL1, CXCL8, 
CXCL9, CXCL10, and CXCL11 in primary human keratinocytes (672). These immunomodulatory 
effects on keratinocytes have not been tested with MMF. However, DMF and to a lesser extent 
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MMF have been shown to decrease keratinocyte proliferation (721, 722). In clinical studies, DMF 
treatment of psoriasis in patients resulted in improved epidermal hyperproliferation, epidermal 
thickness, and keratinocyte differentiation (718). Overall, these direct effects on keratinocytes 
suggest multiple mechanisms that modulate chemoattraction of macrophages, T-lymphocytes, 
and neutrophilic granulocytes and pathologic proliferation of keratinocytes.  
 
FAEs reduce immune cell infiltration in psoriasis and other skin disorders: Psoriasis involves 
infiltration of the dermis by CD4+ T-lymphocytes and the epidermis by CD8+ T-lymphocytes, the 
majority of which are CD45RO+ (memory effector) (723-726). Clinical studies have demonstrated 
that DMF treatment of psoriasis patients for sixteen weeks decreases CD3+CD4+CD45RO+ T-
lymphocytes in the dermis and CD3+ CD8+ CD45RO+ T-lymphocytes in the epidermis (718). 
This FAE effect of decreased immune cell infiltration is supported by the demonstrations of FAE 
efficacy in decreasing immune cell infiltration in other inflammatory skin diseases. These include 
disseminated granuloma annulare (727, 728) and recalcitrant cutaneous sarcoidosis (729), each 
of which involves large number of CD3+ lymphocytes and CD3+/CD68+ mononuclear 
phagocytes, each of which is suspected to result from unregulated Th1 reaction. These in vivo 
findings are consistent with in vitro studies of DMF that demonstrate decreased expression of 
adhesion molecules in endothelial cells (684, 685) and lymphocytes (673) and decreased CCL2-
induced chemotaxis in macrophages (42), resulting in decreased immune cell tissue infiltration 
into tissues. Of note, DMF also decreased T-lymphocyte expression of the chemokine CCR10 
(670), which is often expressed on skin-homing T-lymphocytes. In addition to decreased 
chemotaxis and homing in DMF-exposed macrophage and T-lymphocytes, induction of 
leukocytopenia and lymphocytopenia by DMF might also contribute to DMF efficacy in treating 
psoriasis (633, 634, 717, 730, 731).  
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Multiple sclerosis 
 
Multiple sclerosis is the most common cause of neurological disability in young adults worldwide 
with approximately 2.1 million cases worldwide and 400,000 cases in the United States (322, 732, 
733). Epidemiologic data suggest that multiple sclerosis pathogenesis involves environmental 
influences occurring on a background of genetic susceptibility (734). In most patients, multiple 
sclerosis presents as a relapsing-remitting disease characterized by dynamic inflammatory 
demyelinating lesions in the CNS that are associated with sensory (~30%) or motor (~13%) 
disturbance of the limbs, partial or complete visual loss (~16%) and other signs and symptoms 
(reviewed in (735)). Multiple sclerosis is the first CNS disease successfully treated with FAEs. 
The efficacy of FAEs in multiple sclerosis likely results from their potent anti-inflammatory and 
antioxidant effects within the CNS compartment. 
 
Inflammation and degeneration in multiple sclerosis: Traditionally multiple sclerosis was 
considered to be an autoimmune, inflammatory disease of the CNS mediated by an aberrant T-
lymphocyte attack against CNS elements, particularly myelin, resulting in degeneration of axons 
(736). This view was strongly supported by pathological, laboratory, radiological, genetic, 
epidemiological, and therapeutic data, all of which supported an autoimmune and inflammatory 
phenotype that is driven by Th1 type inflammation in the brain (reviewed in (736)). However, 
recently published studies have posited that multiple sclerosis is primarily a degenerative 
disorder, with a secondary immune response to myelin and other highly immunogenic debris 
(reviewed in (737)). Evidence for this includes reports demonstrating that myelin abnormalities 
might begin at the inner myelin sheath in areas outside focal inflammation (738, 739); patients in 
early stages of multiple sclerosis show little evidence of T-lymphocyte or B-lymphocyte infiltration 
in newly formed demyelinating lesions (although evidence of the innate immune response by 
macrophage infiltration and microglial activation is present, probably for clearing debris) (740, 
741); and the ineffectiveness of autologous hematopoietic stem-cell transplantation to halt the 
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progression of demyelination, axonal degeneration, and brain atrophy despite reducing CNS 
inflammatory activity (742, 743). Regardless of the initial pathologic substrate, the inflammatory 
response present in relapsing-remitting multiple sclerosis plays a critical role in disease 
pathogenesis as evidenced by the success of numerous immune modulators, including interferon 
beta-1b (720) and beta-1a (744, 745), glatiramer acetate (746, 747), fingolimod (699, 748), and 
teriflunomide (749) among many others, in reducing and in some instances eliminating 
neuroinflammation and clinical relapses.  
 
Clinical trials of FAEs for multiple sclerosis treatment: BG-12, an oral FAE formulation containing 
DMF, recently showed strong positive effects in two independent placebo-controlled phase III 
clinical trials (DEFINE and CONFIRM) involving more than 2600 relapsing-remitting multiple 
sclerosis patients (633, 634). Importantly, BG-12 improved clinical outcomes associated with 
suppression of brain inflammation in such patients when given twice daily or three times daily, 
likely due in part to the CNS penetrance of MMF (688). BG-12 therapy in both trials significantly 
reduced the proportion of patients who relapsed and the annualized relapse rate at 2 years by 
~50%. Furthermore, BG-12 reduced the number of gadolinium-enhancing lesions (inflammation) 
and of new or enlarging T2-weighted hyperintense lesions (demyelination). In the DEFINE trial 
(633), BG-12 significantly reduced progression of disability by 38% with BG-12 twice daily and 
34% with BG-12 thrice daily. In the CONFIRM trial (634), BG-12 also reduced progression of 
disability, but the trend was not significant. Given the positive results of these clinical trials BG-12 
was approved for the treatment of multiple sclerosis by the FDA on March 27th, 2013 under the 
brand name Tecfidera™. These results show that the oral DMF formulation (BG-12/ Tecfidera™) 
is effective in modifying CNS inflammation and associated neurological dysfunction in treated 
patients and they suggest that DMF formulations should be considered for use in other 
neuroinflammatory diseases.  
 
FAE immune modulation in multiple sclerosis: The balance between Th2 and Th1 responses 
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plays a key role in multiple sclerosis pathogenesis. Multiple sclerosis lesions contain activated 
CD4+ and CD8+ T-lymphocytes, mononuclear phagocytes, and high expression of IFN-γ, TNFα, 
IL-1, and leukocyte and vascular adhesion molecules(750-752). A shift from a Th1 towards a Th2 
cytokine profile, as induced by FAEs in T-lymphocytes and PBMCs in vitro (667-670, 672), could 
have a beneficial effect on the clinical course of the disease. This is supported by a recent study 
that showed that BG-12-treated multiple sclerosis patients showed increased intracellular 
expression of the Th2 cytokine IL-10 in CD4+ peripheral lymphocytes, with no change in IFN-γ 
expression (753). It has also been proposed that the mild leukocytopenia and lymphocytopenia 
observed in BG-12 treated individuals could contribute to BG-12 efficacy by reducing the number 
of circulating immune cells (754). A possible complimentary mechanism for the efficacy of BG-12 
in multiple sclerosis is the decreased expression of adhesion molecules on endothelial cells (684, 
685) and lymphocytes (673) and decreased CCL2-induced chemotaxis in macrophages (42), 
resulting in decreased immune cell tissue infiltration into the brain. Each of these mechanisms is 
supported by studies of autoimmune encephalomyelitis (EAE), the murine model of multiple 
sclerosis. During chronic EAE, MMF significantly and DMF nonsignificantly reduced the infiltration 
of T-lymphocytes in the spinal cord. Additionally, MMF, and to a lesser degree DMF, significantly 
reduced the infiltration of macrophages into the spinal cord (755). Thus, although the major 
beneficial effects of BG-12/Tecfidera™ in treating multiple sclerosis are likely associated primarily 
with the ability to reduce CNS inflammation, the reduction of levels of circulating T lymphocytes 
and reduction of T-lymphocyte and monocyte/macrophage chemotaxis might also contribute to 
the beneficial effects in multiple sclerosis.  
 
FAE antioxidant response induction in multiple sclerosis: The emerging and prominent role for 
oxidative stress in multiple sclerosis pathogenesis and the well studied protective effects of the 
ARE activation in cell of different lineages in the CNS highlight another probable mechanism of 
FAE efficacy in multiple sclerosis. Oxidative stress associated with mitochondrial dysfunction 
(756) and excessive release of free radicals(757) has been strongly associated with multiple 
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sclerosis pathogenesis, perhaps contributing to increased CNS leukocyte invasion and activation, 
neurodegeneration, and oligodendrocyte damage. Free radicals include reactive oxygen species, 
reactive nitrogen species, and nitric oxide, which are mainly produced by macrophages and 
microglia (758, 759). In addition, myeloperoxidase activity, which produces the cytotoxic oxidizer 
hypochlorous acid and tyrosyl radicals catalyzed from H2O2, is elevated in macrophages and 
microglia in actively demyelinating white matter and cortical lesions in multiple sclerosis (760). 
These data suggest that a reduction in oxidative stress might reduce neuroinflammation and 
associated CNS damage, each of which could be suppressed by BG-12.  
 
BG-12 is the first multiple sclerosis therapy shown to activate the Nrf2-dependent ARE pathway 
and thus reduce oxidative stress. Previous studies have shown that FAE induction of the ARE 
and its effector proteins, including HO-1, prevented oxidative-stress induced astrocyte and 
neuronal injury (687, 688, 761), decreased microglia nitric oxide burst (690), and prevented 
myelin loss within the CNS (688). In EAE studies, DMF treatment attenuated axonal loss and 
reduced astrocyte activation in wild-type mice, but not in Nrf2-/- knockout mice (688), strongly 
suggesting a role for Nrf2-dependent ARE activation in FAE-mediated neuroprotection. This 
finding is supported by in vitro data that demonstrated that Nrf2 knockdown removed the dose-
dependent protective effect of DMF and MMF on astrocyte and neuron cell viability after toxic 
oxidative challenge (687). High concentrations (100 µM) of DMF and MMF have been shown to 
induce the ARE protein HO-1 in oligodendrocytes without evidence of drug cytotoxicity (11). 
However, whether FAEs are directly protective against oxidative injury or other insults in 
oligodendrocytes has not been reported. Despite this strong evidence linking ARE induction to 
protection during CNS oxidative and inflammatory injury in multiple sclerosis, the specific 
antioxidant pathways and effector proteins responsible for these protective effects are not known.  
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Other inflammatory diseases as targets for FAEs 
 
Huntington’s disease: FAEs have been studied preclinically in other diseases linked to 
inflammation and oxidative stress. Huntington’s Disease (HD) is an autosomal dominant, 
progressive neurodegenerative genetic disorder, associated with an expanded trinucleotide 
(CAG)n repeat encoding a polyglutamine stretch in the N-terminus of the huntingtin protein (762). 
Oxidative stress, mitochondrial dysfunction, and other metabolic deficits have been shown to play 
central roles in the pathogenesis of HD (763). Furthermore, symptomatic CNS disease staging in 
HD model mice was associated with increased levels of brain oxygen radicals (764). Treatment of 
these HD model mice with DMF prolonged survival and preserved motor functions and neuronal 
morphology within the striatum and motor cortex,6 likely through the induction of the ARE. These 
findings implicate a central role for oxidative stress in HD pathology and have led to multiple 
clinical trials studying the efficacy of various antioxidants and modulators of the Nrf-2/ARE 
pathway (765), though FAEs have not yet been studied clinically in HD. The efficacy of FAEs in 
this model and in multiple sclerosis suggests a broader applicability to CNS disease states with 
oxidative stress components, regardless of cause.  
 
Herpes stromal keratitis: Herpes Stromal Keratitis (HSK), the leading cause of infectious 
blindness in developed nations (766), is a disease characterized by an immune-based 
pathological reaction that is triggered by herpes simplex virus (HSV) infection of the cornea. In 
HSK, CD4+ Th1 T-lymphocytes are believed to be the principal disease mediators, as the Th1 
cytokines IFN-γ and IL-2 were highly expressed in the HSK cornea (767) and anti-IFN-γ and anti-
IL-2 treatment decreased the incidence and severity of herpetic corneal disease (768, 769). 
Neutrophils and antigen-presenting cells may also play central roles in HSK pathogenesis (770, 
771). In mice exposed to HSV after a corneal scratch, DMF therapy reduced corneal infiltration of 
lymphocytes, polymorphonuclear leukocytes (PMNs), and macrophages and decreased the 
severity and incidence of stromal keratitis (772, 773). Additional studies of these mice 
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demonstrated that DMF treatment increased the expression of Th2 cytokines IL-4 and IL-10 in 
lymphocytes cultured from the spleen, although no changes were seen in expression of the Th1 
cytokines IFN-γ and IL-2 (773). Thus, while Th1 cytokines are associated with HSK progression, 
Th2 cytokines are consistently associated with improvement (773-775). Even though DMF 
treatment improved outcomes in these HSK mouse studies, DMF had no effect on viral titers, 
HSV antibody production, or HSV antigen-specific T cell proliferation (773). These data 
demonstrate that FAEs have therapeutic efficacy in treating virally-induced inflammation and 
immune cell infiltration, and that these effects likely result from direct modulation of the immune 
response rather than interference with virus replication.  
 
12.6 FAEs as Candidate Adjunctive Therapy for Systemic HIV Disease   
 
The FAEs, and specifically the oral DMF preparations (BG-12/Tecfidera™, Fumaderm®), are 
attractive candidates as adjunctive agents for suppressing chronic immune activation, oxidative 
stress, and associated HIV disease progression and comorbidities in antiretroviral therapy (ART)-
treated individuals (reviewed in Figure 12.2). To date, no in vivo or clinical studies have examined 
the efficacy of FAE therapy in HIV infection, however the dual anti-inflammatory and anti-
oxidative mechanisms of FAEs suggest potential potent systemic efficacy. FAEs have been 
studied in in vitro models of HIV macrophage-mediated neurotoxicity where they have shown 
promising results. The CNS penetrance of MMF and the demonstrable suppression of CNS 
inflammation in BG-12-treated multiple sclerosis patients are especially appealing for targeting 
persistent CNS inflammation and oxidative stress in such individuals (see section 12.7 HIV CNS 
Disease).  
 
FAEs as suppressers of systemic immune activation in HIV/AIDS  
 
Through inhibition of the NF-κB signaling, which regulates cytokine and chemokine signaling, oral 
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DMF therapy might provide an additional suppressive effect on the chronic immune activation in 
ART-treated patients. This prediction is supported by the efficacy of oral DMF-formulations (BG-
12/Tecfidera™ and Fumaderm®) in limiting inflammation and immune cell infiltration in multiple 
sclerosis and psoriasis (633, 634, 717, 723-726, 730, 731, 753). Suppression of chronic immune 
activation will likely improve long-term survival, lower risk of associated end-organ diseases, and 
improve quality of life in HIV-infected ART-treated individuals (111, 116). The glucocorticoid 
prednisolone, a potent immunosuppressant, lowered systemic immune activation in both 
untreated and ART-treated patients (776) and postponed CD4+ T-lymphocyte count decreases 
for a median of two years in untreated HIV-infected patients (777, 778). Prednisone, the 
precursor to prednisolone, inhibited monocyte TNFα production without affecting T-lymphocyte 
antigenic responses (779). However, the profound side effects of glucocorticoid therapy make its 
long-term use unattractive as adjunctive therapy. In a small retrospective study, addition of the 
immunosuppressant cyclosporine to ART therapy during primary HIV-1 infection restored CD4+ 
T-lymphocytes to normal levels (both percentage and absolute numbers) and adjunctively treated 
patients maintained higher CD4+ T-lymphocyte levels than those in patients taking ART alone 
(780). In this study, cyclosporine adjunctive therapy did not significantly affect virus-specific CD8+ 
or CD4+ T-lymphocyte responses or viral load (780). However, another study of the effects of 
cyclosporine treatment during acute and early HIV-infection in 48 subjects demonstrated no 
significant improvement in CD4+ T-lymphocyte counts or other markers of disease progression 
(781). Notably, cyclosporine has shown limited efficacy in multiple sclerosis (782-785), in direct 
contrast to the strong and consistent efficacy reported for the immune modulator BG-
12/Tecfidera™ (633, 634), suggesting DMF therapy may similarly prove more effective in HIV-
infection. The central role of chronic immune activation in disease progression in ART-treated 
individuals coupled with these promising findings demonstrating a delayed disease progression 
with suppression of immune activation strongly supports further exploration of immunomodulatory 
therapy for the treatment of HIV infection. The anti-inflammatory effects of DMF in cell lineages 
relevant to HIV-infection coupled with its effectiveness in the chronic inflammatory diseases 
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multiple sclerosis and psoriasis, makes it a promising adjunctive therapy for improving morbidity 
and mortality in ART-treated HIV-infected individuals.  
 
FAEs as possible protectors of the intestinal mucosal barrier in HIV/AIDS 
 
Chronic immune inflammation is believed to occur primarily as a result of microbial translocation 
across the damaged gastrointestinal tract (111), as described above. Beyond direct anti-
inflammatory effects on immune cells, FAE therapy might ameliorate chronic immune activation 
through decreasing microbial translocation by several effects: i) reversing or halting the depletion 
of mucosal CD4+ T-lymphocytes, ii) limiting mucosal immune activation and inflammation, and iii) 
preventing structural damage to the intestinal epithelium. Through inhibition of NF-κB activity in 
mucosal lymphocytes and other mucosal immune cells, FAEs could dampen mucosal immune 
cell activation thereby limiting mucosal inflammation. This decreased inflammation could reduce 
immune activation-induced T-lymphocyte apoptosis (786). Recent in vitro and in vivo mouse 
studies suggest that inducers of the Nrf2-dependent ARE can protect intestinal mucosa from 
inflammation-associated oxidative stress and injury and reduce the associated invasion of 
anaerobic bacteria into the mucosa (663, 787-791). Therefore, oral DMF through induction of the 
ARE might limit microbial translocation across the intestinal mucosa and through NF-κB inhibition 
promote gut immunity, thereby preventing the primary cause of chronic systemic inflammation in 
HIV-infected individuals.  
 
FAEs as suppressors of systemic HIV replication 
 
The ability of DMF and MMF to modulate NF-κB signaling and cellular pathways of cytokine 
production, particularly of TNFα, suggests the possibility of associated effects on replication of 
HIV in immune cells. Increased nuclear translocation of NF-κB, through immune activation 
including TNFα stimulation (158, 792, 793), drives HIV gene expression from the HIV long 
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terminal repeat (LTR) (794, 795). Therefore, FAE-driven inhibition of NF-κB nuclear translocation 
and DNA binding might further limit HIV-replication in vivo. Potent inhibition of HIV replication by 
DMF and MMF pre-treatment in primary human monocyte-derived macrophages has been 
demonstrated in vitro (42). The effect of FAEs on HIV replication in T-lymphocytes, the primary 
targets of HIV infection, has not been reported. In addition, modification of the oxidative state of 
immune cells such as increasing glutathione has been shown to interfere with HIV particle 
assembly, infectivity, and release (159, 796), which suggests another possible inhibitory effect of 
FAEs on the HIV life cycle.  
 
FAEs as Suppressors of Oxidative Stress in HIV/AIDS: In addition to markers of immune 
activation, markers of oxidative stress are consistently elevated and associated with disease 
progression in HIV-infected patients. This role of oxidative stress and glutathione depletion in HIV 
systemic disease pathogenesis and mortality served as the rationale for treatment of HIV-infected 
patients with various direct antioxidants, including N-acetylcysteine (169, 797-800) and selenium 
(801-803). The largest selenium clinical trial was a randomized controlled trial of 262 HIV-infected 
patients (192 receiving ART) that reported that nine-months of selenium supplementation resulted 
in a significant increase in CD4+ T-lymphocyte count and a decrease in viral load (803). Similar 
effects on increasing CD4+ T-lymphocyte counts and decreased viral loads were seen in two of 
the N-acetylcysteine studies (799, 800). These trials suggest that antioxidant therapies have the 
potential to modulate HIV disease progression. However, numerous studies suggest that N- 
acetylcysteine (804-806), selenium (807), and other direct antioxidants (808-810) actually 
suppress the endogenous Nrf2-driven ARE (a pro-oxidative effect), likely due to their direct 
suppression of oxidative stress, which serves as the main inducer of the Nrf2 translocation and 
subsequent ARE induction. Furthermore complicating their clinical usefulness, direct antioxidants 
are expended to elicit their antioxidant effects and thus are often short-lived and need to be 
replenished frequently (811). Therapies that induce sustained activation of the endogenous ARE 
might provide greater protection against oxidative stress than direct antioxidants due to sustained 
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increased expression of multiple antioxidant effector proteins.  
 
The monoamine oxidase B inhibitor selegiline, which had been shown decrease oxygen free 
radicals and enhance the expression of antioxidant enzymes superoxide dismutase and catalase 
(812-814), has been used to attempt to increase dopaminergic neurotransmission and reduce 
neuronal injury caused by oxidative stress in Parkinson’s and Alzheimer’s Disease (815, 816). In 
addition, selegiline has been shown to activate the Nrf2 pathway in neuronal cell lines (817). 
Despite the success of selegiline in other neurocognitive diseases and the evidence that 
selegiline may induce the ARE and limit oxidative stress, a 24-week clinical trial of transdermal 
selegiline therapy (two doses) with a 24-week open-label extension in HIV-infected patients failed 
to show neurocognitive improvement or positive changes in brain or CSF biomarkers of oxidative 
stress (818-820). The reasons for the failure of selegiline therapy to achieve positive outcomes in 
this trial are unclear. The 24-week treatment duration was relatively brief and each treatment arm, 
including placebo, showed no neurocognitive deterioration over 24 weeks of open-label follow-up. 
Some investigators have suggested that augmenting dopaminergic signaling could enhance HIV 
infection of macrophages and promote neuropathological disease progression in simian 
immunodeficiency virus (SIV)-infected macaques (341, 342).  
 
Despite the clinical trial failure of transdermal selegiline, compelling evidence supports oxidative 
stress as a major driving force in HIV neuropathogenesis. Furthermore, the partial clinical efficacy 
of direct antioxidants (N-acetylcysteine, Selenium) strongly supports further study of ARE-
inducing therapies such as DMF for disease suppression in HIV infected individuals.  
 
Potential of FAEs in treating systemic HIV-associated comorbidities 
 
Despite use of ART therapy, HIV-infected individuals have an increased risk of progressive 
dysfunction of major organs. Such HIV disease progression can involve the central nervous 
211 
  
system (brain/cognition, see section VI.B HIV CNS Disease; spinal cord/myelopathy), peripheral 
nerves (neuropathy), heart (atherosclerosis, heart failure), liver (cirrhosis, hepatocellular 
carcinoma), kidney (nephropathy, glomerulonephritis/sclerosis, tubulointerstitial nephritis), and 
bone (osteopenia, osteoporosis) (reviewed in (105, 821, 822)). In these comorbidities, 
inflammation and possibly the associated oxidative stress are thought to play a significant role.  
 
Cardiovascular disease: HIV-infected patients have increased risk of atherosclerosis, myocardial 
infarction, heart failure, and other vascular diseases (823, 824). Increased serum levels of several 
markers of inflammation strongly predict cardiovascular disease and mortality (825-827). 
Although HIV-infected ART-treated individuals are at lower risk for cardiovascular disease than 
HIV-infected individuals not receiving ART, they are nonetheless at higher risk than the general 
population. Risk factors for cardiovascular disease in ART-treated individuals include low-level 
virus replication, chronic immune activation associated microbial translocation, monocyte 
activation, and oxidative stress (reviewed in (828)), each of which is a potential target of DMF 
therapy. Atherosclerosis in particular is driven by persistent inflammation, macrophage and T-
lymphocyte infiltration, endothelial cell activation, and oxidative stress (829, 830). Furthermore, 
studies of transgenic mice expressing HIV Tat, gp120, and Nef suggest that expression of these 
HIV-1 proteins, independent of viral infection, can induce cardiac damage through oxidative 
stress (154). Such damage is associated with elevated cystine/cysteine ratios and altered 
glutathione metabolism in cardiac muscle (154). Similarly, cardiac tissue from Tat-expressing 
transgenic mice showed decreased glutathione levels, mitochondrial damage, and 
cardiomyopathy (831). Thus, the ability of DMF and MMF to decrease inflammation, immune cell 
activation and invasion, endothelial cell activation, and injury due to oxidative stress suggest that 
DMF formulations could decrease the elevated risk of cardiovascular events in ART-treated 
individuals.  
 
Bone disease: Osteopenia and Osteoporosis: A recent meta-analysis showed that the prevalence 
212 
  
of osteopenia and osteoporosis in HIV-infected individuals was more than three times higher than 
that in uninfected controls (832). This could reflect effects of chronic inflammation and associated 
increased bone resorption (833) as well as HIV-driven (and potentially ART-driven) increases in 
osteoclast activity (834). DMF therapy, through limiting systemic inflammation and viral 
replication, could potentially reduce these pro-osteoclast signals. One such signal, NF-κB activity, 
regulates osteoclast differentiation and the inflammatory cytokine TNFα that induces bone loss 
through stimulation of osteoclasts (835-837). Therefore, DMF therapy through inhibition of NF-κB 
and TNFα release from immune cells could have further efficacy in decreasing osteoclast activity.  
 
Hepatic and renal disease: HIV-infected individuals also have increased risk of both kidney (838-
840) and liver (840-842) disease associated with viral replication, low peripheral CD4+ T-
lymphocyte count, and the use of certain antiretroviral drugs (843-848). Given these correlations 
among renal and liver disease, viral replication (despite ART), and T-lymphocyte counts, DMF 
therapy could potentially ameliorate HIV-associated liver and kidney disease. 
 
In summary, DMF therapy in HIV-infected patients could reduce disease progression by limiting 
systemic immune activation and associated oxidative stress. Through induction of the Nrf2/ARE 
and inhibition of NF-κB, DMF therapy could systemically: i) reduce immune cell activation and 
cytokine release, ii) prevent leukocyte tissue infiltration; and iii) inhibit HIV infection and 
replication. Each of these effects has been demonstrated in published studies examining DMF. In 
addition, suggested possible effects of DMF therapy include the following: i) limiting intestinal 
mucosal barrier damage and associated microbial translocation, ii) reducing HIV-associated 
organ comorbidities, and iii) limiting oxidative stress (reviewed in Figure 12.2). Thus, there is 
much promise for the use of oral DMF formulations as adjunctive therapy for systemic disease 
progression and comorbidities in ART-treated HIV-infected individuals. 
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Figure 12.2 Potential effects of dimethyl fumarate (DMF) therapy on systemic and CNS HIV 
disease pathogenesis. Oral DMF, primarily through its active in vivo metabolite monomethyl 
fumarate (MMF), might have potent anti-inflammatory and anti-oxidative effects (marked by 
numbers 1–13 in figure) in HIV-infected cART-treated individuals thereby limiting both systemic 
and CNS chronic immune activation and oxidative stress. This could result in decreased HIV 
disease progression and associated comorbidities. Abbreviations used: monomethyl fumarate 
(MMF), dimethyl fumarate (DMF), blood-brain barrier (BBB), macrophage/microglia (M/M). 
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12.7 FAEs as Candidate Adjunctive Therapy for CNS HIV Disease  
 
As discussed, the oral DMF formulation BG-12/Tecfidera™ decreased relapse rates and 
associated neuroinflammation in patients with multiple sclerosis in two independent Phase III 
clinical treatment trials (633, 634). These studies clearly demonstrate efficacy of oral DMF-
treatment in the CNS and its efficacy against neuroinflammation and oxidative stress may provide 
important adjunctive therapy for HIV-infected patients to prevent and treat HAND.  
 
FAEs as inhibitors of HIV viral infection in monocytes and macrophages 
 
Pretreatment with DMF and MMF decreased HIV infection and TNFα secretion in HIV monocyte-
derived macrophages (HIV-MDM), likely due in part to inhibition of NF-κB nuclear translocation 
and DNA binding (42). It is well established that TNFα exposure increases HIV replication 
through increased nuclear translocation of NF-κB (792, 793), which drives HIV gene expression 
from the HIV long terminal repeat (LTR) (794, 795). However, in addition to decreasing autocrine 
effects of TNFα secretion, there are other possible NF-κB modulating effects of DMF and MMF 
associated with oxidative stress in HIV-MDM. Oxidative stress has been shown to drive HIV 
replication (158-160), likely through NF-κB activation (653-656), and Nrf2 nuclear translocation 
and activation of the ARE have been shown to suppress NF-κB (described above). 
 
DMF and MMF induce activation of the ARE and suppress HIV infection at concentrations that 
are consistent with CSF MMF concentrations in vivo (4.4 µM ) (688). However, inhibition of NF-κB 
may require higher DMF and MMF concentrations (>15 µM) (42), which suggests other ARE-
mediated, NF-κB-independent effects of DMF and MMF on HIV infection. These effects could 
include suppression of HIV entry into monocytes and macrophages and disruption of virion 
assembly and release from infected cells. It has been reported that antioxidants can decrease the 
stability of CXCR4 and CCR5 mRNA transcripts in human monocytes (849). Because CCR5 and 
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CXCR4 are the major cellular co-receptors for HIV, such antioxidant effects of DMF and MMF 
could limit HIV entry into monocytes and macrophages. Furthermore high intracellular glutathione 
levels in macrophages were associated with defective HIV particle assembly and decreased 
virion infectivity and release (159). Thus, DMF and MMF activation of the ARE may limit HIV 
infection of monocytes and macrophages at several steps in the HIV life cycle (entry, replication, 
and particle assembly).  
 
FAEs as inhibitors of macrophage neurotoxin release 
  
One consequence of HIV infection and/or immune activation of macrophages and associated 
inflammation is the production and release of soluble neurotoxins. Beyond promoting HIV-
replication, elevated TNFα levels associated with immune activation increase monocyte entry into 
the brain and drive associated inflammatory cascades; one consequence is the production and 
release of soluble neurotoxins from macrophages, microglia, and astrocytes (850). Activation of 
the ARE pathway decreases macrophage and microglia activation (42, 851-854), probably 
through ARE-mediated inhibition of NF-κB signaling. Work from our laboratory demonstrated that 
DMF and MMF treatment reduces neurotoxin release from HIV-MDM and associated neuronal 
death in an HIV neurotoxicity model system, independent from viral replication (42, 43). We 
further demonstrated that the decrease in HIV-MDM neurotoxin release was partly dependent on 
the ability of DMF and MMF to induce the expression of the Nrf2/ARE effector and cytoprotective 
protein heme-oxygenase-1 (HO-1) (42). HO-1 is the inducible, rate-limiting enzyme that degrades 
pro-oxidative and cytotoxic heme to bilirubin and carbon monoxide, each of which has well-
documented antioxidant and anti-inflammatory effects (42, 418, 855-857). We showed that HIV-
infection of MDM in vitro drastically decreases HO-1 protein expression and that induction of HO-
1 in HIV-MDM lowered neurotoxin production independent of viral replication ; in contrast, 
inhibition of HO-1 enzymatic activity in HIV-MDM increased neurotoxin production (42) (42, 43). 
These data strongly suggest that HO-1 suppression in HIV-MDM plays a pivotal role in 
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macrophage-mediated neurotoxin production during HIV infection and that rescuing this 
suppression with DMF or MMF might suppress neurodegeneration in HAND.  
 
FAEs as modulators of immune cell CNS infiltration and blood brain barrier integrity 
 
In addition to suppression of MDM activation and neurotoxin production, DMF and MMF reduced 
monocyte chemotaxis driven by CCL2 (42), thus potentially limiting transendothelial migration of 
monocytes into the CNS during HIV infection. Less monocyte trafficking into the CNS could limit 
HIV and inflammatory cell entry into the brain and subsequent neuroinflammation. 
Complementing this effect, DMF can decrease endothelial cell adhesion molecule (ICAM-1, 
VCAM-1, and E-selectin) expression, thereby decreasing leukocyte rolling and diapedesis (684, 
685). This could potentially further limit immune cell trafficking into the CNS and its complications 
in HAND. HIV infection also impairs blood brain barrier (BBB) permeability, possibly through 
actions of released viral proteins, induction of oxidative stress, or induction of systemic 
inflammation (reviewed in (858)). Each of these can disrupt the structural integrity of the BBB in 
part through breakdown of tight junctions, thereby increasing microbial invasion and immune cell 
infiltration (858). Recent studies of post-traumatic brain injury (859) and subarachnoid 
hemorrhage (860) in mice suggested that activation of the Nrf2/ARE antioxidant and detoxifying 
enzymes preserve BBB and tight junction integrity. Moreover, Nrf2/ARE activation in choroid 
plexus cells preserved the blood-CSF barrier after oxidative stress injury (861). Therefore, DMF 
therapy could further protect the CNS compartment more globally from microbe and immune cell 
invasion and other systemic insults through direct protection of the BBB and blood-CSF barrier 
through its antioxidants effects.  
 
FAEs as astrocyte and neuron protectants from inflammation and oxidative stress 
 
In addition to macrophages and microglia, astrocytes and neurons are also possible CNS targets 
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for FAEs. DMF has been shown to decrease astrocyte activation and the release of inflammatory 
cytokines (687-689), which could further dampen CNS neuroinflammation. DMF treatment also 
decreased macrophage and microglia activation (674) and associated release of TNFα release 
(42) and likely other HIV-MDM factors (247-256) through ARE induction, which have been shown 
to impair astrocyte glutamate homeostasis and promote glutamate-mediated excitotoxicity. TNFα 
in particular can suppress astrocyte glutamate scavenging through impairment of their high 
affinity glutamate transporters, which are critical for regulation of extracellular glutamate levels 
(246, 862). Furthermore, TNFα released into supernatants of HIV-infected macrophage cultures 
can induce nitric oxide synthase and nitric oxide production and release by exposed astrocytes 
(863); such a process could amplify CNS oxidative stress and associated injury during HIV 
infection. Although such possible effects of DMF and MMF on HIV-MDM-mediated astrocyte 
dysfunction have not been studied, DMF treatment has been shown to directly protect both 
astrocytes and neurons from oxidative injury and glutamate toxicity through Nrf2/ARE induction 
(687-689). Because glutamate mediated excitotoxic injury has been implicated in the 
pathogenesis of HAND, these studies suggest DMF might project neurons directly from HIV-
mediated neurotoxicity as well as indirectly by preventing astrocyte dysfunction.  
 
In summary, DMF therapy in HAND patients could have both direct and indirect neuroprotective 
effects through inhibition of NF-κB activity and Nrf2/ARE induction in different CNS cell types 
(reviewed in Figure 12.2). Direct effects could occur through induction of neuronal cytoprotective 
antioxidant responses. Indirect effects could occur through DMF/MMF actions in 
macrophages/microglia, astrocytes, endothelial cells, and choroid plexus cells. Confirmed 
macrophage effects of DMF and MMF include (42):  i) suppressing neurotoxin production;  ii) 
limiting HIV infection;  iii) impairing monocyte chemotaxis; iv) inhibiting TNFα release;  and v)  
inhibiting NF-κB nuclear translocation. Proposed astrocyte effects include: i) inhibiting release of 
TNFα and other proinflammatory cytokines; ii) preserving glutamate scavenging and glutamate 
homeostasis; iii) limiting production of nitric oxide and associated pro-oxidants. Additionally, 
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indirect neuroprotective effects of DMF and MMF could also occur through actions in endothelial 
cells, which maintain the BBB. Confirmed effects in endothelial cells include:  i) reducing 
adhesion molecule expression; and ii) promoting BBB structural integrity. Finally, DMF therapy 
could preserve the blood-CSF barrier integrity through actions in choroid plexus cells.  Thus, 
there is much supporting evidence for the study of DMF as an adjunctive therapy for 
neuroprotection against HAND in ART-treated HIV-infected individuals. 
 
12.8 Safety of FAE Therapy  
 
FAE therapy safety and adverse events   
 
Oral DMF (240 mg taken 2-3 times daily) has been tested in several clinical trials in individuals 
with psoriasis (717, 730), multiple sclerosis (633, 634, 731), and other inflammatory diseases 
(727, 729). The recent phase III efficacy trials for multiple sclerosis demonstrated no increase 
rate of patient dropout in drug vs. placebo-treated patients, indicating excellent long-term 
tolerability (633, 634). The most common reported adverse events in these trials were flushing in 
~33% of patients, gastrointestinal events (diarrhea, nausea, upper abdominal pain, and vomiting) 
in ~33% of patients, and pruritus and proteinuria in ~9% of patients. Flushing and gastrointestinal 
events decreased after the first month of therapy. Transient eosinophilia has also been reported 
in patients at 4-8 weeks post initiation of FAE therapy (716). DMF formulation treatment was 
associated with a persistent leukocytopenia (~11% reduction in white blood cell count) and 
particularly lymphocytopenia (~30% reduction in circulating T-lymphocytes). White-cell and 
lymphocyte counts decreased in patients over the first year of DMF therapy and eventually 
plateaued at a lower set-point, though the majority of patients’ cell counts remained within the 
normal range. White-cell counts less than 3.0 × 109 per liter and lymphocyte counts of less that 
0.5 × 109 per liter (corresponding to the National Cancer Institute Common Toxicity Criteria grade 
2 or higher leukocytopenia and grade 3 or higher lymphocytopenia, respectively) were seen in 
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~4-7% of patients in the oral DMF groups versus ~1% in patients in the placebo group (633, 634). 
 
Despite the reduced white blood cell and lymphocyte counts, an increase in risk for malignancy or 
infection, including opportunistic infections, has not been reported in any FAE clinical trials or 
retrospective studies during the 20 years of FAE use (730, 864). However, recent case reports of 
progressive multifocal leukoencephalopathy (PML) have been reported in patients taking 
combination formulations of DMF and other fumarate derivatives (Fumaderm® and Psorinovo) 
(865-868). Significant confounding risk factors for PML were present in some of these patients 
(including sarcoidosis, cancer, and efalizumab use) and so the true relative risk for FAE-
associated PML is difficult to assess. Of the 135,000 patients with multiple sclerosis treated with 
the BG-12/Tecfidera™ oral DMF formulation (representing approximately 112,000 person-years 
of exposure as of December 21, 2014), there is only one case report of PML (869).Nonetheless, 
the rare case reports of PML suggest that vigilance in prescribers is critical. Prior to these reports, 
precautions for use such as monitoring blood lymphocyte levels had been suggested. A reduction 
of FAE dose or discontinuation was recommended if the white blood cell or lymphocyte counts fall 
below 3.0 × 109 or 0.5 × 109 cells per liter, respectively (870). This recommendation is especially 
prudent, in view of these recent PML case reports. 
 
Safety of FAE immunomodulatory therapy in HIV-infected individuals   
 
The clinical safety of long-term use of oral FAE therapy in humans is supported by a lack of clear 
evidence of serious adverse events after more than 17 years of its widespread use for the 
treatment of psoriasis, and its recent use in Phase III multiple sclerosis treatment trials involving 
more than 2600 patients (see section III. Safety and Adverse Events for long term clinical safety 
data and recent PML case reports). Nonetheless, its use in HIV-infected individuals has not been 
established, and the potential risks of this application must be considered. Among these concerns 
is the possibility that immunosuppressive FAE therapy in HIV-infected patients would increase 
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their risk for opportunistic infections, malignancy, acceleration of HIV infection, and mortality (871, 
872). However, potent immunosuppressive therapy has been used successfully in HIV-infected 
individuals undergoing organ transplantation for nearly two decades, with no significant increase 
in risk for these complications in comparison with such complications in HIV-negative transplant 
recipients (873-876). Several studies have reported that HIV viral loads and CD4+ T-lymphocyte 
counts were well-maintained after kidney and liver transplantation in HIV-infected patients.(877-
879) Moreover, the largest prospective study of ART-treated HIV-infected recipients of kidney 
transplantation (n = 150) receiving standard immunosuppressive therapy reported one and three 
year survival rates to be 94.6% and 88.2%(879), respectively, which is not significantly different 
from current kidney transplant survival rates as reported by the U.S. Scientific Registry of 
Transplant Recipients (880). Furthermore, the increased risk of de novo or recurrent malignancy 
in HIV-infected patients undergoing solid-organ transplantation and subsequent 
immunosuppressive therapy was low (881). 
 
Other immunosuppressive drugs including prednisolone (776, 777) and cyclosporine (780, 781) 
have also been studied in clinical trials in ART-treated HIV-infected patients and these trials 
revealed no increased risk for opportunistic infections, increased viral load, or disease 
progression. These studies demonstrate that potent immunosuppressive regimens cab be used 
safely in ART-treated HIV-infected individuals and they further suggest that DMF formulations 
could also be safely used in HIV-infected ART-treated individuals. 
 
12.9 Conclusions   
 
DMF formulation therapy reduces inflammation, immune activation, and oxidative stress in 
numerous cell lineages in vitro, particularly cells of the immune system, and such therapy has 
potent clinical efficacy in psoriasis and multiple sclerosis, likely through limiting inflammation and 
associated oxidative stress and immune cell infiltration in these diseases. Based on these effects, 
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this chapter proposes DMF as a potential adjunctive therapeutic in ART-treated HIV-infected 
individuals for improving morbidity and mortality by ameliorating immune activation and 
associated microbial translocation, systemic oxidative stress, and HIV-associated comorbidities, 
particularly HIV-associated neurocognitive disorder (HAND).  
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13.1 Differences in Clade or Transmitted/Founder HO-1 Regulation   
 
HIV-1 clades and transmitted/founder viruses  
 
HIV-1 strains can be classified into four groups (M, N, O, and P), which may represent four 
distinct introductions of cross-species transmission of the simian immunodeficiency virus (SIV) in 
to humans. More than 90% of HIV-1 infections worldwide belonging to group M, which is further 
broken down into nine genetically distinct subtypes or clades (A, B, C, D, F, G, H, J, and K) (882). 
Group O is reportedly restricted to west-central Africa and Group N and P are extremely rare and 
found thus far only in Cameroon (882). The panel of viruses demonstrated in Chapter 10 to 
consistently reduce heme oxygenase-1 (HO-1) protein expression in HIX-MDM are all confirmed 
or presumed Clade B viruses, the most common subtype in Europe, the Americas, Japan, and 
Australia. Whether other HIV-1 clades similarly induce HO-1 protein loss and associated 
glutamate neurotoxicity is currently unknown.  
 
Additionally, all viruses in the previously examined panel were clones or swarms derived from 
chronically infected individuals. Transmission and infection of HIV-1 at mucosal surfaces is 
characterized by a stringent population bottleneck such that clinical infection is established from 
the successful transmission and subsequent propagation of a single virus variant, termed the 
transmitted/founder (T/F) virus. After analysis of plasma viral sequences in subjects who recently 
were infected with HIV-1 (within 2-4 weeks), T/F sequences have been inferred using a model of 
early random virus evolution (52). Recent study of these T/F viruses has demonstrated that they 
are not the consequence of a random stochastic event, but have unique phenotypes distinct from 
viruses isolated chronically infected individuals. T/F viruses have been described to have 
differential utilization of CCR5, higher envelope content, enhanced cell-free infectivity, improved 
dendritic cell interaction, and relative interferon-alpha resistance (883, 884). While many T/F 
viruses are not macrophage tropic, Clade D T/F viruses may have a higher proportion of 
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macrophage-tropic viruses. Whether the HO-1 deficient neurotoxic phenotype is altered in T/F 
viruses is currently unknown. 
 
Clade D transmitted/founder HIV-1 infection of macrophages does not induce HO-1 deficiency  
 
We obtained five full length clones of previously characterized clade D T/F viruses (52) and 
quantified their ability to replicate in monocyte-derived macrophages (MDM) compared to the 
clade B clone 89.6 (Figure 13.1, A and B). While all clade D T/F viruses showed evidence of viral 
replication, two clones in particular (191859 & 191882) replicated to similar, if not higher, levels 
than 89.6. As expected, 89.6 infected MDM demonstrated significant reduction in HO-1 protein 
expression (Figure 13.2, A and B). However, all five clade D T/F viruses failed to significantly 
reduce HO-1 protein expression, even those clones that replicated similarly to 89.6. Similar to 
89.6, clade D T/F viruses did not reduce NQO1, GPX1, or HO-2 protein expression (Figure 13.2, 
C-E). Despite the lack of significant HO-1 reduction in HIV-MDM with any individual clade T/F 
virus, there was a weak, but significant, trend for high replicating infections with clade D T/F to 
correlate with lower HO-1 expression (Figure 13.2 F) This data strongly suggest that clade D T/F 
viruses do not reduce HO-1 protein expression as efficiently as clade B viruses derived from 
chronic infection, and moreover may completely lack the ability to downregulate HO-1. 
 
Clade D transmitted/founder HIV-1 infection of macrophages does induces non-glutamate 
mediated supernatant neurotoxicity  
 
Consistent with our previous results, the HO-1 deficiency in HIV-MDM infected with 89.6 
associated with a significant increase in supernatant glutamate and associated neurotoxicity 
(Figure 13.3, A-C). However, infection with clade D T/F viruses, which was not associated with 
HO-1 loss, did not increase supernatant glutamate content (Figure 13.3, A and B), although 
infection still increased supernatant neurotoxicity (Figure 13.3C). Moreover clade D T/F virus  
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Figure 13.1 HIV-1 clade D transmitter/founder replication in macrophages. MDM were isolated 
and differentiated from 4 independent donors and infected with one of five clade D 
transmitter/founder (T/F) viruses or the clade B molecular clone 89.6. Supernatants were 
collected and media was changed every three days up to day 12 post-infection. HIV replication as 
measured by supernatant reverse transcriptase (RT) activity (A) over the course of infection and 
(B) on Day 12 post infection. A unique symbol shape distinguishes each individual MDM donor. 
Error bars indicate mean ± standard error. Statistical comparisons versus Mock-MDM were made 
by one-way ANOVA with post Holm-Sidak test. * p <0.05,  ***p<0.001. 
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Figure 13.2 HIV-1 clade D transmitter/founder infection of MDM does not significantly 
reduce HO-1 protein expression despite efficient replication. MDM were isolated and 
differentiated from 4 independent donors and infected with one of five clade D transmitter/founder 
(T/F) viruses or the clade B molecular clone 89.6. MDM protein lysates from day 12 post infection 
were subsequently analyzed by Western blot/ (A) Representative Western blot for HO-1, HO-2, 
NQO1, GPX1, and GAPDH expression. Average protein expression of (B) HO-1, (C) HO-2, (D) 
NQO1, and (E) GPX1 expression in HIV-MDM as determined by Western blot (n = 4 donors). (F) 
Correlation between HO-1 protein expression and day 12 viral replication as determined by 
supernatant RT activity. A unique symbol shape distinguishes each individual MDM donor. Error 
bars indicate mean ± standard error. Statistical comparisons versus Mock-MDM or identified 
comparisons were made by one-way ANOVA with post Holm-Sidak test. Correlations were 
assessed by Pearson’s correlation with line of best fit determined by linear regression. * p <0.05, 
**p>0.01,  ***p<0.001. 
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replication did not correlate with extracellular glutamate concentration (Figure 13.3C), but did 
correlate with higher supernatant neurotoxicity (Figure 13.3D). Despite the lack of correlation with 
virus replication and extracellular glutamate, glutamate did correlate weekly with supernatant 
neurotoxicity (Figure 13.3F), suggesting that glutamate may still have a role, albeit a minor one, in 
neurotoxin production from MDM infected with clade D HIV-1. This data is consistent with our 
previous reports suggesting that HO-1 modulates glutamate release in HIV-MDM as the lack of 
HO-1 loss in clade D T/F infection occurs with a corresponding lack in elevated supernatant 
glutamate content. 
 
Discussion and future directions  
 
This data demonstrates for the first time a robust HIV-1 infection of MDM, in this case with clade 
D T/F clones, that does not induce HO-1 protein loss and associated increase in supernatant 
glutamate content similar to clade B viruses derived from chronically infected individuals. Whether 
clade D T/F fail to reduce HO-1 RNA, as would be predicted, is currently unknown. Whether this 
lack of the HO-1 deficient glutamate phenotype is a result of clade differences or a result of the 
T/F phenotype is as yet unknown. We propose to address this question by i) infecting MDM with 
macrophage-tropic viruses derived from chronically infected individuals from multiple HIV-1 
clades (and groups) as well as ii) infecting MDM with macrophage-tropic T/F viruses from clade 
B, although they might be rare. We have shown that MDM infection with clade B HIV-1 takes 6-9 
days to induce HO-1 protein loss (see Figure 10.1). Perhaps there are kinetic, but not magnitude, 
differences in the ability of T/F viruses or viruses from different clades to reduce HO-1 
expression. Examining HO-1 expression over the course of extended HIV-MDM infections (up to 
18 or 21 days post infection) will also be undertaken. These future experiments will further define 
the ability of clade D T/F virus to downregulate HO-1 in HIV-MDM.  
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Figure 13.3 HIV-1 clade D transmitter/founder infection of MDM enhances supernatant 
neurotoxicity, but not extracellular glutamate. MDM were isolated and differentiated from 4 
independent donors and infected with one of five clade D transmitter/founder (T/F) viruses or the 
clade B molecular clone 89.6. Day 12 post-infection supernatant  (A) glutamate concentration, (B) 
fold increase in glutamate compared to Mock-MDM, and (C) supernatant neurotoxicity as 
measured by cell-based MAP2 ELISA (1:10 dilution). Correlations between viral replication (day 
12 RT activity) and supernatant (D) glutamate and (E) neurotoxicity in clade D T/F MDM 
infections in all 4 donors (excludes 89.6 infection data). (F) Correlation between day 12 
supernatant glutamate and neurotoxicity in clade D T/F MDM infections in all 4 donors (excludes 
89.6 infection data). A unique symbol shape distinguishes each individual MDM donor. Error bars 
indicate mean ± standard error. Statistical comparisons versus Mock-MDM were made by one-
way ANOVA with post Holm-Sidak test. Correlations were assessed by Pearson's correlation with 
line of best fit determined by linear regression  * p <0.05, ***p<0.001. 
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The presence of enhanced neurotoxicity in clade D T/F infections, despite no increased 
glutamate, demonstrates the presence of other neurotoxins present in the supernatant. The 
identify of these non-glutamate neurotoxins induced by clade D T/F are as of yet, unknown. It is 
possible that clade D T/F infection of MDM is inducing novel neurotoxins not elicited by 89.6 
infection. Contrastingly, these non-glutamate neurotoxins may also be produced by 89.6 infection 
in addition to the predominant excitotoxin glutamate. Determining whether this clade D T/F 
neurotoxicity is a result of NMDA receptor activation, as it is with 89.6 and Jago (46), is an 
important initial step to understanding this new neurotoxicity profile. Further characterizing these 
non-glutamate neurotoxins is an important step in fully understanding this novel neurotoxic 
phenotype exhibited by clade D T/F viruses.  
 
From these preliminary experiments we have identified two HIV-1 viral clones (191859 & 191882) 
that replicate efficiently in macrophages but not induce HO-1 loss. By creating recombinant 
viruses by swapping segments of the genome with clade B clones (89.6 and YU2) that do induce 
HO-1 loss, we may be able to determine the viral determinants of HO-1 loss. Specifically, we may 
be able to link the differences in the ability to effectively reduce HO-1 to a particular viral gene, 
allowing us to further elucidate the molecular mechanism by which HIV reduces HO-1 expression.  
 
13.2 SIV Infection and HO-1 
 
SIV infection of pigtail macaque MDM may induce HO-1 protein expression  
 
Given the ability of multiple macrophage tropic HIV-1 clade B strains and a macrophage-tropic 
HIV-2 isolate to consistently reduce HO-1 protein expression in infected MDM, we wanted to 
determine whether this phenotype was conserved in SIV-infected macrophages. To this end, 
pigtail macaque (Macaca nemestrina) MDM were infected in vitro with a macrophage-tropic SIV-
strain, SIV/17E-Fr and analyzed similar to HIV human MDM experiments. Despite significant, 
albeit limited, replication, SIV-MDM demonstrated an increase in HO-1 expression on each day 
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(3, 6, 9, 12, and 15) post infection with the induction of HO-1 being most pronounced on days 3 
and 6 and subsequently waning over time (Figure 13.4, A and B). Notably, HO-1 expression in 
SIV-MDM from both pigtail donors was never lower than Mock-MDM at any time point analyzed. 
While these increases in HO-1 expression are not significant (due to the small sample size, n = 
2), these preliminary results are in stark contrast to HIV-1 clade B and HIV-2 infected MDM, 
which predictably decrease HO-1 protein expression (and do not alter HO-1 expression in the 
case of HIV-1 clade D T/F viruses). Whether this induction of HO-1 by SIV-infection of MDM is a 
consistent phenotype of SIV-infection of simian macrophages is unknown. Potentially, this HO-1 
induction response in this preliminary experiment may be relatively unique to the SIV/17E-Fr 
strain or may be a result of species differences in macrophages between pigtail macaques and 
humans. 
 
Thus, in addition to repeating these SIV-MDM experiments to confirm this HO-1 inducing 
phenotype, we need to elucidate whether this phenotype is a conserved feature of SIV-infection 
(and thus a departure from the HIV phenotype), a unique feature of simian macrophage infection 
with the SIV/17-E-Fr strain, or a consequence of host differences in macrophage biology (pigtail 
macaque versus human). To accomplish this we could determine HO-1 expression profiles in 
pigtail MDM infected with additional, unique macrophage-tropic SIV strains and in SIV-MDM 
derived from other simian species, such a rhesus macaques. These experiments will more 
thoroughly define this observed HO-1 inducing phenotype. To further elucidate this phenotype, 
we could quantify the HO-1 protein response in human MDM infected with a chimera SIV virus 
containing a macrophage-tropic HIV envelope gene with an SIV backbone. Determining whether 
this HIV-mediated HO-1 response in macrophages is distinct in SIV-infected macrophages 
compared to HIV-infection is an important future direction; it would identify potential pathological 
differences between SIV and HIV infection that may effect neurological disease progression.  
 
 
 
 
231 
  
 
 
 
 
Figure 13.4 SIV/17E-Fr infection of pigtail macaque MDM does not decrease HO-1 protein 
expression. Monocytes were isolated form fresh whole blood from two healthy, adult, male pigtail 
macaques (Macaca menstrina) by Percoll density gradient and differentiated in vitro into MDM (in 
RPMI 1640 containing 10mM HEPES, 2mM L-glutamine, 20ug/ml gentamycin, 50ng/ml M-CSF, 
2mM sodium pyruvate, and 20% human serum AB). After 7 days in vitro, pigtail MDM were 
infected with a macrophage-tropic SIV-strain, SIV/17E-Fr at 0.05 MOI for 24 hours and 
subsequently washed three times in RPMI and then returned to fresh pigtail MDM media (with 
only 10% human serum). MDM protein lysates and supernatants were collected from Mock-MDM 
and SIV-MDM in duplicate for each pigtail donor every 3 days over the course of a 15-day 
infection. (A) SIV replication as determined by supernatant RT activity for representative pigtail 
SIV-MDM infection. (B) Average protein expression of HO-1 normalized to GAPDH in SIV-MDM 
as determined by Western blot (n=2, except day 9 n = 1). (C) Representative Western blot of HO-
1 and GAPDH over the course of a 15 day SIV-MDM infection. Due to limited sample size (n =2) 
no statistical analyses were performed.  
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13.3 Cytokine and Chemokine Regulation of HO-1 in Macrophages 
 
Chronic immune stimulation with certain cytokines, chemokines, and immune modulators may 
reduce HO-1 expression in MDM 
 
Classically, HO-1 is induced in response to inflammation and cell stress as a protective response 
and thus many studies have examined the ability of cytokines, chemokines, and other immune 
stimulation in inducing HO-1 expression. However, several studies have reported that some 
immune signals, including interferon-alpha (IFNα) (885), interferon-gamma (IFNγ) (886, 887), and 
lipopolysaccharide (LPS) (888) can decrease HO-1 protein expression. Thus, reduced HO-1 
expression in brains from HIV-positive patients and in HIV-infected MDM may be a result of 
inflammatory signaling pathways triggered by HIV infection. To screen for the potential for 
immune signaling to modulate HO-1 expression in MDM, we exposed MDM from 5-6 independent 
donors to a panel of 20 immune modulators and determined HO-1 protein expression by Western 
blot. This panel of immune modulators consisted of cytokines, chemokines, and bacterial 
products (LPS) that have altered levels in HIV-infected individuals and/or known to modulate HIV-
infection in vitro. We treated MDM with each immune modulator for either 9 days to represent 
chronic immune signaling or 24 hours to examine a more acute response. As this experiment was 
designed as an initial screen to identify candidate modulators of HO-1 expression in MDM, we 
analyzed our data using paired-t tests without correction to maximize candidates for further 
validation and follow up. 
 
After 24 hours of exposure, only one cytokine (GM-CSF) significantly altered HO-1 protein 
expression, resulting in a 2-fold reduction in HO-1 levels (Figure 13.5A). However, after 9 days of 
exposure, six cytokines (IL-13, GM-CSF, IL-1β, IL-23, IL-18, and TNFα) resulted in significant 
reduction in MDM HO-1 protein expression (Figure 13.5B). IL-13 and GM-CSF showed the 
greatest reduction in HO-1 protein expression (~4-fold; n = 6 MDM donors). Notably, only one 
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cytokine (IL-4) showed a statistically significant increase in HO-1 protein expression with chronic 
(9 day) exposure. This preliminary data suggests that chronic exposure to some cytokines and 
their subsequent signaling may be able to drive downregulation of HO-1 in macrophages. To 
confirm the ability of these candidate cytokines to decrease HO-1 in MDM, these experiments 
need to be repeated in MDM from additional donors. Initial future directions of this work include i) 
defining candidate cytokine effects on HO-1 RNA in MDM, ii) determining whether different 
combination of candidate cytokines provide synergistic effects on reducing HO-1 expression, and 
iii) determining whether pre-treatment with this candidate cytokines can blunt HO-1 induction, 
such as in response to oxidative stress or pharmacologic HO-1 inducers. This preliminary data 
proposes a potential mechanism whereby chronic inflammatory signaling driven by HIV-infection 
may be responsible for driving HO-1 loss in macrophages. Whether chronic inflammatory 
signaling can result HO-1 loss in other CNS cell types (astrocytes, microglia, oligodendrocytes, 
neurons) is a parallel future direction that we are actively pursuing.  
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Figure 13.5 Chronic cytokine and chemokine exposure in macrophages may result in loss 
of HO-1 protein expression Uninfected MDM isolated from healthy donors were exposed to 
various cytokines, chemokines, or immune modulators for either 9 days (n=6) or 24 hours (n=5). 
For 9-day treatments, media was changed every three days and treatments were refreshed. At 
end of treatments, protein lysates were collected and HO-1 protein expression was analyzed by 
Western blot. Densitometry analysis of HO-1 protein expression normalized to GAPDH for (A) 9-
day and (B) 24-hour treatments. Error bars indicate mean ± SEM. Vehicle HO-1 expression was 
set to 0 (dotted line). One well treated with GM-CSF in the 9-day experiment had overt MDM 
death (data point marked by an X). Screening statistical comparisons to vehicle-treated MDM 
were made by uncorrected paired student’s t-tests. * p <0.05, **p<0.01 
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Discussion: Summary and Implications  
 
The continued prevalence of HIV-associated neurocognitive disorders (HAND) in antiretroviral 
therapy (ART)-treated HIV-infected individual strongly underscores the need for adjunctive 
therapies that target the neuropathological processes, including inflammation and oxidative 
stress, that persist in within the CNS and systemic compartments. To this end, we have identified 
the sentinel, detoxifying enzyme heme oxygenase-1 (HO-1) as a targetable host factor for 
adjunctive neuroprotective therapy in HAND. HO-1 is a member of the antioxidant response 
element (ARE) pathway and is critical for limiting inflammation, oxidative stress, and cellular injury 
in physiological and disease states in both CNS and systemic tissues. This body of work 
suggests a plausible mechanism (HO-1 deficiency) by which HIV infection of brain macrophages 
in ART-treated individuals could exacerbate oxidative stress and glutamate-induced neuronal 
injury, each of which is associated with neurocognitive dysfunction in infected individuals. This 
work further suggests that reversal of this deficiency, particular within the CNS macrophage 
compartment, may reduce HIV-mediated neuronal injury and associated neurocognitive 
impairment within ART-treated HIV-infected individuals.  
 
Through examination of a post-mortem autopsy cohort, we have demonstrated a significant 
deficiency of HO-1 in the prefrontal cortex of HIV-infected individuals with HAND that is 
particularly severe in those subjects with HIV-encephalitis (HIVE). This loss of HO-1 within the 
prefrontal cortex was associated with higher brain and CSF viral load and markers of immune and 
macrophage activation. HO-1 deficiency was not restricted to the prefrontal cortex nor was it a 
global brain phenomenon; we observed a significant reduction in HO-1 protein expression in the 
striatum of subjects with HIVE, but altered HO-1 protein expression was not observed in the 
occipital or cerebellar cortex. This brain protein deficiency appears to be specific for HO-1 relative 
to other members of the ARE-driven gene family, as we saw no consistent changes in other ARE 
proteins or in the heme oxygenase isoform HO-2. We believe that the deficiency of HO-1 
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expression in HAND brain might be unique among neurodegenerative diseases associated with 
CNS inflammation and oxidative stress where increased brain HO-1 is often observed, likely as a 
protective response to injury.  
 
To further explore the role of HO-1 in HIV neuropathology, we genotyped our HIV autopsy cohort 
for an HO-1 promoter region (GT)n microsatellite polymorphism. Longer (GT)n repeat lengths are 
associated with decreased HO-1 expression and inducibility and worse clinical outcomes in 
numerous inflammatory diseases. Our analysis demonstrated a significant positive correlation 
between longer (GT)n repeats and the risk of HIVE in our HIV-positive cohort. Moreover, in the 
HIV-negative cohort, we observed a significant correlation between longer (GT)n repeats and 
levels of the macrophage activation marker CD163. This data suggests that a lower inherent 
ability to induce a protective HO-1 response may promote neuroinflammatory processes, 
particularly macrophage activation, that are associated with the development of HIVE in HIV-
infected individuals. While our cohort was underpowered to examine a role of this promoter 
polymorphism in HAND, these data linking HO-1 and neuroinflammation further corroborates our 
prefrontal cortex protein expression data, thus strengthening our hypothesis for a role for HO-1 in 
modulating HIV neuropathogenesis, macrophage activation, and associated cognitive 
impairment.  
 
Previously, we have demonstrated that infection of monocyte-derived macrophages (MDM) with 
two HIV-1 viruses (Jago and 89.6) reduces HO-1 protein expression in conjunction with 
neurotoxin production. This work now expands on these initial observations to further 
characterize this neuropathological HIV-MDM phenotype. We showed that HO-1 loss in HIV-
MDM was progressive and time-dependent, typically showing a significant drop within 6-9 days 
after virus inoculation and that this loss of HO-1 occurred concomitantly with elevated HIV-MDM 
supernatant neurotoxicity and glutamate, a HAND-associated neurotoxin. This loss of HO-1 
protein tightly correlated with loss of HO-1 mRNA, suggesting at least part of the reduction in HO-
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1 protein is occurring by a pre-translational mechanism. This deficiency of HO-1 was relatively 
specific, as other members of the ARE-driven gene family and the heme oxygenase isoform HO-
2 were unaffected. We further demonstrated that this selective loss of HO-1 and associated 
glutamate release and neurotoxin production is a conserved feature of MDM infection with 
macrophage-tropic clade B HIV-1 strains that correlates closely with the extent of replication. This 
HIV-driven loss of HO-1 did not require the HIV-1 accessory genes nef, vpr, or vpu. Additionally, 
we demonstrated the ability of a macrophage-tropic HIV-2 strain to reduce HO-1 expression; this 
initially suggested this HO-1 deficient phenotype may be conserved among all macrophage-tropic 
human immunodeficiency viruses. However, preliminary data examining HIV-1 clade D 
transmitted/founder (T/F) viruses demonstrates that these isolates appear to replicate efficiently 
in MDM without reducing HO-1 protein expression. Whether this absence of decreasing HO-1 is 
associated with differences among HIV-1 clades or the T/F phenotype is currently an active area 
of investigation. Additional preliminary results suggest that simian immunodeficiency virus (SIV) 
infection of simian MDM may in further contrast induces HO-1 protein expression, highlighting 
potential neuropathologic differences between HIV and SIV, which is often used to study HIV 
disease in simian models.  
 
Despite the correlation of HO-1 loss and viral replication, our data clearly demonstrate that even 
low-level HIV replication in macrophages can promote HO-1 loss, leading us to study the 
association between HIV replication and HO-1 deficiency in the context of clinically-relevant ART 
regimens. We demonstrated that ART exposure at CNS-relevant concentrations fails to prevent 
HO-1 loss and neurotoxicity in HIV-MDM once infection is already established. This suggests that 
long-lived CNS macrophage reservoirs in HIV-infected individuals, even those on suppressive 
ART, could maintain an HO-1 deficient, neurotoxic phenotype. Our current findings suggest that 
induction of HO-1 deficiency associated with excess glutamate production and neurotoxicity is a 
highly conserved phenotype of macrophage-tropic HIV strains, which can persist in the 
macrophage compartment in the presence of ART. The failure of ART to prevent this HO-1 loss in 
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established infection highlights the potential value of HO-1-inducing drugs as adjunctive therapy 
to ART. 
 
Using pharmacologic and genetic approaches to modulate HO-1, we confirmed a direct role for 
HIV-driven HO-1 loss in modulating glutamate neurotoxicity from HIV-MDM. Pharmacologic 
inhibition of heme oxygenase (HO-1 and HO-2) enzymatic activity and selective HO-1 knockdown 
increased glutamate and associated neurotoxicity in HIV-MDM without altering viral replication. 
This enhanced neurotoxic phenotype in response to further HO-1 deficiency suggests a potential 
therapeutic benefit of restoring HO-1 in HIV-infected brain macrophages. Using both 
pharmacologic inducers and genetic derepression, we demonstrated that HO-1 induction 
decreased HIV-MDM glutamate production and associated neurotoxicity. However, the 
contribution of other protective ARE-induced genes (e.g. NQO1), which were induced to varying 
extents by these approaches, cannot be ruled out. Nonetheless, these data support a role for 
induction of HO-1 expression as a protective strategy against HIV disease progression.  
 
From this work, we propose further study into testing HO-1 inducers as potential adjunctive 
therapy for prevention of HAND in ART-treated subjects. In March of 2013 an oral dimethyl 
fumarate preparation, Tecfidera™, received FDA approval for the treatment of multiple sclerosis, 
a CNS disease characterized by recurrent neuroinflammation and oxidative stress. DMF and its 
primary metabolite monomethyl fumarate  (MMF) are potent inducers of HO-1 expression and 
MMF is detectable within the CSF after oral delivery of DMF at concentrations (4.4µM) that we 
have demonstrated effectively induce macrophage HO-1 expression and suppress production of 
neurotoxic levels of glutamate. In addition to DMF/MMF’s induction of HO-1 expression and 
associated decrease in glutamate-associated neurotoxicity, DMF/MMF’s other anti-inflammatory 
effects in macrophages (inhibition of NF-κB and reduction of CCL-2 mediated chemotaxis) may 
also have beneficial effects in HIV-infected ART-treated individuals. Thus, considerable evidence 
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therefore supports the testing of HO-1 inducers such as DMF as adjunctive therapy for prevention 
of HAND in HIV-infected individuals already virally suppressed on ART.  
 
These data identify HO-1 deficiency as a plausible mechanism by which HIV infection of brain 
macrophages in ART-treated individuals could exacerbate oxidative stress and glutamate-
induced neuronal injury, each of which is associated with neurocognitive dysfunction in infected 
individuals. The mechanism by which HIV drives HO-1 loss in infected macrophages and within 
the brain parenchyma is unclear and is an active area of investigation. Elucidating the mechanism 
of HO-1 downregulation by HIV in infected macrophages and the brain will further define this 
conserved HIV neuropathological phenotype and may provide additional insights into potential 
adjunctive therapies for preventing this loss. In addition to defining a pathologic role of HO-1 
deficiency in HIV neurological disease, this work identifies induction of HO-1 as a potential 
therapeutic goal in HIV-individuals with HAND. Therapies, such as DMF, that induce HO-1 could 
ameliorate this brain HO-1 deficiency in chronic HIV infection and thereby provide additional 
neuroprotection to HIV-infected individuals already virally suppressed with ART. We have initiated 
studies to evaluate the efficacy of oral DMF therapy in limiting systemic and CNS inflammation 
and associated disease in the SIV rhesus macaque model. Moreover, we are exploring other 
candidate HO-1 inducing compounds as potential adjunctive therapeutics for individuals with 
HAND. This work supports the initiation of future translational studies to determine the safety and 
efficacy of DMF and other clinically relevant HO-1 inducing compounds in HIV-infected subjects 
in pilot clinical trials.  
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